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ABSTRACT 
VOLATILE ORGANIC COMPOUND EXPOSURE AND CARDIOMETABOLIC 
SYNDROME RISK IN A NATIONALLY REPRESENTATIVE COHORT 
Stacey L. Konkle 
March 20, 2020 
BACKGROUND: The relative importance of environmental exposures such as 
volatile organic compounds (VOCs) is one of the paramount public health priorities 
of our time, yet is presently unstudied. VOCs are ubiquitous in the environment 
and have been associated with numerous adverse health effects, including a 
number of cardiovascular and metabolic effects that are components of 
Cardiometabolic Syndrome (CMS). 
OBJECTIVES: To examine the relationship between CMS and individual-level 
exposures to VOCs, measured as urinary metabolites of VOCs (UM-VOCs), in a 
nationally representative sample. 
METHODS: Associations between urinary biomarkers of exposure to 19 parent 
VOCs and CMS were assessed using the National Health and Nutrition 
Examination Survey (NHANES). To isolate effects from environmental VOC 
exposures, analyses were stratified by tobacco-smoke exposure status. CMS was 
treated dichotomously as well as ordinally and associations with VOCs were 
considered from a single pollutant, as well as multi-pollutant perspectives. 
Potential important groupings and interactions among VOCs, and their 
vi 
associations with CMS were evaluated using numerous traditional regression 
modeling and exploratory modeling methods including: backwards-selection 
model-building, factor analysis, LASSO penalized regression, and a cumulative 
VOC exposure score. 
RESULTS: Concentrations of eight UM-VOCs were significantly different between 
individuals with and without CMS. Among the non-smoke exposed participants, 6 
UM-VOCs were significantly associated with increased odds of CMS. These 
associations were observed with metabolites from acrolein, 1,3-butadiene, 
crotonaldehyde, cyanide, and ethylbenzene/styrene. Furthermore, dose-response 
type relationships were observed with metabolites of acrolein, 1,3-butadiene, and 
crotonaldehyde. Metabolites from acrolein and ethylbenzene/styrene were 
associated with disease progression in ordinal logistic regression models and a 
cumulative VOC exposure score was significantly associated with the progression 
of disease towards clinically diagnosable CMS (OR: 1.015, 95% CI: 1.007, 1.024). 
DISCUSSION: This novel quantitative and nationally representative study 
investigated associations between individual-level exposures to VOCs and CMS. 
The results of this study point toward a potential causal role for certain VOCs in 
the development of CMS, a condition which ultimately greatly increases one’s risk 
of the deadliest non-communicable disease in the world, cardiovascular disease. 
These findings are important for the development of public health interventions and 
policies surrounding modifiable environmental pollution exposures. 
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Rationale and significance of the study 
Cardiometabolic syndrome (CMS) describes a spectrum of dysfunctional 
cardiovascular and metabolic system functions (1). CMS begins with insulin 
resistance, often leading to metabolic syndrome and pre-diabetes and finally 
progresses to more sever conditions including cardiovascular disease and type II 
diabetes mellitus (T2DM) (1). These conditions are grouped together under the 
umbrella terms “cardiometabolic syndrome” or “cardiometabolic disease” due the 
shared risk factors among the conditions; risk factors such as overweight and 
obesity, dyslipidemia, and high blood pressure (1). 
The consequences of CMS are severe. Cardiovascular disease is the 
leading cause of death, both globally and in the United States (U.S.) and type II 
diabetes has grown to epidemic proportions (2-4). Cardiovascular disease is 
responsible for 30% of all death in the U.S. and it has been estimated that by 2030 
the rate of diabetes in the U.S. will have risen from 17.7 million in 2000 to nearly 
30.3 million (3, 5). Considering the associated morbidities, decreased quality of 
life, high social costs, and economic costs (U.S.: 80 billion dollars annually), CMS 
is among the leading priorities of our time. 
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It is well established that suboptimal diet and physical inactivity are the two 
most important modifiable risk factors for the development of CMS (6, 7). Still, 
understanding all contributing factors in the development of CMS, particularly 
modifiable risk factors such as environmental air pollution exposures, is needed. 
Environmental air pollution is the leading environmental risk factor that 
contributes to the global burden of disease (8). 6.5 million deaths were attributed 
to air pollution exposure in 2012 (9); more recent estimates indicate that more than 
9 million deaths per year may be attributable to air pollution exposure (8). This 
upward trend in deaths attributable to air pollution exposure suggests that the 
contribution of air pollution to global mortality may be increasing (10). 
Volatile Organic Compounds (VOCs) are one of a number of constituents 
of air pollution. VOCs directly contribute to the formation of secondary organic 
aerosols, a major component of fine PM (≤2.5 μm in aerodynamic diameter; 
PM2.5), and tropospheric ozone (O3) (11-13). PM2.5 levels in ambient air have been 
shown in previous epidemiologic cohort studies to be significantly associated with 
all-cause and cardiorespiratory mortality as well cardiovascular disease risk and 
progression (8, 14, 15). Such associations have also been observed even at 
concentrations of PM2.5 and O3, that are below the current U.S. standards (16). A 
number of studies have also indicated that adverse health effects of PM vary with 
the composition of the polluted air (17-21). 
Although most previous work has found that PM2.5 levels are associated 
with adverse health outcomes, polluted air contains a variety of gaseous co-
pollutants such as ozone and nitrous oxides. Additionally, polluted ambient air, 
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particularly in urban locations, contains a wide range of VOCs, such as benzene, 
acrolein, xylene, and formaldehyde (22). It has been shown widely in the literature, 
both in animal exposure models and human studies, that exposure to VOCs is 
associated with systemic, immunologic, neurologic, reproductive, developmental, 
genotoxic, and carcinogenic effects (23). Furthermore, several of the VOCs of 
interest have been placed on the federal Substance Priority List as being among 
the chemicals of top public health concern (23). 
Specific Aims of the study 
Current evidence for the direct effects of VOCs on cardiovascular and 
metabolic outcomes is not robust; however, there are strong implications that 
environmental pollutants such as VOCs play a role in cardiometabolic syndrome. 
CMS is defined by the World Health Organization (WHO) as the presence of 
dysglycemia, plus two or more of the following criteria: abdominal obesity, high 
triglycerides, low-high density lipoproteins, hypertension, and/or the presence of 
microalbuminuria (14, 24). The available epidemiologic and experimental data 
suggest that exposure to VOCs contributes to the cause of cardiovascular disease, 
hypertension, and metabolic dysfunction, but further investigation is needed. 
Furthermore, it is well established by both epidemiological and toxicological 
studies that particulate matter (PM), a constituent of air pollution, is significantly 
associated with CMS (14). One method for assessing the health effects of PM, is 
to classify it by aerodynamic diameter: PM10>PM2.5>ultra fine particles (UFP). In 
brief, the smaller the particle, the more hazardous it is to health, as the smaller 
particles can travel more deeply into the lungs (14). VOCs contribute to the 
4 
composition, as well as to the mass of PM, but it is not known if particle mass or 
the chemical properties of constituent VOCs or a combination of the two is the 
most harmful to cardiometabolic health. Until the relative importance of VOCs’ 
contribution to particle mass and their chemical properties is determined and until 
the most harmful compounds are identified, the only practical approach to plausibly 
reducing adverse health effects would be to reduce overall emissions of VOCs. 
Therefore, information regarding the links between VOC and CMS would strongly 
reinforce priorities in public health policy and planning and incentives for pursuing 
specific strategies to change unhealthy environmental contributions and ultimately 
reduce cardiometabolic health–related burdens. An investigation of the 
associations between VOCs with CMS will lend insight into the contribution of one 
of the major modifiable constituents of PM and its role in CMS. 
The aim of this study is to assess whether exposure to VOCs is associated 
with CMS. Therefore, national cross-sectional associations between personal-
level exposures to VOCs and the prevalence of CMS will be examined. For this 
analysis, data will be obtained on individual-level exposure and disease status 
from participants of the National Health and Nutrition Examination Survey 
(NHANES). Individual-level exposure will be estimated by the concentration of the 
urinary metabolites of VOCs (UM-VOCs), which correspond to individual-level 
exposures to VOCs (25). 
We hypothesize that increasing levels of UM-VOCs will be positively 
associated with an increase in the prevalence of CMS. Associations with VOCs 
and CMS will be examined linearly and categorically and from both individual and 
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multi-pollutant exposure perceptive. 
These novel nationally-representative estimates of personal-level exposure 
to VOCs derived from individual participants’ urinary metabolites of VOCs provide 
unique insight into associations and patterns of personal exposure to VOCs and 
their associations with CMS in the United States. To date, quantitative and 
nationally representative associations of individual-level exposure to VOCs using 
urinary biomarkers of exposure and their associations with CMS have not been 
reported. 
To address these gaps in knowledge, the objective of the analysis is to 
evaluate the association between VOC exposures and CMS. The central 
hypothesis for this dissertation is that cardiometabolic syndrome (CMS) is 
positively associated with increasing concentrations of urinary metabolites 
of volatile organic compounds (UM-VOCs). 
The hypothesis will be tested with the following specific aims: 
Specific Aim 1: Statistically describe and compare distributions, trends, and 
cohort characteristics of the 2005-2006, 2011-2012, and 2013-2014 NHANES UM-
VOC sub-sample. 
Specific Aim 2: Study the effects of individual continuous UM-VOCs and prevalent 
CMS after adjusting for select covariates. 
Specific Aim 3: Evaluate the dose-response relationships of individual categorical 
UM-VOC exposures and CMS. 
Specific Aim 4: Explore combinatory effects of VOCs on CMS. 
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Literature Review 
Volatile Organic Compounds 
Volatile organic compounds (VOCs) are numerous and ubiquitous in the 
environment. VOCs are a class of organic compounds whose molecules contain 
carbon (26). VOCs are generally considered any organic compound with and initial 
boiling point of less than 250˚C (482˚F) measured at standard atmospheric 
pressure (101.3Kpa) (27). VOCs are naturally occurring as well man-made 
chemicals, and are volatile by nature because of their low intermolecular attractive 
binding forces (27). 
VOCs have high vapor pressures, due to their low boiling points, which 
leads to the high tendency for these chemicals to vaporize, which is known as 
volatility. Volatile organic compounds exist in the vapor phase, particle phase, or 
both, depending on the situational equilibrium properties (e.g., vapor pressure) and 
particle surface composition (e.g., water content) (28). Since the volatility of a 
compound mostly increases as temperature increases and the boiling point of 
VOCs is relatively low, the state of the compound, whether vapor or particle, is 
dependent on temperature. It has been estimated that for every one degree 
increase in temperature there is a 1.3±0.4% increase in daily total motor vehicle 
VOC emissions (28). In addition to the effects of temperature on volatility, exposure 
to sunlight also increases chemical reaction rates (29). Temperature and sunlight 
are important consideration, as their presence or lack thereof, impact secondary 
pollutant formation. 
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Volatile organic compounds are released directly into the air, or by 
incomplete combustion in the burning of organic matter. Volatile organic 
compounds are of concern as both indoor and outdoor air pollutants, and while 
industrial emission sources of VOCs in the U.S. have been identified and are 
regulated, their extensive use in industry and transportation make them quite 
abundant in the environment and therefore, currently exposure to anthropogenic 
VOCs is virtually unavoidable (30, 31). Common sources of exposure to 
anthropogenic VOCs are industrial emissions, tobacco smoke and automobile 
exhaust, additionally common house hold sources of exposure to VOCs include 
paints, pesticides, deodorizers, cleaning and degreasing agents, personal care 
products, and solvents (30-33). 
In addition to anthropogenic sources of VOCs there are significant natural 
sources of VOCs. In fact, in the United States, it has been estimated that biogenic 
sources of VOCs account for approximately 74% of VOC emissions and globally 
as approximately 90% of VOC emissions (34, 35). While biogenic sources 
comprise the vast majority of VOC emissions, anthropogenic sources are of 
particular interest for a number of reasons. First anthropogenic VOCs, in contrast 
with biogenic VOCs, are extremely concentrated exposures (36). In fact 
anthropogenic emissions of VOCs (automobile exhaust, vapors from fueling 
vehicles, solvents from paints, etc.) are largely concentrated in urban areas, which 
cover only approximately three percent of the Earth's surface (37). This means, 
that approximately 10% of the total VOC emissions produced by humans are highly 
concentrated where most of the human population lives. So in urban areas, 
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anthropogenic VOC emissions are about 4 times stronger than the average 
background of natural emissions (36). These highly concentrated VOC emissions 
occur where most of the human population lives and thus have a much larger effect 
on human exposure than do natural emissions (36). Additionally many of these 
highly concentrated VOCs have been associated with adverse health effects (34). 
Anthropogenic VOCs may tip a delicate natural balance causing pollutants to 
interact in ways they otherwise would not. Lastly, anthropogenic sources of VOCs 
are of particular interest because they can be decreased through regulatory and 
voluntary actions, leading to improvements in air quality (34). 
Several agencies and countries have varying definitions of VOCs. The 
Canadian definition is focused on commonly encountered VOCs that affect air 
quality such as benzene, toluene, and methane (38). The U.S. Environmental 
Protection Agency’s (EPA) definition is focused on reactive chemicals, which 
create photochemical smog. The U.S. EPA definition states, “volatile organic 
compounds (VOC) means any compound of carbon, excluding carbon monoxide, 
carbon dioxide, carbonic acid, metallic carbides or carbonates and ammonium 
carbonate, which participates in atmospheric photochemical reactions, except 
those designated by EPA as having negligible photochemical reactivity” (39). 
There is an abundance of VOCs in the environment from both natural and 
man-made sources. For the purpose of this review, volatile organic compounds 
with measurable urinary metabolites will be assessed. Namely the metabolites of 
the parent VOCs of interest are: acrolein, acrylamide, acrylonitrile, vinyl chloride, 
ethylene oxide, benzene, 1-bromopropane, 1,3-butadiene, crotonaldehyde, N, N- 
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dimethylformamide, ethylbenzene, styrene, propylene oxide, tetrachloroethylene, 
toluene, trichloroethylene, and xylene. 
Health Effects of Volatile Organic Compounds 
Individual VOC Effects 
Nearly 200 air toxics have been associated with adverse health effects in 
occupational, epidemiologic, and/or laboratory studies. The 19 parent VOCs of 
interest in this investigation have all been associated with adverse health effects. 
The majority of the literature on the health effects of VOC exposures is related to 
the carcinogenicity of individual VOC exposures. The descriptions below include a 
brief overview of the physical description, common sources, common routes of 
exposure, and health effects of each parent VOC of interest in this investigation. 
The tables included for each of the 19 parent VOCs in the following summary 
descriptions provide important information on reported health effects for the given 
route of exposure for both human and animal exposures (40). 
Acrolein 
Acrolein is a colorless or yellow liquid which has an acrid smell (41). Acrolein 
is used industrially as an intermediate in chemical synthesis and as a biocide. It is 
generated in the breakdown or burning of lipids and organic matter (42). Acrolein 
is also a natural byproduct of many pollutants found in outdoor air, and is produced 
in the burning of tobacco and other plant material including coal and gasoline. 
Acrolein exposures can occur via industrially contaminated air and water. 
Additionally, because acrolein is produced when fats are overheated, small 
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amounts of acrolein are can be found in food (41). 
Due to inadequate evidence, acrolein has not been classified as a 
carcinogen by the Department of Health and Human Services (DHHS), 
International Agency for Research on Cancer (IARC), or the U.S. Environmental 
Protection Agency (U.S. EPA) (41). However, acrolein is capable of inducing sister 
chromatid exchange, DNA cross-linking, and mutations under certain conditions. 
Additionally, acrolein has been established as a cardiovascular, hematological, 
ocular, and respiratory irritant and disrupter (41). Acute high dose exposures may 
cause death while acute low dose exposures may cause irritation to the nasal 
cavity, lowered breathing rate, damage to the lining of the lungs, stomach irritation, 
vomiting, stomach ulcers and bleeding. The effects of chronic moderate acrolein 
exposure are not well established (41). Figures 1.1 and 1.2 below provide a 
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Figure 1.2. Existing Animal Information on Health Effects of Acrolein (41) 
Acrylamide 
Acrylamide is a white/colorless, odorless, crystalline chemical that is highly 
soluble in water (43). Acrylamide is used industrially as a reagent in the synthesis 
of polymers, pulp and paper, and textiles (43). Acrylamide is generated in the 
heating of starch-rich materials (43). 
Acrylamide exposures in humans generally occur through contact with 
contaminated water and food. It has been reported that consumption of starch-rich 
foods is the primary exposure source to the non-smoke exposed general public 
(44). Smoking and exposure to highly polluted air are the greatest sources of 
acrylamide in the non-occupationally exposed general public (44). 
Acrylamide is considered to be a potential carcinogen and is classified as a group 
2A carcinogen (probably carcinogenic to humans) by the International Agency for 
Research in Cancer (IARC) (44). Exposure limits have been set by both the 
Occupational Safety and Health Administration (OSHA) and the National Institute 
for Occupational Safety and Health (NIOSH) (44). These exposure limits are set 
12 
to protect the national work force and are considered to be the upper limit of the 
acceptable concentration of a hazardous substance in workplace air (45). Figures 
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Figure 1.4. Existing Animal Information on Health Effects of Acrylamide (46) 
Acrylonitrile 
Acrylonitrile is a colorless, highly flammable liquid with a pungent onion-like 
smell. Acrylonitrile is highly soluble in water (47). Acrylonitrile is used industrially 
to produce rubber, resins, plastics, elastomers, synthetic fiber, pharmaceuticals, 
antioxidants, and dyes, and in the manufacture of carbon fiber (47). Previously, 
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acrylonitrile was used as a pesticide fumigant but all pesticide uses have been 
discontinued. 
Acrylonitrile exposure is generally associated with occupational exposures 
but pathways of exposure to the general public include industrial releases, 
automobile exhaust, food packaging, and cigarette smoke (48). Exposures 
associated with contaminated air, water, and soil from locations in close proximity 
to acrylonitrile factories or hazardous waste sites have also been reported (48). 
Acute high dose exposures of acrylonitrile generally effect the nervous 
system and have been reported to cause headaches, nausea, disorientation and 
death (48). Other reported effects from high dose exposures to acrylonitrile include 
damage to red blood cells and liver, skin blistering and peeling, increased number 
of tumors occurring in the brain, salivary glands, and intestines and increased 
incidence of lung cancer (48, 49). Additionally, reproductive effects and birth 
defects have also been observed in animals (48). 
 Acrylonitrile is considered reasonably anticipated to be a human 
carcinogen by the Agency for Toxic Substances and Disease Registry (ATSDR) 
and is classified by the U.S. Environmental Protection Agency  (U.S. EPA) as a 
B1; probable human carcinogen, and as a group B2; possibly carcinogenic to 
humans, by the International Agency for Research on Cancer (IARC) (48-50). 
Figures 1.5 and 1.6 provide a summary of existing information on the health effects 
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Figure 1.6. Existing Animal Information on Health Effects of Acrylonitrile (51) 
Vinyl Chloride 
Vinyl chloride is a flammable colorless gas, with a mild sweet odor (52). 
Vinyl chloride is a manmade chemical chiefly used in the production of the polymer 
polyvinyl chloride (PVC). Vinyl chloride is one of the top 20 largest petrochemicals 
in production worldwide and is used to make a variety of plastic products including 
pipes, wire and cable coatings, packaging materials, upholstery, house ware, 
automobile parts, etc. (52). Vinyl chloride was previously used as an aerosol 
propellant, a coolant, and in some cosmetics (52). 
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Vinyl chloride is commonly found in the air near vinyl chloride manufacturing 
and processing plants, hazardous waste sites, and landfills and is also present in 
tobacco smoke. In addition to air exposures, individuals can also be exposed to 
vinyl chloride though contaminated water sources (52). 
Acute high dose exposures of vinyl chloride affect the central and peripheral 
nervous system casing dizziness, drowsiness, unconsciousness, headache and 
death. Animal studies have shown extremely high levels exposures of vinyl 
chloride can cause liver, kidney, lung, and heart damage and prevent blood 
clotting. Chronic exposure to vinyl chloride causes a set of symptoms that is 
characterized by Raynaud's phenomenon, joint and muscle pain and scleroderma-
like skin changes. Other symptoms include eye, nose, throat, and skin irritations, 
weight loss, and abdominal pain. Vinyl Chloride exposure is associated with 
developing liver, brain and lung cancer as well as cancer of the lymphatic and 
hematopoietic system (53). 
Vinyl chloride is considered to be a known human carcinogen with sufficient 
evidence in both humans and animals. This distinction is also recognized by IARC, 
the U.S. EPA, ATSDR and several other agencies (50, 52, 53). Figures 1.7 and 

















































































Inhalation • • • • • • • • • • 
Oral 
Dermal • • 
Human 















































































Inhalation • • • • • • • • • • 
Oral • • • • 
Dermal • 
Animal 
Figure 1.8. Existing Animal Information on Health Effects of Vinyl Chloride (54) 
Ethylene Oxide 
Ethylene oxide, also called oxirane by the International Union of Pure and 
Applied Chemistry (IUPAC), is a flammable, colorless, faintly sweet smelling gas 
(55). Ethylene oxide dissolves easily in water, alcohol, and most organic solvents. 
Ethylene oxide is widely used as a chemical intermediate in industry to make 
detergents, thickeners, solvents, plastics, as a sterilizing agent for medical 
supplies and food, as an insecticide fumigant, and as a bactericidal, fungicidal, and 
sporicidal disinfectant (55). 
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Ethylene oxide is not widely found in the general environment and due to 
lack of information it is not known if exposures of ethylene oxide are common from 
contaminated air, water, or soil near hazardous waste sites. Most ethylene oxide 
exposures are occupational exposures of medical staff or agricultural workers (56). 
Although ethylene oxide is commonly used on food crops it is not known if this is 
a source of exposure to the general public (56). 
Acute ethylene oxide exposures consist mainly of central nervous system 
effects and irritations of the eyes, nose, skin, and mucous membranes. Chronic 
exposures cause functional problem in the brain and nerves and have been 
associated with increased incidence of leukemia, stomach cancer, cancer of the 
pancreas, and Hodgkin's disease. There is also evidence of increased rates of 
miscarriage and birth defects (56). 
Ethylene oxide is classified as a probable/suspected human carcinogen 
(Group B1) by IARC and the U.S. EPA but is classified as a known human 
carcinogen by ATSDR and the National Toxicology Program (50, 56, 57). Figures 

















































































Inhalation • • • • • • • • 
Oral 
Dermal • • 
Human 















































































Inhalation • • • • • • • • • • 
Oral • • • • 
Dermal • • 
Animal 
Figure 1.10. Existing Animal Information on Health Effects of Ethylene Oxide (58) 
Benzene 
Benzene is a colorless, highly flammable, sweet smelling aromatic liquid. 
Benzene is a good solvent for many organic and inorganic substances and is 
therefore widely used as an important industrial solvent and precursor. Benzene is 
one of the top twenty chemicals in productive volume and is widely used in the 
United States (59). 
Benzene is an important industrial solvent and precursor in the production 
of drugs, plastics, synthetic rubber and dyes and is a natural constituent of crude 
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oil (59). While industrial emission sources have been identified and are regulated, 
benzene’s extensive use in industry and transportation make it quite abundant in 
the environment and therefore industrial exposure sources are virtually 
unavoidable (60). In addition to the abundant industrial emission exposures, the 
general public is exposed to benzene via numerous common-use products. 
Benzene is present in every-day products, such as, tobacco smoke, automobile 
exhaust, industrial emissions, combustion of petrochemicals, polymers, glues, 
paints, resins, synthetic fibers, furniture wax, and detergents (60). 
Benzene is one of the 188 hazardous air pollutants listed by the EPA and 
has long been known to act as carcinogen of human blood components; In-fact the 
first case of “benzene associated lymphoma” was reported by French researchers 
in 1947 (59, 61). It has been well established that benzene decreases hematologic 
parameters, causes dysfunctional liver activity and enzymes and reduce 
circulating immunologic cell counts (62). Studies have also reported significant 
changes in developmental, reproductive, neurobehavioral, and respiratory function 
(62). Additionally, exposure to low levels of benzene can cause eye and skin 
irritation, drowsiness, dizziness, rapid heartbeat, headaches, nausea, tremors, 
confusion, and unconsciousness (63). Figures 1.11 and 1.12 provide a summary 
of existing information on the health effects of benzene (64). Benzene is classified 
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Figure 1.12. Existing Animal Information on Health Effects of Benzene (66) 
1-Bromopropane 
1-Bromopropane is a colorless liquid, which is slightly soluble in water (67). 
1-Bromopropane is used in the production of commercial chemicals such as 
pesticides, flavors and fragrances, pharmaceuticals, and is used as a solvent in 
the adhesives, dry cleaning, vapor degreasing, and electronic and metal cleaning 
industries (68). 
1-Bromopropane exposures can occur through dermal contact or through 
inhalation. Measurable quantities of 1-bromopropane have been detected in 
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ambient air but most documented exposures are occupational related (68). 
Workers in industries that make or use 1-bromopropane, such as degreasing 
operations for cleaning metals, plastics, and electronic components, dry cleaning, 
asphalt production, aircraft maintenance, and synthetic fiber manufacturing, have 
the highest exposures (68). 
Health effects of 1-bromopropane exposure generally involve the central 
nervous system and peripheral nervous systems and include symptoms such as 
respiratory and skin irritation, headache, nausea, and lower extremity numbness, 
pain, and weakness, blurred vision, nervousness, dizziness, and unconsciousness 
(68). 
Currently 1-bromopropane is not listed as a toxicant or carcinogen in the 
U.S. but has been classified by the European Chemicals Agency as a reproductive 
toxicant and a "substance of very high concern" (69). Figures 1.13 and 1.14 
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Figure 1.14. Existing Animal Information on Health Effects of 1-Bromopropane 
(70) 
1,3-Butadiene 
1,3-Butadiene, also commonly known as divinyl, is a synthetic, colorless, 
gas with a gasoline-like odor, which is insoluble in water but soluble in ethanol, 
ether, acetone, and benzene (71). 1,3-Butadiene is widely used in the manufacture 
of polymers and as an industrial chemical intermediate. Over half of the 1,3-
butadiene produced is used in the manufacture of man-made rubber (72). 
1,3-Butadiene exposures predominantly occur through the inhalation route 
but can occur through ingestion and dermal contact (72). The most common 
exposure sources of 1,3-butadiene are; vehicle exhaust, gasoline fumes, tobacco 
smoke, burning wood, burning rubber and plastic, forest fires, and industrial 
releases (72). 1,3-Butadiene is a product of gasoline combustion and is therefore 
commonly found in ambient air samples particularly in the urban and suburban 
areas. 
Acute 1,3-butadiene exposures generally cause mucosal and eye irritation, 
headache, fatigue, decreased blood pressure and pulse rate, central nervous 
23 
system damage blurred vision, and unconsciousness. Chronic exposures have 
been associated with cardiovascular disease, leukemia, liver and blood disorders, 
other cancers, and central nervous system disturbances (72). 1,3-Butadiene is 
classified by ATSDR and the U.S. EPA as a known human carcinogen (72, 73). 
Figures 1.15 and 1.16 provide a summary of existing information on the health 






































































































































































Figure 1.16. Existing Animal Information on Health Effects of 1,3-Butadiene (74) 
Carbon Disulfide 
Carbon disulfide is a colorless, highly flammable, poisonous liquid with a 
pleasant sweet-smelling odor. Carbon disulfide evaporates readily at room 
24 
temperature; the vapor is more than two times heavier than air so it is often found 
a ground level. Carbon disulfide is used industrially as a non-polar solvent and 
organic building block in chemical reactions (75). Production of viscose rayon and 
cellophane film are the primary industrial uses of carbon disulfide.  Carbon disulfide 
is also commonly used to dissolve rubber to produce tires and in the production of 
some pesticides (76). 
The vast majority of carbon disulfide in the environment is from industrial 
releases. Once carbon disulfide makes it into the environment it rapidly evaporates 
and descends to ground level where it generally remains for a period of days to 
weeks until disturbed or degraded. Carbon disulfide does not bind tightly to soil, 
thus leaving it very mobile to move down into ground water (76). Generally, 
exposures to carbon disulfide occur in the workplace. Individuals’ may be exposed 
by breathing, eating, drinking or by skin contact with contaminated soil, air, water 
or other substance that may contain it (76). 
Exposure to carbon disulfide can result in symptoms such as dizziness, 
headaches, poor sleeping, fatigue, nausea, vomiting, nervousness, anorexia, low-
weight, mood changes, psychosis, polyneuropathy, ocular changes, coronary 
heart disease, gastritis, kidney damage, liver damage, eye damage, skin burns, 
dermatitis, decreased sperm count and libido in men, and menstrual disturbances 
in women (75). Carbon disulfide is a central nervous system (CNS) disrupter and 
high dose exposures may lead to death due to CNS complications. Chronic 
exposures have been shown to cause behavioral and neurophysiological changes 
and have been epidemiologically linked to increased incidence of coronary heart 
25 
disease and angina (75). Carbon disulfide has not been classified as a human 
carcinogen (75). 
Carbon disulfide is lipophilic and is therefore more highly concentrated in 
organs such as the live and brain, where it is metabolized to thiocarbamates (76). 
Conjugation of carbon disulfide or carbonyl sulfide with endogenous glutathione 
results in the formation of thiozolidine-2-thione-4-carboxylic acid and 2-
oxythiazolidine-4-carboxylic acid, which are excreted in the urine (76). These 
thiocarbamates are potent antithyroid substances and may be involved in direct 
injury to the endothelium coupled with hypothyroidism (77). Within a few hours of 
inhalation exposure to carbon disulfide approximately 70% is metabolized 
excreted; the remaining 30% is slowly excrete or metabolized and then excreted 
in the urine (78). Figures 1.17 and 1.18 provide a summary of existing information 
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Figure 1.18. Existing Animal Information on Health Effects of Carbon Disulfide 
(79) 
Crotonaldehyde 
Crotonaldehyde is highly flammable, clear, colorless to straw colored liquid 
with a pungent suffocating odor. Crotonaldehyde is used in the manufacture of 
sorbic acid, a yeast and mold inhibitor and as a versatile intermediate in organic 
solvents and foodstuffs. Crotonaldehyde is used industrially as a chemical 
intermediate in the surfactants, textiles, paper, fuels, insecticides, and leather 
tanning industries. Crotonaldehyde is also used in chemical warfare (80). 
Crotonaldehyde is emitted from the combustion of gasoline, the burning of 
wood and the burning of tobacco. The general public is most often exposed to 
crotonaldehyde by inhaling tobacco smoke, gasoline and diesel engine exhausts, 
and smoke from wood burning (80). Occupational inhalation and dermal exposures 
occur in industrial processes which utilize liquid crotonaldehyde in chemical 
reactions (80). 
Symptoms of vapor inhalation, ingestion and dermal or eye absorption 
exposure include eye irritation, respiratory irritation, cough, burning sensation, 
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sore throat, labored breathing, pulmonary edema, eye redness, pain, lacrimation, 
severe deep burns, diarrhea, nausea, vomiting. High-dose exposures of 
crotonaldehyde may cause a build-up of fluid in the lungs resulting in death (81). 
The possible carcinogenicity of crotonaldehyde is supported by studies of chronic 
exposure activities in F344 rats. These studies found that crotonaldehyde, 0.6 mM 
dose, for 113 and 84 weeks, induced neoplastic lesions of the liver in 9 of 27 rats; 
2 rats had hepatocellular carcinomas, and 9 rats had neoplastic nodules. It also 
caused altered liver cell foci in 23 of 27 rats (82). 
The International Agency For Research On Caner evaluates 
crotonaldehyde as currently not classifiable as to the carcinogenicity to humans 
based on inadequate evidence in both human and animal studies but the American 
Conference of Governmental Hygienists recognizes crotonaldehyde as a 
confirmed animal carcinogen and the U.S. Environmental Protection Agency 
classifies crotonaldehyde as a possible human carcinogen (50, 83, 84). 
Cyanide 
Any chemical compound that contains a monovalently bound carbon and 
nitrogen atom is considered a cyanide.  Cyanides are usually found joined with 
other chemicals to form compounds and can be found in various states of matter 
depending on their chemical composition. Hydrogen cyanide is a colorless gas 
with a faint, bitter, almond-like odor. Sodium cyanide and potassium cyanide are 
both white solids with a bitter, almond-like odor in damp air (85). Industrially 
cyanides are used in electroplating, metallurgy, organic chemicals production, 
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photographic developing, manufacture of plastics, fumigation of ships, and some 
mining processes (85). 
Cyanide can be found naturally in the soil and in a number of plants and 
foods such as: almonds, millet sprouts, lima beans, soy, spinach, bamboo shoots, 
and cassava roots. Exposure to cyanide in the general public commonly occurs 
from breathing air, drinking water, touching soil, or eating foods that contain or 
have been contaminated with cyanide. Additionally, smoking cigarettes and 
exposure to smoke from fires and fire places are a major sources of cyanide 
exposure (85). Exposures of airborne cyanide as low as 200ppm are sufficient to 
cause death in minutes (85). 
Cyanide exposure causes the inhibition of the enzyme cytochrome c 
oxidase in the fourth complex of the electron transport chain, which prevents the 
transport of electrons from cytochrome c to oxygen resulting in the inability to 
aerobically produce adenosine triphosphate (ATP) for energy. The inability to 
aerobically produce ATP results in histotoxic hypoxia, which is more pronounced 
in tissues that rely heavily on aerobic respiration, notably the heart and central 
nervous system. Symptoms of cyanide exposure are; rapid difficulty breathing, 
seizures, unconsciousness, chest pain, vomiting, blood changes, headaches, and 
enlargement of the thyroid gland. Thiocyanate, the main metabolite of cyanide, is 
a reactive metabolite and is known to be responsible for damage to the thyroid 
gland and suspected to be the cause of the endocrine effects associated with 
cyanide exposure (85). The carcinogenic effects of cyanide are not well studied. 
Animal studies have demonstrated metabolic effects, decreased serum albumin 
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and lowered calcium and potassium levels, reductions in mitochondrial respiratory 
control ratios, and reduced tissue ATP levels in the liver and heart (86, 87). Figures 
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Figure 1.20. Existing Animal Information on Health Effects of Cyanide (88) 
N, N-Dimethylformamide 
N, N-Dimethylformamide, also known as dimethylformamide or DMF for 
short, is a clear liquid, which is miscible with water and the majority of organic 
liquids. N, N-Dimethylformamide is widely used industrially as a solvent, additive, 
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and/or as an intermediate in chemical processing due to its miscibility with most 
common organic solvents (89). N, N-Dimethylformamide is often used in the 
production of fibers, films, and surface coatings. The primary end users of N, N-
dimethylformamide are pharmaceutical, electronic components, butadiene, and 
urethanes manufactures. It is also used as a resin cleanup solvent, reaction 
solvent, and processing solvent in the manufacture of polyimides, optical 
brighteners, semipermeable membranes, and pesticides (90). 
N, N-Dimethylformamides’ wide application has led to its selection as one 
of the four priority compounds for human field studies by the National Toxicology 
Program (NTP) of the US National Institute of Environmental Health Sciences 
(NIEHS). Exposures to N, N-dimethylformamide occurs most commonly in 
occupational setting through inhalation, or dermal contact. The general public has 
the greatest potential for exposure to N, N-dimethylformamide though pesticide 
use and exposure to contaminated air in the vicinity of industrial point sources (91). 
Chronic low dose exposures to N, N-dimethylformamide generally result in 
symptoms such as gastrointestinal distress, abdominal pain, nausea, vomiting, 
fatigue, headache, dizziness, skin irritation, conjunctivitis, changes in blood 
pressure, liver injury, tachycardia & electrocardiography (ECG) abnormalities. 
Very low dose exposure to N, N-dimethylformamide, may cause alcohol 
intolerance. 
There is limited evidence that N, N-dimethylformamide is carcinogenic for 
humans and the International Agency for Research on Cancer has evaluated N, 
N-dimethylformamide as not classifiable as a carcinogen in humans (Group 3) 
31 
(50). Studies have reported increased incidence of testicular tumors, and tumors 
of the buccal cavity and pharynx, as well as increased frequency of miscarriages 
with chronic N, N-dimethylformamide (92). Additionally, excess mortality from 
ischemic heart disease and cardiac disturbances, including tachycardia and 
palpitations, have been reported in studies of N, N-dimethylformamide-exposed 
workers. Genotoxic effects have also been reported in humans, while reproductive, 
developmental, and neurological effects have been observed in animal studies 
(91). 
The metabolism of N, N-dimethylformamide takes place primarily in the 
liver, where it is metabolized by the microsomal cytochrome p-450 into mainly N-
hydroxymethyl- N-methylformamide (HMMF), which is unstable and readily 
decomposes to N-methyformamide (NMF). However, the detailed mechanism of 
its exact toxicity remain unclear (92). 
Ethylbenzene 
Ethylbenzene is a colorless, highly flammable liquid, with an odor similar to 
gasoline. Ethylbenzene is more dense that air but less dense than water and 
insoluble in water; hence ethylbenzene floats on the surface of water (93). 
Ethylbenzene is commonly used industrially as a solvent in the production 
of other chemicals. One of the main consumers of ethylbenzene is the manufacture 
of styrene where it is used as an intermediate and in the production of polystyrene. 
Ethylbenzene is also used in the production of inks, insecticides, jet fuel, and 
paints, and can be found naturally in products such as coal tar and petroleum (63). 
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 Ethylbenzene is released into the environment from burning oil, gas, and 
coal, and from discharges of ethylbenzene from factories.  Ethylbenzene is most 
commonly found in the air as a vapor and the general public is exposed to 
ethylbenzene from gasoline or from the use of pesticides, carpet glues, varnishes, 
pesticides, inks, and paints, and use of tobacco, which all contain ethylbenzene 
(63). Heavily trafficked areas and industrial manufacturing are known to be large 
sources of ambient ethylbenzene exposure (63). 
High dose exposures of ethylbenzene are known to cause eye and throat 
irritation, dizziness, and distressed breathing. Ethylbenzene is known to affect the 
central nervous system and cause liver damage. In vivo studies have 
demonstrated deleterious effects of ethylbenzene on the inner ear, kidney function, 
liver, and kidney tumor development (94). Ethylbenzene is classified as a possible 
carcinogen by the International Agency for Research on Cancer (IRAC), and as a 
confirmed animal carcinogen with unknown relevance to humans by the American 
Conference of Governmental Industrial Hygienists (ACGIH), however the 
Environmental Protection Agency (EPA) has not determined ethylbenzene to be a 
carcinogen (93, 94). In humans ethylbenzene is mainly metabolized in the liver to 
mandelic acid (65-70%) and phenylglyoxylic acid (20-25%) (95). Figures 1.21 and 
1.22 provide a summary of existing information on the health effects of 
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Figure 1.22. Existing Animal Information on Health Effects of Ethylbenzene (96) 
Styrene 
Styrene, also known as vinyl benzene, is a colorless oily liquid with a strong 
sweet aromatic smell. Styrene is primarily a man-made chemical used in the 
production of rubber and plastics and is present in organic combustion products 
such as cigarette smoke and automobile exhaust. Common consumer products 
that contain styrene include: packaging materials, insulation products, fiberglass, 
plastics, many “food use” items and carpeting materials. While styrene is primarily 
a man-made chemical, it can also be found naturally existing in a wide variety of 
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foods such as fruits, vegetables, nuts, beverages, and meats and is used as a 
flavoring ingredient and an ion-exchange resins in food processing (63, 97).  
Styrene can be found in air, soil, and water, but is not commonly found in 
drinking water. People are most often expose to styrene though contaminated air, 
food, or water but can also be absorbed through the skin. Point source releases to 
ambient air occur in the vicinity of styrene manufactures, while other common 
exposure sources include automobile exhaust, cigarette smoke, and photocopy 
machines (98). Occupational exposures are not uncommon; people working in the 
reinforced-plastics industry have the highest potential for exposure. Additionally, 
individuals who work in styrene polymerization, rubber manufacturing, and 
styrene-polyester resin facilities and workers at photocopy centers may also be 
exposed to styrene (98). 
Acute high dose exposures, generally occurring in occupational settings, 
commonly involve the nervous system and include symptoms such as: changes in 
color vision, irritation of the eyes, nose, and throat, lethargy, feeling drunk and/or 
dizzy, headache, slowed reaction time, concentration problems, and balance 
problems. Chronic exposures have also reported nervous system affects but with 
more sever neurological complications such as: depression, concentration 
problems, muscle weakness, personality changes, and anxiety. In-vivo studies 
have shown significant liver damage, reproductive and developmental problems. 
The Agency for Toxic Substances and Disease Registry has classified styrene as 
reasonably anticipated to be a human carcinogen and the International Agency for 
Research on Cancer has classified styrene as possibly carcinogenic to humans 
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(Group 2B) (48, 50, 98).  Metabolic activation is considered to be a critical step for 
styrene-induced toxicity. The CYP2E1 has been identified as the main cytochrome 
P450 isoform involved in human styrene metabolism. Styrene-7,8-oxide is a 
primary oxidative metabolite and 4-vinylphenol, a phenolic metabolite formed by 
aromatic hydroxylation has also been detected as a styrene metabolite (99, 100). 
Figures 1.23 and 1.24 provide a summary of existing information on the health 
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Figure 1.24. Existing Animal Information on Health Effects of Styrene (98) 
Propylene Oxide 
Propylene oxide, also known as epoxypropae, is a clear colorless volatile 
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liquid with a sweet, alcoholic, and ether-like odor. Propylene oxide vapor is heavier 
than air and highly soluble in water (102). Propylene oxide is produced on a large 
scale industrially with the majority of production being converted to polyether 
polyols, building blocks in the production of polyurethane plastics (102). Propylene 
oxide is also used in the production of propylene glycol and as a fumigant of 
foodstuffs and plastic medical instruments and as a herbicide, as a solvent, and in 
the preparation of lubricants, surfactants, and oil demulsifiers (103, 104). 
 Occupational exposures of propylene oxide through both inhalation and 
dermal routes in industries that produce, store, transport or use propylene oxide 
may be significant. The general public may be exposed to propylene oxide by point 
source releases from industrial plant as well as from the use of herbicides, plastics, 
or the consumption of fumigated food products (102, 103). 
Acute propylene oxide exposure causes eye, skin, and respiratory irritation 
and lesions, coughing, dyspnea (difficulty in breathing), and pulmonary edema. 
Dermal contact may result in delayed burns and lesions. Propylene oxide is a 
known mild central nervous system depressant and acute high dose exposures 
may result in headache, motor weakness, incoordination, ataxia, and coma in 
humans. Chronic exposures in animal studies have shown neurological and tumor-
causing effects, decreased weight gain, and increased mortality. The U.S. 
Environmental Protection Agency and the International Agency for Research on 
Cancer have classified propylene oxide as a Group B2, probable human 
carcinogen and the American Conference of Governmental Industrial Hygienists 
have classified propylene oxide as a confirmed animal carcinogen with unknown 
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relevance to humans (49, 50, 103). Propylene oxide reacts with DNA at neutral PH 
to yield two principal products, n-7-(2-hydroxypropyl)guanine and n-3-(2-
hydroxypropyl)adenine (50). 
Tetrachloroethylene 
Tetrachloroethylene, also known as perchloroethylene, is a colorless sweet 
smelling liquid that is volatile, highly stable, and nonflammable (105). It is a man-
made chemical that is widely used in dry-cleaning fabrics and metal degreasing 
operations (106). Tetrachloroethylene is an excellent solvent and is used as a 
chemical building block in the production of many consumer products such as: 
water repellents, silicone lubricants, fabric finishers, spot removers, adhesives, 
and wood cleaners (63). 
People usually are exposed to tetrachloroethylene by breathing 
contaminated air. Tetrachloroethylene is released into the environment, air, soil, 
and water, from industrial sources and/or industrial waste sites, but can also be 
exposed by drinking contaminated water and eating contaminated food. 
Tetrachloroethylene can stay in the air for a long time before it is broken down and 
easily travels through the soil and into ground water supplies (63, 106, 107). 
Acute high dose exposures of tetrachloroethylene may result in: skin 
irritation, dizziness, headache, sleepiness, confusion, nausea, difficulty in 
speaking and walking, mood and behavioral changes, unconsciousness, liver and 
kidney damage, and even death (63). Chronic exposure to tetrachloroethylene can 
cause nervous system problems, such as memory loss and concentration 
problems, impairments in cognitive and motor neurobehavioral functioning, and 
38 
color vision impairment. Tetrachloroethylene exposure may also cause adverse 
effects in the kidney, liver, immune system, and hematologic system, and on 
developmental and reproductive systems. Studies of people exposed in the 
workplace have found associations with several types of cancer including bladder 
cancer, non-Hodgkin lymphoma, multiple myeloma, as well as reproductive 
complications such as menstrual disorders, altered sperm structure, and reduced 
fertility and inconclusive evidence of birth defects (106). Studies of dry-cleaning 
workers exposed to tetrachloroethylene have shown associations between 
exposure to tetrachloroethylene and several types of cancer, specifically bladder 
cancer, non-Hodgkin lymphoma and multiple myeloma. There is also limited 
evidence suggestive of associations with esophageal, kidney, cervical and breast 
cancer (106). In vivo studies of tetrachloroethylene exposures have reported 
mononuclear cell leukemias and liver and kidney tumors in male rats (106). The 
Agency for Toxic Substances and Disease Registry classifies tetrachloroethylene 
as likely to be carcinogenic in humans by all routes of exposure and the 
International Agency for Research on Cancer classifies tetrachloroethylene as 
probably carcinogenic to humans (Group 2A) (50, 107). 
The disposition of an absorbed dose of tetrachloroethylene occurs primarily 
through pulmonary excretion; metabolism is less important than for other 
chlorinated solvents, such as trichloroethylene. Mass-balance studies in rats with 
14C-labeled tetrachloroethylene indicated that 70% or more of an oral or inhaled 
dose can be recovered in expired air as the parent compound. The next most 
important excreted fraction occurs in urine and feces, which may collectively 
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account for up to 23% of an administered dose. A small portion of the dose (less 
than 3%) may be converted to CO2 and exhaled. Most of the radioactivity 
recovered in urine can be attributed to formation of trichloroacetic acid, a 
nonvolatile metabolite of tetrachloroethylene that is excreted primarily in urine. This 
general pattern of disposition of tetrachloroethylene appears to be consistent after 
both oral and inhalation dosing (108). Figures 1.25 and 1.26 provide a summary 
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Toluene is a colorless, aromatic liquid with a distinct odor (110). It is 
less dense than, and insoluble in water. Toluene occurs naturally in petroleum and 
coal tar and is synthesized industrially for use as a solvent (111). 
Toluene is an important industrial solvent and is widely used in making 
paints, paint thinners, fingernail polish, lacquers, adhesives, and rubber, and in 
some printing and leather tanning processes. Additionally, toluene is a major 
component in jet fuel (63). Toluene’s extensive use in industry and transportation 
make it quite abundant in the environment and therefore industrial exposure 
sources are virtually unavoidable. In addition to the abundant industrial emission 
exposures, the general public is exposed to toluene via numerous common-use 
products. Toluene is present in every-day products such as automobile exhaust, 
glues, solvents, and tobacco smoke (63). 
Acute high dose exposures of toluene in humans have been reported to 
cause light-headiness, dizziness, sleepiness, unconsciousness, kidney damage 
and death (63). Animal studies have shown that moderate or high levels of toluene 
can cause liver, kidney, and lung dysfunction and damage (63). Additionally, 
chronic low dose exposures have been reported to include effects on the central 
nervous system, depression, difficulty concentrating, muscle weakness, memory 
loss, and personality changes (111). Figures 1.27 and 1.28 provide a summary of 
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Figure 1.28. Existing Animal Information on Health Effects of Toluene (113) 
Trichloroethylene 
Trichloroethylene, also known as trichloroethene, is a man-made sweet 
smelling, nonflammable, colorless liquid. Trichloroethylene is commonly used as 
an industrial solvent and degreaser for metal parts, as a building-block in the 
production of the refrigerant HFC-134a, and is used as an inhalation anesthetic for 
short surgical procedures where light anesthesia with good analgesia is required. 
Trichloroethylene has also been used as an extraction solvent for greases, oils, 
fats, waxes, and tars; by the textile processing industry to scour cotton, wool, and 
other fabrics; in dry cleaning operations; and as a component of adhesives, 
42 
lubricants, paints, varnishes, paint strippers, pesticides, and cold metal cleaners 
(114, 115). 
People are exposed to trichloroethylene from breathing contaminated air or 
eating, drinking, or touching contaminated foodstuffs or consumer products. 
People who live near facilities that utilize or manufacture trichloroethylene or 
individuals who live near hazardous waste sites may have higher exposures to 
trichloroethylene. Individuals who live near these locations are at higher risk not 
only from breathing contaminated air but also because trichloroethylene breaks 
down slowly in the soil and in the water, making these sources additional potential 
chronic exposure sources (115). In fact ATSDR reports that trichloroethylene is the 
most frequently reported organic contaminant in groundwater (115). The general 
public is most likely to be exposed to trichloroethylene by drinking 
trichloroethylene-contaminated water. Individuals may also be exposed to 
trichloroethylene by breathing trichloroethylene released into the air from 
contaminated water. Individuals who work in the degreasing industry or other 
industry where trichloroethylene is used, may be exposed by breathing in 
trichloroethylene-contaminated air or by contacting the chemical with your skin. 
Acute effects of trichloroethylene generally involve the central nervous 
system and include symptoms such as: sleepiness, fatigue, headache, confusion, 
hearing, sight and balance, changes and feelings of euphoria; and effects of the 
liver, kidneys, lung, heart, gastrointestinal system, and skin have been noted (116). 
Relatively short in vivo trichloroethylene exposures have resulted in harmful effects 
on the nervous system, liver, respiratory system, kidneys, blood, immune system, 
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heart, and body weight. Chronic occupational exposure reports are similar to acute 
exposure reports and include symptoms of the central nervous system such as: 
dizziness, headache, sleepiness, nausea, confusion, blurred vision, facial 
numbness, and weakness. Chronic exposures have also been shown to affect the 
liver, kidneys, immune and endocrine systems and have been reported to cause 
scleroderma (a systemic autoimmune disease). Interestingly, studies have shown 
that simultaneous alcohol consumption and trichloroethylene inhalation increases 
the toxicity of trichloroethylene in humans. Epidemiologic studies have suggested 
trichloroethylene exposure may be associated with increased incidence of 
mismanages and congenital heart disease in children and animal studies have 
reported developmental effects from exposure to trichloroethylene and its 
metabolites (trichloroacetic acid [TCA] and dichloroacetic acid [DCA]) (63, 115, 
116). 
Several well-designed epidemiologic studies have been published reporting 
trichloroethylene exposure to be associated with several types of cancers in 
humans, including; especially kidney, liver, cervix, and lymphatic system. These 
results are supported by molecular epidemiology studies showing specific renal 
cell mutations found primarily in renal cell carcinoma patients exposed to 
trichloroethylene, and in vivo studies showing increases in lung, liver, kidney, and 
testicular tumors and lymphoma (116). The Agency for Toxic Substances and 
Disease Registry and the International Agency for Research on Cancer (IARC) 
have determined that trichloroethylene is "carcinogenic to humans" (50, 115). 
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Early studies showed that approximately 11% of absorbed trichloroethylene 
is eliminated unchanged from the lungs and another 2% is metabolized and 
eliminated by the lungs; 58% of absorbed trichloroethylene is eliminated in the 
urine and about 8% of the retained trichloroethylene is excreted as metabolites in 
the feces. Other more recent studies have shown up to 73% of the 
trichloroethylene retained after inhalation could be recovered in the urine. The 
trichloroethylene metabolites found in the urine are; monochloroacetic acid, 4%; 
trichloroacetic acid, 19%; & trichloroethanol, 50%. In humans, excretion of the 
metabolites of trichloroethylene is fastest for monochloroacetic acid, intermediate 
for trichloroethanol, and the slowest for trichloroacetic acid. Trichloroethylene is 
metabolized by hepatic P450 system and to a much lesser degree by direct 
conjugation with glutathione. The metabolite trichloroacetic acid is considered a 
principal metabolite responsible for trichloroethylene-induced liver cancer in mice 
(117). Figures 1.29 and 1.30 provide a summary of existing information on the 
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Figure 1.30. Existing Animal Information on Health Effects of Trichloroethylene 
(115) 
Xylene 
Xylene is a colorless, sweet smelling aromatic liquid, which is less dense 
than, and insoluble in water (119). Xylene occurs naturally in petroleum and coal 
tar and is synthesized industrially for use as a solvent. Xylene is one of the top 30 
chemicals in productive us in the US (120). 
 Xylene is an important industrial solvent and is used widely in the printing, 
rubber, and leather industries as well as in cleaning agents, paint thinners, and in 
paints, varnishes, jet fuel and gasoline. While industrial emission sources have 
been identified and are regulated, xylene’s extensive use in industry and 
transportation make it quite abundant in the environment and therefore industrial 
exposure sources are virtually unavoidable (120). In addition to the abundant 
industrial emission exposures, the general public is exposed to xylene via 
numerous common-use products. Xylene is present in every-day products, such 
as gasoline, paint varnish, shellac, rust preventatives, and cigarette smoke (120). 
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Acute high levels of exposure to xylene have been reported to cause 
headaches, lack of muscle coordination, dizziness, confusion, impaired balance, 
skin irritation, eye irritation, nasal irritation, throat irritation, difficulty in breathing, 
delayed reaction time, memory difficulties, stomach discomfort, nausea, vomiting, 
unconsciousness and death, all of which are indicative of affects to the central 
nervous system. Chronic exposure to xylene may alter liver and kidney function 
(120). Xylene has been found to be associated with cancer in both mouse and 
human studies but the current evidence is non-conclusive (50, 121). Figures 1.31 
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Figure 1.32. Existing Animal Information on Health Effects of Xylene (122) 
Multipollutant VOC Effects 
Nearly 200 air toxics have been associated with adverse health effects in 
occupational, epidemiologic, and/or laboratory studies. All 19 parent VOCs of 
interest in this investigation have been associated with adverse health effects. 
Table 1.1 summarizes the existing information on the health effects of each 
of the VOC of interest, as reported by Agency for Toxic Substances and Disease 
Registry (ATSDR). The “H” indicates evidence from a human study what the “a” 
indicated evidence form an animal study. The letters indicate that one or more 
studies provide information associated with that particular effect. They do not 
necessarily imply anything about the quality of the study or studies. As shown in 
Table 1.1, all the VOCs of interest in this studies have been associated with 
numerous adverse health effects including cardiovascular and metabolic effects 
(40). 
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Table 1.1. Compilation of Existing Information on Health Effects of the VOCs 
Known Health Effects of VOC Exposures 














































































Acrolein a H,a  a a a a a a a 
Acrylamide a H,a a a H,a a a a H,a 
Acrylonitrile  H,a H,a  a s H H,a  H,a  H,a  H,a  H,a 
Vinyl Chloride H,a  H,a  H,a H,a  H,a  H,a  H,a  H,a  H,a  H,a 
Ethylene Oxide  a H,a  H,a H,a  H,a  H,a  H,a  a H,a  H,a 
Benzene H,a  H,a  H,a H,a  H,a  H,a  H,a  H,a  H,a  H,a 
1-Bromopropane a a H,a a a a a a a a 
1,3-Butadiene a H,a  a H,a  a H,a  a a H,a  H,a 
Carbon-disulfide H,a H,a H,a H,a H H,a H,a H,a a H 
Cyanide H,a H,a a H,a a H,a a a a 
Ethylbenzene a H,a a H  H,a a a H H,a 
Styrene a H,a H,a H,a H,a  H,a H,a H,a H,a H,a 
Tetrachloroethylene H,a H,a H,a H,a a H,a H,a H,a H,a H,a 
Toluene H,a  H,a  H,a H,a  H,a  H,a  H,a  H,a  H,a  H,a 
Trichloroethylene H,a  H,a  H,a H,a  H,a  H,a  H,a  H,a  H,a  H,a 
Xylene H,a  H,a  H,a H,a  H,a  H,a  H,a  H,a  H,a  H 
*a=animal study, H=Human Study
Exposure to volatile organic compounds is ubiquitous but generally the 
health effects of the VOCs of interest in this investigation have been studied in the 
single exposure context, as exemplified in Table 1.1. However, because people 
are virtually never expose to one single pollutant, studying pollutant mixtures in a 
more natural exposure spectrum has been greatly desired. Recent advances in 
both pollutant measurement capabilities and statistical techniques have finally led 
to the ability to conduct miltipollutant exposure analyses. 
Emerging techniques are being developed, which allow environmental 
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pollutant mixtures to be studied in a more natural exposure spectrum i.e. mixtures 
of pollutant. These techniques are referred to as multipollutant models (123, 124). 
These techniques address the multicollinearity of the environmental exposures 
and provide more robust statistics for addressing or adjusting for multiple 
comparisons, confounding, and significant covariates. 
To date, there have only been a handful of studies that have investigated 
VOC exposures from a multipollutant prospective (123, 125-128). More 
conventional "two-stage" approaches which estimate exposures and health 
outcomes first and then combined them into one model have been used to assess 
the associations between VOCs and non-accidental, cardiovascular, and cancer 
mortality, as well as fasting glucose, insulin, HOMA-IR, adiponectin, resistin, leptin, 
and HbA1c. Theses conventional “two-stage” models have been very successful 
in demonstrating the value of exposure-based research analytic approaches but 
lack the sophistication of adjusting for or calculating estimates of uncertainty. 
There has been a recent recognition of the importance of mixtures 
investigations in exposure science. While, there have been a handful of 
multipollutant exposure investigations on VOCs and numerous single-exposure-
type investigations of the health effects of VOCs; this is the first investigation to 
study the combinatory effects of these specific VOCs, to utilize urinary metabolites 
of VOCs, or to investigate mixtures of these UM-VOCs and their associations with 
CMS. 
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Volatile Organic Compounds and Cardiometabolic Syndrome  
While the carcinogenicity of many of the VOCs of interest is relatively well 
established, very little is understood about the effect of VOCs on cardiometabolic 
syndrome. However, various links between aspects of CMS and exposures 
containing, or associated with, VOCs have been assessed in a variety of research 
discussed below. 
A systematic review of all studies published between 1950 and 2007 of 
associations between long-term exposure to ambient air pollution and the risks in 
adults of non-accidental mortality and the incidence and mortality from cancer and 
cardiovascular and respiratory diseases showed that a 10μg/m3 increase in long-
term exposure to PM2.5 was associated with a 6% increased risk of non-accidental 
mortality, independent of age, gender, and geographic region. The corresponding 
risk for cardiovascular disease was 12%–14% (129).  
A large cohort study of 57,053 participants of the Danish Diet, Cancer and 
Health cohort in the Hospital Discharge Register, assessed exposure to traffic 
related air pollution, which contains PM and VOCs, showed that traffic related air 
pollution contributes to non-specified fatal stroke (adjusted Hazard Ratio (HR): 
1.79 (1.19-1.49)) (130). A study assessing long-term exposure of PM2.5 found an 
incidence rate ratio (IRR) for hypertension of 1.48 (95% CI, 0.95-2.31) for every 
10-mg/m3 increase in PM2.5 and a corresponding IRR for diabetes mellitus of 1.63 
(95% CI, 0.78-3.44) (131). Additionally, a cross-sectional investigation of more 
than 8,000 participants recruited form a diabetes-screening study found a 
significant increase in odds of Type 2 Diabetes (T2DM) for individuals who lived 
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within 250 meters of a main roadway 1.44 (95% CI, 1.01-2.05) (132). Traffic-
associated excess cardiovascular mortality, assessed using single pollutant 
models has shown significant associations with excess increased risk of CVD 
mortality with exposure to propylene, benzene, and xylene (133). A large cohort 
study of more than 58,000 Toronto residents assessed VOC variation within urban 
areas, and showed associations with CVD mortality and exposure to benzene, 
hexane, and total hydrocarbon (126). An evaluation of the health effects of 72,000 
individuals living within half-a-mile of 258 Superfund sites found excessive rates of 
stroke and T2DM, these rates were associated with exposure to elevated level of 
VOCs, such as benzene in drinking water (134). A recent case-control study found 
an increase in cumulative traffic near the home was associated with a 4% increase 
in the odds of acute myocardial infarction (MI) per interquartile range (95% CI 2-
7%), and living near a major roadway was associated with a 5% increase in the 
odds of acute myocardial infarction (95% CI, 3-6%). Furthermore, a case-
crossover study of 2,134 myocardial infarctions, demonstrated a statistically 
significant association between concentrations of benzene and the onset of MI; the 
percent increase in risk of MI for a 1μg/m3 increase in ambient benzene 
concentration in the previous 0, 0-1 and 1 day before the MI was 10.4 (95% CI, 3-
18.2), 10.7 (95% CI, 2.7-19.2) and 7.2 (95% CI, 0.3-14.5), respectively (135). 
Acrolein is a well-established cardiovascular toxicant based on in vitro and 
in vivo studies (136). It is believed that acrolein generates free oxygen radicals the 
heart; which decreases endothelial nitric oxide synthase phosphorylation and nitric 
oxide formation, allowing for the formation of cytoplasmic and nuclear protein 
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adducts with myocyte and vascular endothelial cell proteins and causes 
vasospasm (136). Therefore chronic exposure to acrolein can cause myocyte 
dysfunction, myocyte necrosis and apoptosis, which ultimately would lead to 
cardiomyopathy and cardiac failure (136). While these pathways and effects have 
been well established in both in vitro and in vivo studies, rigorous epidemiologic 
investigations are needed to establish acrolein’s cardiovascular toxicity in humans 
(136). Acrolein has also been shown to play a role in the disruption of lipid 
metabolism and neurogenic inflammatory responses (137, 138). 
In a study of residential proximity to trichloroethylene-emitting sites, CHD 
risk was over three-fold greater among infants of exposed mothers compared to 
infants of none-exposed mothers (adjusted OR=3.2 (95% CI: 1.2-8.7)) and reports 
of trichloroethylene-exposures linked to diabetes have been published (139, 140). 
Occupational exposures to VOCs have also been associated with aspects 
of CMS. An Italian cohort analysis of 1,658 male workers exposure to vinyl chloride 
found associations with excess CVD (RR=2.25) (141). A prospective cohort study 
of vinyl chloride exposed workers found a marginally significance relative risk for 
CVD of 1.4 (95% CI: 1.0-1.8) for exposed persons as compared to non-exposed 
persons (142). In an evaluation of 25 liver biopsies of non-obese, highly exposed 
vinyl chloride workers it was found that the prevalence of steatohepatitis was 80%, 
indicative of toxicant-associated steatohepatitis, which is characterized by insulin 
resistance, elevated proinflammatory cytokines and normal liver enzymes (143). 
An epidemiologic study published in 2007 showed that a benzene exposed 
group had higher rates of hypertension than a non-exposed, control group but the 
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study did not monitor the concentration and/or extent of the benzene exposure 
(144). An age- and sex- matched case-control study of 345 petrochemical factory 
workers found increased odds of arterial hypertension with both benzene- and 
xylene- exposure 2.44 (95% CI, 1.24-4.85), 2.00 (95% CI, 1.11-3.61) respectively. 
Pathologic changes on electrocardiogram were also observed for both benzene 
and xylene-exposed subjects 2.34 (95% CI, 0.99-5.63), 2.75 (95% CI, 1.28-5.97) 
respectively (145).  
Excess mortality from ischemic heart disease in N, N-dimethylformamide-
exposed workers at an acrylonitrile fiber plant was observed. The investigation 
looked at workers in a plant exposed to N, N-dimethylformamide between1950 and 
1982 (146). Among the plant workers there were 62 deaths due to ischemic heart 
disease, which was significantly higher than expected (40.3 expected for company) 
(p-value< 0.01); However, the seemingly increased rate was not significant when 
compared with the state rates (146). Similarly a second group of 1,329 employees 
at a plant where workers were potentially exposed to both N, N-dimethylformamide 
and acrylonitrile observed a significantly higher number of deaths among workers; 
65 deaths among the plant workers, when 48.3 was expected for company (p-
value< 0.05) (146). However, again the observed number of deaths was not 
significantly higher than expected when compared to state or national rates (146). 
A small study in which electrocardiographic (ECG) monitoring was performed on 
workers at a synthetic leather plant where N, N-dimethylformamide was used 
found isolated ventricular premature beats after 2 hours of work, without 
pathological alterations (147). Reports of ECG changes, and cardiac disturbances, 
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including tachycardia and palpitations have also been reported in workers exposed 
to N, N-dimethylformamide (148-150). 
Cyanide exposure has been linked to diabetes through consumption of 
cassava and cassava workers exposed to hydrogen cyanide have been shown to 
have significantly higher triglycerides and atherogenic plasma; acute cyanide 
exposures have also demonstrated sever cardiovascular disruption (151-153). 
One report of chronic carbon disulfide exposure causing severe vascular 
disease has been published and a critical review of epidemiologic literature 
conducted in 2002 found consistent reports of associations with carbon disulfide 
exposure and dyslipidemia (154, 155). Carbon disulfide poisoning has also been 
shown to significantly increase the risk of metabolic syndrome in Korean viscose 
rayon factory workers (prevalence ratio=1.57 (95% CI: 1.25-1.98)) (156). 
1,3-Butadiene has well established laboratory and epidemiologic 
associations with cardiovascular disease as well as atherosclerosis and cardiac 
injury (157). A longitudinal epidemiologic investigation found significant 
associations between occupational exposure to 1,3-butadiene and CVD (157). In 
an analysis of mortality data, collected from more than 12,000 male workers at 
eight 1,3-butadiene-styrene polymer manufacturing plants in the U.S. and Canada 
from 1943 to 1982, a significant increase in the standardized mortality ratio for 
arteriosclerotic heart disease (SMR= 1.48) was found among black maintenance 
workers, as compared to the levels expected from those for the general population 
(158). 1,3-Butadiene has also been shown to significantly increase atherosclerotic 
plaque size in multiple in vivo and in vitro studies (157, 159, 160). Taken together, 
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these studies suggest that VOC exposure might be an important contributing factor 
to CMS risk. 
Cardiometabolic Syndrome 
Many studies have demonstrated the mounting problem posed by 
cardiometabolic syndrome both within the United States and worldwide (161-169). 
Given the associated monetary costs (U.S.: 80 billion dollars annually) and 
dramatically effected quality and longevity of life for those affected it is important 
to understand the driving factors of CMS, areas for future research, and how public 
health, clinical, and research communities may address this growing issue in our 
society (170). 
Definition of Cardiometabolic Syndrome 
Cardiometabolic syndrome (CMS) is a combination of maladaptive 
cardiovascular, renal, metabolic, prothrombotic, and inflammatory abnormalities 
that independently and interdependently dramatically increases an individual’s 
cardiovascular disease (CVD) risk (1). The increased CVD risk associated with 
CMS has been shown to be a significant predictor of premature and severe CVD, 
coronary heart disease, myocardial infarction, and stroke and therefore highly 
associated with increased CVD morbidity and mortality (1). 
There is no universally accepted definition of CMS. To date at least five 
organizations have proposed clinical criteria for diagnosing CMS (24). The most 
common characteristics for defining CMS are abdominal obesity (high body mass 
index (BMI), waist circumference, waist-to-hip circumference ratio (WHR)), insulin 
resistant glucose metabolism (hyperinsulinemia, impaired fasting glucose, 
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impaired glucose tolerance, type II diabetes (T2DM)), dyslipidemia (high serum 
triglyceride and low serum high-density lipoprotein-cholesterol concentrations), 
and increased blood pressure. The criteria proposed by the World Health 
Organization (WHO) are the most widely accepted criteria, and will be utilized as 
the criteria of interest in this paper (Table 1.2) (24). 
The WHO defines CMS as the presence of dysglycemia, which is abnormal 
blood glucose levels (measured by impaired fasting glucose (IFG)/ impaired 
glucose tolerance (IGT)/ T2DM)), plus 2 or more of the following criteria: visceral 
obesity (measured as; men: >0.90 WHR or BMI ≥30 kg/m2, women: >0.85 WHR 
or BMI ≥30 kg/m2), dyslipidemia (classified by elevated triglycerides (≥1.7mmol/L)) 
and low HDL-cholesterol (defined as men: <0.9 mmol/L, women: <1.0 mmol/L), 
hypertension (≥140/90 mm Hg), and/or the presence of Microalbuminuria (defined 
as urinary excretion ≥ 20≥ 20 µg/min or Albumin:Creatinine ratio ≥30 mg/g (24). 
Table 1.2. World Health Organization Definition of Cardiometabolic Syndrome 
Condition WHO* 
1. Dysglycemia IFG/IGT/T2DM 
2. Visceral obesity
Men >0.90 WHR and/or BMI >30 kg/m2 
Women >0.85 WHR and/or BMI >30 kg/m2 
3. Triglycerides ≥1.7 mmol/L (150 mg/dL) 
4. HDL-cholesterol
Men <0.9 mmol/L (35 mg/dL) 
Women <1.0 mmol/L (39 mg/dL) 
5. Hypertension ≥140/90 mm Hg 
6. Microalbuminuria
Urinary albumin excretion ≥ 20 µg/min or 
Albumin:Creatinine ratio ≥30 mg/g 
IFG=impaired fasting glucose; IGT= impaired glucose tolerance; T2DM=type 
2 diabetes mellitus; WHR=waist-to-hip circumference ratio 
*IFG/IGT/T2DM plus 2 or more criteria
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Dysglycemia 
Dysglycemia is a broad term used in reference to any abnormalities in blood 
glucose levels (171). Dysglycemia is often tested with the impaired fasting glucose 
(IFG) test and impaired glucose tolerance (IGT) test (24, 171). IFG is defined as 
an elevated fasting plasma glucose (FPG) concentration (≥100 and <126 mg/dl) 
and IGT is defined as an elevated two hour plasma glucose concentration (≥140 
and <200 mg/dl) after a 75 gram glucose load on the oral glucose tolerance test in 
the presence of an FPG concentration <126 mg/dl (172). Both the IFG and IGT 
are early indicators of abnormal glucose metabolic abnormalities that precede 
diabetes (172). Diabetes is a group of diseases marked by high levels of blood 
glucose resulting from insulin dysfunction.  Current estimates indicate that up to 
70% of individuals with IFG or IGT in a pre-diabetic state will eventually develop 
T2DM, (172) hence the WHO criteria of displaying an abnormal IFG or IGT test or 
having been diagnosed the T2DM (172). A diagnosis of T2DM encompasses they 
presence of dysglycemia (171). 
There are two main classes of diabetes: type I and type II diabetes: type I 
diabetes, which accounts for approximately 5% of all adult diabetes, is due to a 
limited or eliminated production of insulin by the beta cells in the pancreas (173). 
Type II diabetes, which accounts for 95% of diagnosed diabetes cases, is a result 
of insulin resistance, which can lead to a gradual loss of the ability of the beta cells 
in the pancreas to produce enough insulin as the insulin demand from 
malfunctioning cells rises (174). There are other types of diabetes that result from 
other medical complication such as surgery, medications, infections, pancreatic 
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disease, pregnancy, or other illnesses, but these forms of diabetes are rare and 
only account for 1-5% of all diagnosed diabetes cases (173, 174). 
Other common indicators of dysglycemia are the hemoglobin A1c (HbA1c) 
test and the homeostasis model assessment of insulin resistance (HOMA-IR) 
score. HbA1c is used to measure long-term (2-3 months) blood glucose stability 
(175). A recent study suggests that an HbA1C ≥6.0% approximately doubles the 
rate of progression to diabetes in the IFG/IGT population (176). The ‘homeostasis 
model assessment of insulin resistance’ (HOMA-IR) is an insulin resistance and 
sensitivity indices. An insulin resistance score is calculated using the HOMA-IR 
indices and is calculated by multiplying an individual’s fasting plasma glucose 
(mmol/l) by his/her fasting serum insulin (mU/l) and then dividing that by 22.5 (177). 
Visceral Obesity 
Visceral obesity is associated with insulin resistance; however, causation 
has not been established (i.e. it is not known if visceral obesity is a causal factor 
of insulin resistance or if visceral obesity and insulin resistance are simply 
associated). While visceral fat is only a small percentage of total body fat (10-15%), 
it has been postulated to play a strong role in insulin resistance due to direct portal 
vein entry of fatty acids during lipolysis, which delivers fatty acids directly to the 
liver (178). 
Measures of visceral obesity that have been established as predictors of 
CVD and CMS are body-mass index (men: BMI ≥30 kg/m2, women: BMI ≥30 
kg/m2), waist-to-hip circumference ratio (WHR) (men: WHR >0.90, women: WHR 
>0.85), and waist circumference (WC) (men: WC ≥94cm or >102cm, women: WC 
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≥ 80cm or >88cm) (179, 180). It is recognized that abdominal fat mass, also 
referred to as central visceral fat, can also be an important consideration in 
identifying individuals with increased risk of obesity-related morbidity and mortality.  
Waist-to-hip ratio is an index of both subcutaneous and intra-abdominal 
adipose tissue distribution and has long been shown to be a good, noninvasive, 
anthropometric indicator of abnormal adiposity and increased disease risk. In 1997 
the WHO Expert Consultation on Obesity convened to discuss the efficacy of WHR 
and WC as additional measures in assessing risk. In 2000 the WHO suggested 
waist-to-hip ratio and waist circumference as additional measures to BMI, to aid in 
discerning body fat distribution. 
A longitudinal cohort study, published by Larsson et al. in 1984, showed 
that waist-to-hip ratio in men was better at distinguishing increased risk of 
myocardial infarction, stroke, and premature death, than BMI (181). In women BMI 
was more associated with increased risk; however the study found that WHR was 
a stronger independent indicator of risk than BMI (181). Additionally, a recent study 
found that WC is a better indicator of CVD risk than BMI and proposed WC cut-
point values that are more sensitive than the BMI cut-points for predicting CVD risk 
(179).  
While waist-to-hip ratio and waist circumference have proven to be a 
valuable tool in assessing risks associated with abnormal fat mass; the cut-points 
for diagnosing abnormal fat mass have been highly variable. The variability in the 
cut-point definitions is a result of the fact that WHR and WC cut-points are 
dependent on population characteristics (sex, age, ethnicity) and the outcome of 
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interest, whether that be increased risk of CVD, diabetes, or overall mortality. The 
2008 Waist Circumference and Waist-Hip Ratio report of a WHO Expert 
Consultation summarizes the complexities of defining cut-points and the existing 
evidence to support recommended cut-point action levels (182). While population-
specific cut-points may be useful, at the present time the WHO consultation 
reported too many unresolved issues in defining population-specific cut-points and 
opted for simple and universally applicable cut-points. The WHO consultation 
agreed that BMI, WHR, and WC are all predictive of the risk of chronic disease 
and may therefore be used independently or in conjunction with BMI (182, 183). 
The report indicates that a BMI of 30 is comparable in increased disease risk to a 
waist circumference of >94cm for men and >80cm for women and a substantially 
increased risk at >102cm for men and >88cm for women and a waist-to-hip ratio 
of cut-point of 0.91 for both me and women (Table1.3) (182, 183). The 
designations “increased” risk and “substantially increased” risk, referenced to in 
Table 1.3 and designated in the WHO report are based on the increased relative 
risks observed in a Netherlands study of a random sample of 2,183 men and 2,698 
women aged 20-59 years. The Netherlands study found that compared with 
individuals below the identified waist measurement cut-points, the age and lifestyle 
adjusted odds ratios for having at least one cardiovascular risk factor (total 
cholesterol > or = 6.5 mmol/l, high density lipoprotein cholesterol < or = 0.9 mmol/l, 
systolic blood pressure > or = 160 mm Hg, diastolic blood pressure > or = 95 mm 
Hg) was 2.2 (95% CI, 1.8-2.8) in men with a waist measurement of 94-102 cm and 
1.6 (95% CI, 1.3-2.1) in women with a waist measurement of 80-88 cm. In men 
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and women with larger waist measurements these age and lifestyle adjusted odds 
ratios were 4.6 (95% CI, 3.5-6.0) and 2.6 (95% CI, 2.0-3.2) respectively (184). 
The International Diabetes Federation recommends WC cut-points of 
>94cm for men and >80cm women of European descent, and >90cm for men and 
>80cm for women of South Asian, Chinese and Japanese descent (180, 185, 186). 
The recommendations made by the United States National Cholesterol Education 
Program (NCEP) of the NIH’s National Heart, Lung, and Blood Institute are a single 
set of sex-specific cut-point of >102cm for men and >88cm for women (122). 
It is recommended that WC or WHR be used in conjunction with BMI, as 
increased waist circumference can also be a marker of increased risk even in 
person of normal weight (187). Furthermore, increases in WC have been shown 
to be useful predictors of changes in CVD risk (188). 
Table 1.3. World Health Organization Cut-Points and Risk of Metabolic 
Complications (182, 184) 
Indicator Cut-point Risk of Metabolic 
Complications 
Waist circumference >94cm (M); >80cm (W) Increased 
Waist circumference >102cm (M); >88cm (W) Substantially increased 
Waist-hip ratio ≥0.90cm (M); ≥0.85cm (W) Substantially increased 
Body Mass Index >30.0 kg/m2 Substantially increased 
*M, men; W, women
Dyslipidemia 
Atherosclerotic cardiovascular disease (CVD) risk and diabetes mellitus risk 
are significantly increased in patients with CMS. The increased risk is due to insulin 
resistance and atherogenic dyslipidemia (189). Atherogenic dyslipidemia is 
defined as the presence of low high-density lipoprotein (HDL) cholesterol and high 
triglyceride levels (79, 190). 
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Alterations in free fatty acid metabolism are theorized to have a major role 
in the pathogenesis of dysglycemia and dyslipidemia associated with 
cardiometabolic syndrome (24). It is thought that increased plasma free fatty acids 
may impair the ability of insulin to stimulate muscle glucose uptake and suppress 
hepatic glucose production (24). Increased free fatty acid in the liver increases very 
low-density lipoprotein (vLDL) production and plasma triglyceride concentrations 
(24). The increase in plasma triglyceride concentration increases the rate of vLDL 
to HDL transfer, thereby increasing the overall HDL clearance and decreasing 
plasma HDL concentrations (24). Plasma HDL cholesterol concentrations are 
tested with a simple blood test. The WHO criteria for HDL-cholesterol as a risk 
factor for cardiometabolic syndrome is <0.9 mmol/L, for men and <1.0 mmol/L for 
women (1). The WHO criteria for increased plasma triglycerides is, ≥1.7 mmol/L, 
which has been shown to be a significant predictor for increased risk of developing 
cardiometabolic syndrome and is associated with increased CVD morbidity and 
mortality (24).   
Hypertension 
Insulin resistance and hypertension have a long-standing, well-established 
relationship and the mounting evidence of a linear relationship between blood 
pressure and cardiovascular mortality and interaction between hypertension and 
diabetes support a strong association between hypertension and several vascular 
and metabolic abnormalities that are components of the cardiometabolic 
syndrome. A recent report stated more than 80% of hypertensive patients present 
with at least one associated metabolic risk factor (58, 88). 
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In clinical terms, hypertension is recognized as having elevated systolic 
and/or diastolic blood pressure. Each hypertensive stage definition and criteria are 
included below (51): 
• Stage one hypertension: Systolic blood pressure from 140-159 mm
Hg or a diastolic blood pressure of 90-99 mm Hg (51). 
• Stage two hypertension: Systolic blood pressure over 160 mm Hg or
a diastolic pressure over 100 mm Hg (51). 
Individuals who exhibit resistance to insulin have a decreased or 
even a complete loss of the vasodilatory effects of insulin (which in normal 
functioning individual, insulin acts as a vasodilator) (24). Individuals who have a 
decreased vasodilatory effect often maintain sodium reabsorption, leading to a 
significantly increased blood pressure (191). It has been shown that 25-47% of 
patients with hypertension are also insulin resistant and/or have IGT, providing 
epidemiologic support that hypertension and insulin resistance may be causally 
related (1). 
Microalbuminuria 
Microalbuminuria has been associated with visceral obesity, dyslipidemia, 
and dysglycemia (1). Clinically, microalbuminuria is recognized as urinary 
excretion of albumin of 20 to 200 μg/min (30–300 mg/d). Microalbuminuria is used 
as a predictor of CVD and premature CVD mortality.  According to a recently 
published article in Diabetes Care, which investigated 3,606 subjects with and 
without metabolic syndrome, researchers found that microalbuminuria is the most 
strongly associated cardiometabolic syndrome criteria among all subjects who 
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died from cardiovascular disease (relative risk: 2.80 (95% CI, 1.62-4.83)) (1, 192). 
Despite the very strong association between microalbuminuria with CVD the 
mechanism is still not understood (1). 
Cardiometabolic Syndrome Descriptive Epidemiology 
Cardiometabolic syndrome (CMS) has become a major problem in the 
United States and worldwide. An analysis of data from the National Health and 
Nutrition Examination Survey (NHANES III) (1988-1994), found the age-adjusted 
rate of CMS in the United States was approximately 24% of the adult population 
(non-institutionalized U.S. population over the age of 20) (54, 118). This study 
found that among the U.S. male population, white and Mexican Americans had the 
highest prevalence of abdominal obesity, hypertriglyceridemia and low HDL levels, 
while African American males had the highest hypertension rates (age-adjusted) 
(118). Among the female U.S. population, Mexican Americans and African 
Americans had the highest rates of obesity (age-adjusted), while Mexican 
Americans had the highest rates of hypertriglyceridemia and low HDL levels, and 
hyperglycemia (118). The study found that prevalence of CMS differed by race 
with the highest prevalence being found in the Mexican American (31.9%) 
population, and the lowest rates in the White (23.8%) and African American 
(21.6%) populations (54). The study also suggested a linear relationship exists 
between CMS and age with a prevalence of approximately 7% for 20-29 year olds 
and 45% of individuals over the age of 60 (54). Notably, this study also suggests 
that CMS prevalence is steadily increasing (54). It has also been shown that rates 
have of CMS have been steadily increasing the U.S. A study published in 2004 
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compared CMS prevalence from NHANES 1988-1994 with NHANES 1999-2000 
and found that age-adjusted prevalence was 24.1 and 27.0% respectively (101). 
Other analyses of more recent NHANES data have published adult (≥20 years of 
age) U.S. age–adjusted prevalence rates ranging from 35-39% (46, 74, 109). It 
has also been shown that the prevalence of CMS dramatically increases with age. 
One study found that the prevalence increased from 6.7% among participants 
aged 20 through 29 years to 43.5% and 42.0% for participants aged 60 through 69 
years and aged at least 70 years, respectively (118). 
It is very common that individuals who have been diagnosed with one 
cardiometabolic syndrome risk factor, such as IFG and IGT, will present with or 
develop multiple associated CVD and CMS risk factors. A recent analysis of 
overweight subjects (BMI ≥25) aged 45 to 74 years found that 17.1% of had IGT, 
11.9% had IFG, 22.6% had prediabetes, and that 5.6% of subjects had both IGT 
and IFG (193). The study determined 12 million people age 45-74 in the U.S. have 
dysglycemia that will likely evolve into T2DM (1). These individuals along with other 
insulin resistant individuals have been shown to have a nearly threefold increase 
of CVD and stroke incidence (1). Often individuals with insulin resistance and 
dysglycemia manifest other components of CMS, which amplify the CVD morbidity 
and mortality (163). 
Cardiometabolic risk factors are increasingly acquired at alarming rates in 
the United States. A study of NHANES data showed a substantial increase of more 
than 3% in the median childhood BMI (ages 6-17) from two different study periods 
(1963-1970 and 1988-1994) (113). It has been estimated that by 2030 the rate of 
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diabetes in the U.S. will have risen from 17.7 million in 2000 to nearly 30.3 million 
(5). 
Currently T2DM afflicts 9.3% of the U.S. population, (29.1 million people), 
and is responsible for over 73,000 deaths per year (174). The prevalence of IFG 
and IGT in the U.S. are currently estimated to be approximately 26% and 15% 
respectively, but expected to steadily increase (172). Estimates of adult (age 20 to 
74 years) dyslipidemia rates in the U.S. are approximately 36%, while the 
prevalence of hypertension in the U.S. is estimated at 24-29% of the adult 
population (≥20years) (70, 96, 164, 165, 194, 195). The prevalence of creatinine 
normalized microalbuminuria was found to be 6.1% in the U.S. male population 
and 9.7% in the U.S. female population in an analysis of NHANES participants 20 
years of age and older (196). 
Risk Factors, Potential Covariates and Effect Modifiers 
Cardiovascular and diabetic diseases encompassed in the definition of 
cardiometabolic syndrome are the leading and preventable causes of death 
worldwide (161). Currently, the leading preventable risk factor associated with 
these diseases is tobacco smoke exposure (161). While tobacco smoke exposure 
has declined over the past half-century, it is estimated that over 34 million 
Americans still use tobacco (161, 197). Tobacco smoke exposure is cited as the 
number one preventable risk factor of CVD, CMS, and metabolic syndrome and is 
included in nearly all publications and analysis of these conditions (161). Increased 
odds of metabolic syndrome have been observed in currently smoking individuals 
as compared to individuals self-reporting they are nonsmokers (198). An analysis 
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of individuals included in the National Health and Nutrition Examinations 1988-
1994 found that currently smoking men have a 1.5 times greater odds (95% CI, 
1.1-2.2) of having CMS compared with men who report never smoking and 
currently smoking women have a 1.8 times greater odds (95% CI, 1.2-2.6) of 
having CMS compared with women who report never smoking (198). It is currently 
hypothesized that cigarette smoke is linked to cardiometabolic syndrome through 
its effect on insulin resistance (198). 
Cardiometabolic syndrome is thought to develop as a result of both genetic 
factors and acquired/environmental factors. It is hypothesized that genetic factors 
predispose individuals to magnified effects of environmental exposures, which in 
conjunction amplify the effects if cardiovascular and metabolic adversities (199). It 
is unutterably difficult to parse out all the covariates that could be considered for 
this analysis, as many may not be known. Of the immense number of potential 
covariates that could be considered, several of those deemed most significant are 
discussed below. 
Each of the factors associated with developing cardiometabolic syndrome 
have no shortage of covariates associated with their onset. Covariates that have 
been assessed previously for their association with increased risk of 
cardiometabolic syndrome are: socioeconomic status, sex, age, ethnicity, alcohol 
consumption patterns, physical activity, BMI, dietary habits, and for women 
menopausal status (198, 200, 201). A recent analysis of adults (≥20 years old) who 
met the criteria for metabolic syndrome among NHANES data estimated the 
prevalence of metabolic syndrome to be similar among men and women, with a 
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slightly elevated relative risk in postmenopausal versus premenopausal women 
(198). The risk of cardiometabolic syndrome and related complications increases 
with age. Evidence suggests that peak prevalence for the onset of cardiometabolic 
syndrome is around 60 years of age (198). Also, rates of cardiometabolic 
syndrome are highly stratified by ethnicity with black men having the lowest rates 
(13.9%) and Mexican Americans women having the highest rates (27.2%) (202). 
BMI is also a very highly associated factor for the development of cardiometabolic 
syndrome (198). In an NHANES analysis only 6% of normal weight adults meet 
the diagnostic criteria for metabolic syndrome, while 60% of moderately obese 
individuals (BMI ≥ 30) meet the diagnostic criteria for metabolic syndrome (198). 
Numerous studies have linked socioeconomic status and education level with 
various cardiovascular risk factors including impaired glucose tolerance, diabetes, 
obesity, hypertension, and smoking rates (79, 169, 198, 203, 204). 
Epidemiologically, low to moderate consumption of alcohol has been shown 
to decrease risk of cardiovascular disease possibly due to the beneficial alteration 
of HDL and blood pressure (202). The same decreased risk associated with low to 
moderate alcohol consumption has been shown to reduce metabolic syndrome 
potentially due to the same beneficial alteration of HDL and blood pressure (202). 
It has been shown that a diet high in carbohydrates increases the risk of 
cardiometabolic syndrome (198). 
Comorbidities  
There are a large number of comorbidities associated with CMS. Diabetes, 
one of the diseases defined within CMS affects many parts of the body. Diabetes 
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is associated with an increased risk of heart disease, stroke, blindness, kidney 
failure, microvascular disease, and lower-limb amputation (189). People with 
diabetes also have an increased risk of developing, non-alcoholic fatty liver 
disease, periodontal (gum) disease, hearing loss, erectile dysfunction, depression, 
and complications during pregnancy (174). A recent study conducted in Spain of 
more than 1,800 hypertensive patients, found that 50–70% and patients with 
metabolic syndrome also had hypertension (189). CMS often progresses to CVD. 
CMS and CVD share many comorbidities and risk factors. Cancer has recently 
been identified as a comorbidity of CVD. This is a recent finding but it is reasonable 
to assert that if CVD and cancer are comorbid conditions and CMS is often a 
precursor to CVD than CMS and cancer may also be comorbid conditions, 
especially given the common shared risk factors (poor diet, smoking, obesity, and 
diabetes) (205). 
Summary 
The relative importance of environmental exposures such as volatile 
organic compounds is one of the paramount public health priorities of our time, yet 
is presently unstudied and effectively unknown. CMS, a collection of dysfunctional 
cardiovascular and metabolic functions, is associated with an abundance of 
comorbidities and dramatically increases ones risk of CVD morbidity and mortality. 
The consequences of CMS are severe both socially and economically. A number 
of studies have found associations between numerous health effects, including 
both cardiovascular and metabolic outcomes and individual VOCs; however, to 
date there have been no investigations of the associations between VOCs and 
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CMS at a population level, nor have there been any investigations of the 
combinatory effects of the VOCs of interest with CMS. Exposures relating to or 
associated with VOCs have previously been significantly associated with 
hypertension, atherosclerosis, type II diabetes, stroke, and CVD mortality. 
However, the specific components of the broad classification-exposures (e.g., PM 
or “traffic-associated” exposure) assessed in these investigations that may be 
primarily responsible for these adverse health effects have not been identified. This 
study is a novel investigation of nationally representative individual-level data, 
which will interrogate associations between CMS and VOCs, from both an 
individual VOC exposure perspective and a multipollutant exposure perspective. 
The findings from this investigation are relevant and important for the development 
of public health interventions and policies surrounding modifiable environmental 
pollution exposures and their potential role in CMS, a condition which ultimately 
greatly increases one’s risk of the deadliest non-communicable disease in the 





Source of Study Population- National Health and Nutrition Examination Survey 
(NHANES) 
The National Health and Nutrition Examination Survey (NHANES) is a 
cross-sectional, nationally representative survey of the non-institutionalized civilian 
population in the United States and is designed to assess the health and nutritional 
status of adults and children in the country (206). NHANES is conducted by the 
National Center for Health Statistics (NCHS; Centers for Disease Control and 
Prevention (CDC), Atlanta, GA), which is part of the CDC and is responsible for 
producing vital and health statistics for the nation. 
The National Health and Nutrition Examination Survey began in 1960, as 
the National Health Examination Survey. In 1971 a nutritional assessment and an 
environmental component were added to the survey thus assuming the name The 
National Health and Nutrition Examination Survey. NHANES I was conducted from 
1971 to 1975 and a subset of this phase of NHANES, consisting of individuals over 
the age of 25, which became a longitudinal follow-up study through1992 known 
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as the NHANES I Epidemiological Follow-up Survey (NHEFS). NHANES II was 
conducted from 1996 to 1980, NHANES III was conducted from 1988 to 1994, and 
in 1999 NHANES became a continuous annual survey, with data released to the 
public in 2-year intervals. The continuous NHANES assessment utilizes multistage 
stratified probability sampling of approximately 5,000 persons throughout fifteen 
counties across the U.S. each year. The multistage stratified probability sampling 
is based on selected counties, blocks, households, and individuals. Over sampling 
of certain vulnerable population, such as, non-Hispanic black individuals, Hispanic 
individuals, low-income white individuals, and older adults, 80 and older, is 
necessary to ensure estimates of these groups are adequately representative. The 
NCHS Research Ethics Review Board approves the NHANES study protocols and 
all participants provide written informed consent. 
NHANES is the only national survey that collects extensive health and 
nutrition information from face-to-face interviews and medical examinations. The 
interview portion of NHANES includes demographic, socioeconomic, dietary, and 
health-related questions, while the examination component consists of medical, 
dental, and physiological measurements, as well as laboratory tests. 
NHANES is designed to produce statistics for a nationally representative 
sample and is a complex, continuous survey. Therefore, design-based analytic 
procedures must be explicitly considered and features of the survey design, such 
as differential selection probabilities and geographic clustering considerations 
need be considered in the analysis. The product of a properly weighted NHANES 
analysis results in statistics that are generalizable to the national residential civilian 
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noninstitutionalized U.S. population. 
The primary design-based components of the NHANES survey that must 
be accounted for when conducting an analysis to generate nationally 
representative results are the clustering variable or the primary sampling unit 
(PSU), the weight variable or the two-year sample weight, and the stratification 
variable or stratum. The primary sampling units are counties or small groups of 
contiguous counties across the US. From the approximately 15 counties or PSUs 
visited each year a block containing a cluster of households is selected and 
specific addresses from the cluster is then chosen (207). Primary sampling units 
always include all four regions of the U.S. as well as metropolitan and 
nonmetropolitan representatives. Each selected address is contacted by a field 
interviewer who conducts a screener to enumerate the household and to determine 
the eligibility of individuals in the household for the survey. Eligibility is based on 
each individual in the households age, sex, race/ethnicity and income. Based on 
the screening information collected, a computer algorithm randomly selected one, 
some, all, or none of the individuals in the household to participate in the survey. 
On average 12,000 individuals are selected to participate, 10,500 individuals agree 
to complete the household survey, and 10,000 persons participate in data 
collection in the mobile exam center (207). A weight variable is assigned to every 
person and is considered a measure of the number of people in the U.S. 
represented by that particular sample participant. For example, if a man in the 
sample represents 12,000 men in his race and ethnicity-income-age category, then 
his sample weight to begin with is 12,000. The weighting variable takes into 
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account the differential probability of selection for the individual domains, 
nonresponse to survey instruments, and differences between the final sample and 
the total population (207). 
The first step in assigning a sample weight is to compensate for the unequal 
probability of selection, given that some groups are oversampled. Next, the 
weighting variable is adjusted for participant nonresponse and finally the sample 
weights are post-stratified to match the noninstitutionalized U.S. population as 
represented by the U.S. Census Bureau (208). Stratification is the partitioning of a 
population of sampling units into exclusive categories (208). Stratification is used 
in NHANES for subpopulation analysis to increase the precision of estimates (208). 
Research organizations, universities, healthcare providers and educators 
frequently use NHANES data to train, research, and educate. However, the 
primary users of NHANES data are the National Institutes of Health (NIH), the 
Food and Drug Administration (FDA), the CDC and various other governmental 
agencies. These agencies rely on NHANES to assess the implementation and 
evaluation of various national programs and policies. Some of the most important 
accomplishments to date of NHANES have included national and global growth 
chart reference standards, blood lead level standards and policy to eliminate lead 
from gasoline and foodstuffs, national prevalence of overweight and diabetes and 
means of tracking national obesity and diabetes trends, national vitamin and 
mineral fortification regulations, identification of vulnerable populations for 
targeting national programs to reduce hypertension and cholesterol levels, and the 
development of new measures of lung function to help better describe the burden 
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of asthma in the United States (209-215).   
Volatile Organic Compounds in NHANES  
The continuous NHANES survey has a changing focus on a variety of health 
and nutrition measurements to meet emerging needs. Through a partnership with 
the U.S. Environmental Protection Agency, NHANES has provided a platform for 
continued study of many important environmental influences on health. Three data 
release cycles, 2005/2006, 2011/2012, and 2013/2014 have included a urinary 
analysis of volatile organic compound metabolites in a subset of participants.  
The metabolites were quantified using ultra performance liquid 
chromatography coupled with electro spray tandem mass spectrometry (UPLC-
ESI-MS/MS) (25). Chromatographic separation is achieved in a column with 15 
mM ammonium acetate and acetonitrile as the mobile phases. The eluent from the 
column is then ionized using an electrospray interface to generate and transmit 
negative ions into a mass spectrometer. Comparison of relative response factors 
(ratio of native analyte to stable isotope labeled internal standard) with known 
standard concentrations yield the individual analyte concentrations. 
To the best of my knowledge only a handful of peer-reviewed publication 
have been published which utilized the NHANES urinary metabolites of VOCs 
(UM-VOCs) dataset. Four studies specifically address UM-VOC levels in children, 
one assesses differences in UM-VOCs in premium and discount cigarettes, and 
one analyzes UM-VOCs in marijuana users (216-220). Additionally, one study 
published in environmental toxicology and pharmacology in 2015 used the 
NHANES urinary metabolites of VOCs data to show that the distribution of 19 
76 
urinary metabolites differs among some age, race, gender, and smoking 
demographic subsections (32). More specifically smokers were found to have 
significantly higher adjusted metabolites of acrolein, acrylamide, acrylonitrile, 1,3-
butadiene, carbon-disulfide, crotonaldehyde, cyanide, N,N-dimethylformamide, 
ethylbenzene-styrene, propylene oxide, styrene, and xylene as compared to non-
smokers (32). Female nonsmokers had lower adjusted levels of acrolein, carbon-
disulfide, and N,N-dimethylformamide metabolites than male nonsmokers but 
female smokers had higher levels of each of the metabolites than male smokers 
(32). Additionally, female smokers also had higher adjusted levels of 1,3-
butadiene, crotonaldehyde, cyanide, and ethylbenzene/styrene metabolites as 
compared to male smokers (32). Suggesting males and females metabolize and 
excrete some VOCs differentially. The study also reported that non-Hispanic 
whites had higher adjusted levels of 8 metabolites compared with non-Hispanic 
blacks and non-Hispanic blacks had significantly lower adjusted levels than 
Hispanics for 5 VOC metabolites and lower levels than non-Hispanic Asians for 6 
metabolites (32). Hispanics had statistically higher levels than non-Hispanic 
Asians for 5 metabolites (32). Importantly the paper reported that levels of 11 
metabolites increased with age (32). 
Other methods of assessing VOC exposures have been employed in 
NHANES as well. Several studies have been published using serum VOC data. 
Cigarette smoke exposure has been established as a primary source of exposure 
for benzene, toluene, and styrene and an important source of exposure for xylene 
and ethylbenzene, showing clear dose-response relationships in NHANES data 
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sets (33, 221). Marijuana use has also been established as a significant source of 
VOC exposure via serum VOC measurements from participants of the 2005-2012 
NHANES surveys (220). NHANES serum VOC measurements have also been 
shown to have a positive dose-response effect with self-reported daily alcohol 
consumption (221). 
A study assessing the effects of serum VOC measurements on 
neurobehavioral performance used principal component analysis to group 10 
blood VOCs into 3 principle components mixtures, these three mixture principle 
components were used in quantile and ordinary least regression models. The 
study found impaired reaction times in the 90th percentile of exposure (222). A 
study characterizing the national trends in VOCs from 1988-2004 utilized 
occupational and cotinine adjusted linear quantile models to show that while trends 
varied by VOC, there were overall decreasing tends for all quartiles of VOCs on 
the nation (223). For example, it was estimated that for m,p-xylene and 
tetrachloroethene there was a median exposure declined of 2.5 and 6.4 percent 
per year over the 15-year period, respectively (223). This pattern most probably 
reflects national occupational exposure regulations and general environmental 
regulations implemented during the time period (223). 
Another method NHANES has used to assess VOC exposures is via 
passive air monitoring. In the 1999-2000 NHANES cohort, 851 participants wore 
passive exposure monitors for 48-72 hours, from which 10 VOCs were measured 
(207). A study using this data, published in 2014, found that overall, personal 
exposure was dominated by the home setting, although a large fraction of indoor 
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VOC concentrations were due to outdoor sources (224). Another study looking at 
the 1999-2000 passive exposure monitoring dataset found that males had higher 
mean levels of all VOCs except toluene and benzene and that exposures were 
elevated in smokers and Hispanics (225). The study also found results which 
suggest that having an attached garage, closed windows, pumping gasoline and 
use of paint thinners results in higher exposure to VOCs (225). An analysis which 
built multiple linear regression models with the 1999-2000 passive exposure 
monitoring dataset to investigate the relationships between VOC levels in air and 
blood, while adjusting for effects of smoking and demographic factors, found that 
while levels of VOCs in blood were positively correlated with the corresponding air 
levels, the strength of association (R2) widely varied (0.02-0.68) (226). 
A study assessing the associations between VOC exposures and asthma 
utilized factor analysis coupled with multiple logistic regression in the 1999-2000 
passive exposure monitoring dataset. The study found the odds of physician-
diagnosed asthma was significantly higher among those exposed to aromatic 
compounds, adjusted OR=1.63 (95% CI, 1.17-2.27), and a significant increase in 
odds was observed for one to two wheezing attacks for aromatic compounds, 
adjusted OR=1.68 (95% CI, 1.08-2.61) and chlorinated hydrocarbons, adjusted 
OR=1.50 (95% CI, 1.01-2.23) as compared to no wheezing (227). Another study 
which employed factor analysis and the 1999-2000 passive exposure monitoring 
dataset identified four common exposure sources: gasoline vapor and vehicle 
exhaust, methyl tert-butyl ether (MBTE) as a gasoline additive, tap water 
disinfectant products, and household cleaning products (228). 
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NHANES VOC measurements have also been used to verify national mean 
levels of VOCs in various studies, to derive population-based blood/air distribution 
coefficients and to assess extreme values distributions (30, 229-232).   
Study Population 
All three waves of the National Health and Nutrition Examination Survey 
(NHANES) with data for urinary metabolites of volatile organic compounds (UM-
VOCs), 2005-2006, 2011-2012, and 2013-2014 were used in the analysis for the 
current study. Participants with available UM-VOC data were compiled/appended 
(n05/06 = 3,516, n11/12= 2,551, n13/14= 2,724, N= 8,791). This analysis was limited to 
individuals who were twenty years of age or older (n=6030) and who have data 
available for all components of CMS (n=7070). Individuals who were pregnant 
(n=233) or breastfeeding (n=49) at the time of sample collection or who have 
diagnosed cardiovascular disease (n=614) were excluded (Figure 2.1).  
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Figure 2.1. Schematic diagram depicting inclusion/exclusion criteria for 2005-
2006, 2011-2012, and 2013-2014 NHANES subjects used to generate the study 
populations for further analysis.  
To combine, or append the 2005-2006, 2011-2012, and 2013-2014 
NHANES cohorts a new weighting variable was calculated. The 2005-2006 UM-
VOC cohort was from a ½ sample of the full 2005-2006 NHANES cohort and the 
2011-2012 and 2013-2014 UM-VOC cohorts were from a 1/3 sample of the full 
2011-2012 and 2013-2014 NHANES cohorts. Because the sample size was 
smaller and therefore the weight of an observation may potentially be larger in the 
2011-2012 and 2013-2014 cohorts, the weighting variable for the appended cohort 
was calculated by multiplying the 2005-2006 weights by 3/7, and the 2011-2012 
and 2013-2014 cohort weighting variables by 2/7. The appended cohort weighting 
variable generated data representative of the non-institutionalized civilian 
population in the United States. 
81 
Exposure Measurements 
Concentrations of 27 urinary metabolites of volatile organic compounds 
(UM-VOCs) from 19 parent VOCs were measured by ultra performance liquid 
chromatography coupled with electro spray tandem mass spectrometry (UPLC-
ESI/MSMS) (25). The Division of Laboratory Sciences (DLS), National Center for 
Environmental Health (NCEH), CDC, preformed the UM-VOC laboratory tests. 
Samples were stored at -20ºC until they were able to be shipped to NCEH for 
analysis. Metabolite levels lower than the detectable limit are reported in NHANES 
as the limit of detection divided by the square root of two (206). Exact laboratory 
protocol can be found in Alwis et al. (2012) and https://wwwn.cdc.gov/nchs/data/ 
nhanes/2011-2012/labmethods/UVOC_G_ MET_VOC_Metabolites.pdf (25). 
Residual stored urine samples were used to measure UM-VOCs from a 
one-half subsample of participants 12 years of age or older from the 2005-2006 
NHANES wave. The 2011-2012 and 2013-2014 urine samples collected for UM-
VOC analysis were collected from a one-third subsample of participants 6 years of 
age of older (66).The UM-VOCs of interest and their parent VOC are listed in Table 
2.1.
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VOC metabolite (IUPAC name) 
Acrolein 
CEMA N-Acetyl-S- (2-carboxyethyl)-L-cysteine 
3HPMA N-Acetyl-S- (3-Hydroxypropyl)-L-cysteine 
Acrylamide 










Benzene PMA N-Acetyl-S-(phenyl)-L-cysteine 
1-Bromopropane BPMA N-Acetyl-S-(n-propyl)-L-cysteine 
1,3-Butadiene 



























MA Mandelic acid 
Tetrachloroethylene TCVMA N-Acetyl-S-(trichlorovinyl)-L-cysteine 






2MHA 2-Methylhippuric acid  
3&4MHA 3-Methylhippuric acid + 4-Methylhippur acid 
83 
Outcomes of interest 
Cardiometabolic Syndrome 
Dichotomous health outcome 
A dichotomous variable generated to identify if an individual had prevalent 
cardiometabolic syndrome was created. The variable was generated using a 
modified World Health Organization (WHO) definition for clinically diagnosing 
cardiometabolic syndrome. The definition is considered modified because the 
definition for CMS used in this investigation does not include triglycerides; 
NHANES only conducts fasting analyses (needed for triglycerides measures) on a 
subset of participants which would have resulted in a significantly depressed 
sample size. For this analysis CMS was defined as the presence of dysglycemia, 
which is abnormal blood glucose levels (measured by self-reported type II diabetes 
mellitus (T2DM) status or HbA1c ≥ 5.7), plus 2 or more of the following criteria: 
1. Visceral obesity measured as body mass index (BMI) ≥30 kg/m2 or a
waist circumference (WC) greater than 102cm for men or greater than 
88cm for women. 
2. Dyslipidemia classified by depressed HDL-cholesterol of ≤35 mg/dL in
men or ≤39 mg/dL in women. 
3. Hypertension defined as systolic blood pressure ≥140mm Hg or diastolic
blood pressure ≥90 mm Hg or self-report “currently taking blood 
pressure medication”. 
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4. Presence of Microalbuminuria measured as urinary albumin ≥30mg/g
(24). 
Table 2.2 shows the definitions and variables for each risk factor of 
cardiometabolic syndrome that will be used in the subsequent investigation. 
Table 2.2. Cardiometabolic Syndrome Risk Factor Variables and Definitions. 
Condition Yes No 
CMS* 
Dysglycemia plus two other CM 
risk factors 






>102 cm waist circumference 
and/or BMI >30 kg/m2 
≤102 WC and  
BMI ≤30 kg/m2 
Women 
>88 cm waist circumference 
and/or BMI >30 kg/m2 
≤88 WC and  
BMI ≤30 kg/m2 
†Triglycerides ≥1.7 mmol/L <1.7 mmol/L 
3. HDL-cholesterol
Men HDL ≤35 mg/dL >35 mg/dL 
Women HDL ≤39 mg/dL >39 mg/dL 
4. Hypertension
blood pressure medication or 
Systolic BP ≥ 140 mm Hg or 
Diastolic BP ≥ 90 mm Hg 
No medication 
and 
<140/90 mm Hg 
5. Microalbuminuria
urinary albumin:creatinine ratio 
≥30mg/g 
<30mg/g 
CMS, Cardiometabolic Syndrome; CM, Cardiometabolic; T2DM, type 2 
diabetes mellitus; BP, blood pressure  
*T2DM or HbA1c≥5.7 plus 2 or more CM risk factor criteria
†Triglycerides were removed as a risk factor for this analysis because 
only a fasting subset of participants have triglyceride measurements.  
Ordinal health outcome 
An ordinal score variable was generated to assess an individual’s severity 
of cardiometabolic risk factors. The variable was generated using the above 
modified World Health Organization (WHO) definitions and variables for clinically 
diagnosing cardiometabolic syndrome. For the ordinal CMS-Risk Score (CMS-RS) 
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outcome variable individuals were assigned a score based on individual 
prevalence of CMS risk factors. Individuals with 0 risk factors were assigned a 
CMS-RS of 0. Individuals with 1 risk factor were assigned a CMS-RS of 1. 
Individuals with 2 risk factors were assigned a CMS-RS of 2. Individuals with 3 risk 
factors, but not considered to have CMS (not having dysglycemia as a risk factor) 
were assigned a CMS-RS of 3. Individuals with 4 risk factors, but not considered 
to have CMS (not having dysglycemia as a risk factor) were assigned a CMS-RS 
of 4. Individuals with CMS, that is they had dysglycemia plus 2 additional risk 
factors were assigned a CMS-RS of 5. Individuals with CMS plus 1 additional risk 
factor, that is they had dysglycemia plus 3 additional risk factors were assigned a 
CMS-RS of 6. Finally, individuals with CMS plus 2 additional risk factors, that is 
they had dysglycemia plus 4 additional risk factors were assigned a CMS-RS of 7. 
Table 2.3 shows the number of risk factors and distinction of diagnosable CMS for 
each CMS-RS. 
Table 2.3. Cardiometabolic Syndrome Risk Score. 
CMS-RS Number of Risk Factors CMS 
0 0 No 
1 1 No 
2 2 No 
3 3 No 
4 4 No 
5 CMS Yes 
6 CMS + 1 Yes 
7 CMS + 2 Yes 
Note: CMS-RS= cardiometabolic syndrome 
risk score; CMS= cardiometabolic syndrome 
Covariates of Interest 
Cardiometabolic syndrome is thought to develop as a result of both genetic 
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factors and acquired/environmental factors. It is hypothesized that genetic factors 
predispose individuals to magnified effects of environmental exposures, which in 
conjunction amplify the effects of cardiovascular and metabolic adversities (199). 
Of the immense number of potential covariates that could be considered, this 
analysis will a priori consider socioeconomic status, gender, age, ethnicity, alcohol 
consumption patterns, physical activity, body mass index (198, 200, 201). Other 
covariates may additionally be considered for the analysis. 
Sociodemographic 
Participants self-reported information regarding age, educational statues 
and race. Age information was specified as continuous. Race information was 
classified as either Non-Hispanic White, Non-Hispanic Black, Mexican American 
Other Hispanic, and Other/Multi-Racial. Educational status was classified 
according to traditional U.S. grades; Less than high school graduate/GED, versus 
more than a high school graduate/GED was used in this analysis. Annual house 
hold income was used to assess Socio-economic status. Having an annual house 
hold income of less than $20,000 a year was defined as the cutoff point for living 
below the poverty level (above would indicate not). 
Anthropometry 
Body mass index (BMI) was calculated as weight in Kilograms divided by 
the square of height in meters. BMI was assessed as a continuous variable. No 
modifications or adjustments were made for race or ethnic group. Within the CMS 
definition individuals were considered to be obese with a BMI >30 kg/m2. Waist 
circumference was measured to the nearest 0.1 cm at the level of the iliac crest. 
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Females were considered obese within the CMS definition if they had a waist 
circumference of >88 cm. Males were considered obese in the CMS definition if 
they had a waist circumference of >102 cm. 
Medical History 
Participants participated in a home interview. They were asked about family 
members medical history. For the purpose of this question, a family member was 
defined as an immediate blood relation living or deceased, which would include 
grandparents, parents, brothers and sisters. Participants were asked about family 
history and personal history of doctor diagnosed heart disease and cancer. 
Blood pressure was measured using a mercury sphygmomanometer. 
These measurements were taken while the participant was seated. Participants 
were asked about, physician diagnosed hypertension, or current medication use 
for elevated blood pressure. 
Non-fasting serum levels of HDL-cholesterol were measured using the 
Roche/Boehringer-Mannheim Diagnostics direct HDL method. 
In the NHANES III data sets, fasting measures of triglycerides were 
obtained for only approximately 50% of participants attending the morning 
examinations. This resulted in a significantly reduced sample size of participants 
with triglyceride measurements making a measure of triglycerides unavailable for 
use in the definition for CMS for the analysis. 
Lifestyle Factors 
Self-reported tobacco use and self-reported use of tobacco and cigarette 
use questions and a question about the occurrence of in-home smoking were used 
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in conjunction with serum cotinine levels to classify each participant as a ‘current 
smoker”, “secondhand smoke exposed”, or “non-exposed” to smoke. A variable 
“Smoking exposure” combined these self-reported responses with serum cotinine 
cut points of current smoker (> 15 ng/mL cotinine), secondhand smoke exposed 
(>0.05 ng/mL cotinine to <15 ng/mL coninine), non-exposed (<0.05 ng/mL 
coninine). 
With respect to physical activity, the participants were asked about work, 
and recreational activity. If a participant reported no vigorous or moderate work or 
recreational physical activity they were considered physically inactive. Activity was 
defined by self-reported heart rate or breathing increase; activities that require hard 
physical effort and cause large increases in breathing or heart rate, and 'moderate-
intensity activities' are activities that require moderate physical effort and cause 
small increases in breathing or heart rate for more than 10 minutes. 
Power 
A minimum detectable effect size for each UM-VOC was calculated. To test 
the hypothesis Ho: μ1= μ2 vs. H1: μ1≠ μ2 with the alterative | μ1- μ2|=Δ, significance 
level α=0.05, and power 80% a two-tailed minimum detectable effect size was 





)] . (233) 
Where (μ1, σ1) and (μ2, σ2) are the means and standard deviation of each non-
survey weighted creatinine normalized log-transformed UM-VOC for participants 
with CMS and participants without CMS and n1 and n2 and the sample sizes of the 
two respective groups (Table 2.4). 
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For a two-tailed difference in means there was sufficient power to detect 
differences in at least 8 non-survey weighted, creatinine normalized, log-
transformed UM-VOCs. 
Table 2.4. Non-Survey Weighted Minimal Detectable Difference Calculation Data 
Statistical Analysis Overview 
All statistical analyses were performed using SAS, version 9.4 or R 3.3.2. 
SAS survey procedures were used in all appropriate analyses and sampling design 
variables, sample weights, cluster and stratification weightings were incorporated 
in all appropriate analyses to address the complex survey design of NHANES. SAS 
survey procedures incorporate the complex sampling design and sampling 
weights, which without accounting for the cluster design and differential probability 
of selection in NHANES would result in bias parameter estimates and overstated 
statistical significance. Specific analyses are discussed in subsequent sections. 
Parent Compound Metabolite n mean SD n mean SD 
CEMA 791 4.741 0.781 3769 4.540 0.825 0.201* 0.088 0.901 0.816
3HPMA 791 5.570 0.937 3765 5.568 0.977 0.002 0.104 0.851 0.803
Acrylamide AAMA 781 3.889 0.757 3723 3.995 0.818 0.105* 0.087 0.906 0.817
GAMA 791 2.477 0.677 3782 2.494 0.697 0.017 0.078 0.954 0.830
Acrylonitrile CYMA 790 1.293 1.891 3751 1.495 2.051 0.202* 0.200 0.699 0.758
Acrylonitrile, vinyl chloride, 
ethylene oxide 
HEMA 791 -0.046 0.893 3762 0.037 0.964 0.083 0.100 0.855 0.804
Benzene PMA 783 -0.459 0.748 3748 -0.476 0.775 0.017 0.085 0.919 0.821
1-Bromopropane BPMA 781 1.462 1.335 3752 1.495 1.368 0.033 0.144 0.776 0.781
DHBMA 793 5.687 0.493 3781 5.587 0.526 0.100* 0.059 1.079 0.860
MHBMA3 779 1.901 0.984 3721 1.881 1.076 0.020 0.110 0.825 0.795
Carbon-disulfide TTCA 793 2.774 1.090 3782 2.691 1.035 0.083 0.118 0.838 0.799
Crotonaldehyde HPMMA 791 6.248 0.930 3751 6.138 0.981 0.109* 0.103 0.850 0.802
Cyanide ATCA 780 4.642 1.159 3728 4.507 1.227 0.136* 0.127 0.795 0.787
N, N - Dimethylformamide AMCC 791 5.072 0.860 3779 5.000 0.961 0.072 0.097 0.857 0.804
Ethylbenzene, styrene PGA 789 5.124 0.844 3747 4.963 0.987 0.162* 0.096 0.849 0.802
Propylene oxide 2HPMA 788 3.509 0.933 3763 3.555 0.979 0.046 0.104 0.851 0.803
PHEMA 786 -0.325 0.828 3752 -0.330 0.857 0.005 0.093 0.887 0.813
MA 783 4.928 0.732 3739 4.920 0.710 0.009 0.083 0.938 0.826
Toluene BMA 792 2.050 0.890 3775 1.974 0.880 0.076 0.098 0.877 0.810
2MHA 766 3.432 1.162 3655 3.571 1.099 0.139* 0.127 0.825 0.795
3&4MHA 791 5.414 1.090 3776 5.502 1.079 0.088 0.119 0.827 0.796




*Difference in means sufficient to detect minimum detectable difference. †mean and standard deviation for non-survey-weighted 









The majority of the current knowledge, associations, and regulations of 
VOCs and cardiovascular and metabolic dysfunction have been linked to or 
studied in terms of particulate matter (PM) exposure. However, more than 98% of 
urban air pollution is composed of gasses or vapor-phase compounds such as CO, 
nonmethane hydrocarbons, and volatile organic compounds (VOCs). Each of 
these components of ambient air pollution may have independent, synergistic, or 
antagonistic effects with each other and/or with PM; for this reason the effects of 
VOCs on health need to be considered both in an individual manner (addressed in 
aim 2 and aim 3) and also from a global viewpoint i.e. multipollutant combinatory 
modeling, (addressed in aim 4) (14). 
The hypothesis is that CMS is positively associated with increasing UM-
VOCs. The methods for exploring this hypothesis used the 2005-2006, 2011-2012, 
and 2013-2014 NHANES UM-VOC sub-sample cohorts, as described above. The 
hypothesis was tested as outlined in the following aims. 
Analyses of Aim 1 
Specific aim 1 is to statistically describe and compare distributions, trends, 
and cohort characteristics of the 2005-2006, 2011-2012, and 2013-2014 NHANES 
UM-VOC sub-sample. 
Demographic characteristics of the cohort including sample size, mean, 
percent, and standard error were generated using SAS survey procedures 
SURVEYFREQ and SURVEYMEANS. Demographic characteristic proportional 
distribution statistics describe and compare the cohort according to CMS status. 
The two mutually exclusive groups were individuals with cardiometabolic 
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syndrome and individuals without cardiometabolic syndrome. SAS versions 9.4 
SURVEYREG was used to generate weighted basic linear regression models and 
calculate p-values for the differences in continuous demographic variables by CMS 
status and NHANES wave. SAS SURVEYFREQ was used to conduct first-order 
Rao-Scott chi-square tests to generate p-values across levels of categorical 
variables. These survey procedures were also used to generate demographic 
descriptive and comparative statistics between NHANES waves (2005/06, 
2011/12, and 2013/14). 
 The Rao-Scott chi-square test is a design-adjusted version of the Pearson 
chi-square test, which corrects for design effects of the table cell proportion 
estimates and, for two-way tables, the design effects of the marginal proportion 
estimates (234). The Rao-Scott design-adjusted chi-square goodness-of-fit test 
involves differences in observed and expected frequencies with a default null 
hypothesis of equal proportions. For this analysis the first-order Rao-Scott chi-
square statistic for the goodness-of-fit test was computed as 𝑄𝑅𝑆𝐼 = 𝑄𝑃/𝐷. Where 
𝑄𝑃  is the Pearson chi-square based on estimated totals and 𝐷 is the first-order 
design correction 𝐷 = ∑ (1 − ?̂?𝑐)𝐷𝑒𝑓𝑓(?̂?𝑐/(𝑐 − 1)𝑐 . Where 𝐷𝑒𝑓𝑓(?̂?𝑐) = 𝑉𝑎?̂?(?̂?𝑐)/
𝑉𝑎𝑟𝑠𝑟𝑠(?̂?𝑐). Where ?̂?𝑐 equals the proportion estimate for level c and 𝑉𝑎?̂?(?̂?𝑐) is the
variance estimate.  For a first-order one-way table with 𝐶 levels, the Pearson chi-
square is computed as 𝑄𝑃 = (
𝑛
?̂?
) ∑ (𝑁?̂? −𝑐 𝐸𝑐 )̂
2/𝐸𝑐. Where n is the sample size, ?̂? is
the estimated overall total, 𝑁?̂?  is the estimated total for level 𝑐  and 𝐸𝑐  is the
expected total level of 𝑐  under the null hypothesis of equal proportions. The 
expected total for each level is 𝐸𝑐 = ?̂?/𝐶. Under the null hypothesis the first-order 
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Rao-Scott chi-square statistic 𝑄𝑅𝑆𝐼  approximately follows the chi-square 
distribution with (𝐶 − 1)  degrees of freedom (234). First-order Rao-Scott chi-
square tests for two-way tables tests associations between row and column 
variables; for two-way tables 𝑄𝑃 = (
𝑛
?̂?
) ∑ ∑ (𝑁𝑟?̂? −𝑐 𝐸𝑟𝑐)̂
2
𝑟 /𝐸𝑟𝑐 , where n is the 
sample size, ?̂? is the estimated overall total; 𝑁𝑟?̂? is the estimated total for cell (𝑟, 𝑐)
and 𝐸𝑟𝑐  is the expected total cell (𝑟, 𝑐)  under the null hypothesis of equal 
proportions/no association. The expected total for each level is 𝐸𝑟𝑐 = ?̂?𝑟?̂?𝑐/?̂? 
(234). Under the null hypothesis the first-order Rao-Scott chi-square statistic 𝑄𝑅𝑆𝐼 
approximately follows the chi-square distribution with (𝑅 − 1)(𝐶 − 1) degrees of 
freedom (234). 
Urinary metabolites of volatile organic compounds in the NHANES dataset 
were first assessed for level of detection insufficiencies. The level of detection or 
LOD is the lowest quantifiable level that is able to be detected by the laboratory 
protocol for each metabolite (235). For this analysis, any metabolite with less than 
15% of participants at or below the LOD was removed from any further analysis 
due to unreliability of statistical tests with very limited sample sizes. For 
metabolites with greater than 15% of samples measured above LOD; values of 
analytes with analytic results below the LOD, were reported by NHANES using the 
standard imputations method of 𝐿𝑂𝐷
√2
⁄  (236). UM-VOCs were normalized to
individual level urinary creatinine concentration to adjust for dilution/concentration 
of the urine. 
The same SAS survey procedures as discussed above were used to 
describe the basic descriptive statistics for volatile organic compound urinary 
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metabolites. The geometric mean, median, standard error, and quartiles 
distributions for each metabolite by NHANES wave (2005-06, 2011-12, and 2013-
14) as well as for the full-appended cohort were described. The appended cohort
was further stratified by CMS status and the same descriptive statistics were used 
to describe UM-VOCs by CMS status; UM-VOCs by CMS status were also be 
further stratified by smoking status. Additionally, levelplots using the lattice 
package in the statistical software R version 3.3.2 were used to generate 
correlation matrices in order to gain an initial assessment of any possible 
collinearity of the UM-VOCs. 
Analyses of Aim 2 
Specific aim 2 is to study the effects of individual continuous UM-VOCs and 
prevalent CMS after adjusting for select covariates. 
The main objective for this aim was to determine whether particular UM-
VOCs, treated continuously, are associated with CMS status, measured as a 
dichotomous variable. The null hypothesis was that a particular UM-VOC was not 
associated with CMS (Ho: B1=0), with an alternative hypothesis being that a 
particular UM-VOC is associated with CMS (H1: B1 ≠0). 
Multivariable logistic regression models were used to determine whether a 
particular UM-VOC, treated as a continuous variable, was associated with CMS 
prevalence. Variables were considered for inclusion in the final model based on 
both a priori knowledge of an important role of a variable in the relationship 
between UM-VOCs and CMS, as well as their statistical significance in the model 
(discussed in more detail below). 
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A priori adjustments were identified as important from both the scientific 
literature as well as from statistically significant differences in population 
descriptive statistics stratified by CMS status, identified in the aim one of this 
dissertation. Age was significantly different (p-value <0.0001) between individuals 
with and without CMS in the study cohort. Individuals with CMS were more likely 
to be older than individuals without CMS. Older age is associated with the majority 
of the diseases that define CMS and the prevalence of CMS significantly increases 
with age (192). Significant increases in the prevalence of CMS are observed at 
about age 30, with peak increases in prevalence for men occurring between the 
ages of 50 to 70; and peak increases in prevalence for women occurring 
approximately a decade later, between the ages of 60 to 80 (198). Sex was not 
significantly different between individuals with and without CMS in the study cohort 
but significant sex differences exist for the majority of the metabolic and 
cardiovascular conditions used the define CMS (3, 198). Obesity, systolic blood 
pressure, BMI, and diabetes have all been shown to vary significantly by sex (237). 
Additionally, rates of change in the prevalence of the CMS risk factors have been 
reported to be different by sex since the 1980s, indicating the need to account for 
these differences in population-level analyses(237). Race was significantly 
different (p-value <0.0001) between individuals with and without CMS in the study 
cohort. Rates of cardiometabolic syndrome and a number of the conditions used 
to define CMS are highly stratified by ethnicity. Mexican American women have 
the highest rates of CMS in America while Black men have the lowest rates (202). 
These ethnic differences persist even after adjusting for age, smoking and drinking 
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habits, socioeconomic status, physical inactivity, and menopausal status among 
women (198, 238, 239). Twelve of the 21 VOC concentrations in this investigation 
were significantly different between the NHANES cohort years (2005/06, 2011/12, 
and 2013/14) (Table A.3). Konkle et. al confirms these observations in a 2020 
publication showing significant increasing trends in urinary VOC metabolite 
concentrations over this time period (2005 to 2014) (10). 
Models were initially a priori adjusted for age, sex, race, and NHANES 
cohort year. Interactions between each of these terms were assessed using 
product terms in the model; a significant interaction was observed with sex and 
race. Additional potential variables of interest that may have had some impact on 
the relationship, such as cancer and socioeconomic status, were assessed based 
on a liberal p-value threshold for statistical significance (p<0.2). These analyses 
did not reveal any further significant effects and did not confound the association 
between VOCs and CMS, and therefore were not included in the final models. 
Covariates were removed individually via backwards elimination to assess 
potential confounding effects with the remaining variables in the model. Variables 
that resulted in a 10% change of the odds ratio (OR) of the exposure of interest 
would be re-inserted into the model. Based on the significance of the covariates 
and interaction terms (p<0.1), and the lack of confounding, the final models were 
adjusted for age, sex and race interaction, and NHANES cohort year. 
Age, sex, race, and NHANES cohort year as well as the interaction between 
race and sex were found to be significant in multivariate logistic regression models 
of individual VOCs and CMS. In the interest of parsimony and comparability of 
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models, all adjusted models were adjusted for age, sex, race, sex and race 
interaction, and NHANES cohort year.   
Because of the large number of exposures examined, a multiple 
comparisons adjustment was implemented by using a new significance threshold 
identified by a modified Bonferroni correction. The Bonferroni adjustment is one of 
the most frequently and widely used multiple testing approaches because of its 
ease of uses and intuitive interpretability (240). However, the traditional Bonferroni 
approach is often viewed as being overly conservative and suffers from poor 
statistical performance when used with correlated test data. Therefore, adaptation 
of the traditional Bonferroni adjustments have been developed to help overcome 
these shortcomings (241). One such modified Bonferroni adjustment is based on 
the concept of intraclass correlation to imposes a correction for the number of 
classes/groups of correlated data, rather than adjusting for every test; therefore, 
producing a less conservative adjustment (242).  
For this analysis the number of classes of correlated data were identified by 
Factor Analysis. The corrected significance threshold was calculated by dividing 
the type I error rate, α (0.05) by the number of independent classes/groupings of 
VOC metabolites identified by factor analysis. The factor analysis was performed 
using log-transformed metabolites.  
Due to the number of moderate to highly correlated data in the tobacco 
smoke exposed cohort (Figure A.1, and Figure A.2), the factor analysis was 
conducted using only the non-tobacco smoke exposed sub-populations of the 
study cohort.  Additionally, UM-VOCs with less than 40% of sample above LOD 
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were excluded in the factor analysis; therefore, 16 UM-VOCs were included in the 
factor analysis. Creatinine normalized log-transformed UM-VOCs were assessed. 
The maximum likelihood estimation factor extraction method with squared multiple 
correlations prior communality estimates were used in the SAS Proc FACTOR 
procedure. 
Analyses of Aim 3 
Specific aim 3 is to evaluate the dose-response relationships of individual 
categorical UM-VOC exposures and CMS. 
The objective of this aim was to determine whether a dose-response 
relationship exists between each UM-VOC and CMS. The dose-response 
relationship was explored using urinary metabolite concentrations as an estimation 
of dose. Because tobacco smoke exposure was used as a chronic high-dose 
exposure and the dose-response analyses were not impacted but correlations; the 
analysis in this section was conducted using the entire study cohort. To visually 
assess if a dose-response relationship exists, each UM-VOC was placed into 
equally numbered quintiles i.e. approximately the same number of participants 
were placed in each quintile, and figures were generated by plotting CMS 
prevalence on the y-axis against UM-VOC quantile concentration cut-points on the 
x-axis. To examine trends that were not adjusted for any covariables, chi-square 
tests for trend were applied to UM-VOC quantile concentration cut-points. Logistic 
regression models were built to assess trends after adjusting for age, sex, race, 
and NHANES cohort year. In the models, the UM-VOC quintiles were first treated 
ordinally to assess linear trends, and second treated categorically, to examine 
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whether any of the quintiles had significantly higher odds of CMS versus the 
referent category (lowest exposure quintile). 
Analysis of Aim 4 
Specific aim 4 is to explore combinatory effects of VOCs on CMS. 
The main research question for this aim was: which combinatorial UM-
VOCs are more likely to predict CMS? To examine this research question, 
exploratory analyses were conducted, including: ordinal logistic regression using 
a CMS-risk score (CMS-RS); a traditional backwards-selection regression model-
building approach to examine two-way interactions; factor analysis; and LASSO 
penalized regression; as well as a multipollutant approach using a cumulative VOC 
exposure score. These methods used in this aim are complementary of each other 
and are used to identify potential important groupings and interactions among UM-
VOCs, and their associations with CMS. The methods used in this aim were 
independent, unrelated exploratory analyses conducted in order to add evidence 
that combinatory VOC exposures are predictive of CMS.   
Ordinal Logistic Regression 
The ordinal logistic regression analysis was conducted assuming that an 
intrinsic order in the increase in CMS components is associated with an increased 
disease state, but that the distance between the level of increase in disease 
progression is unknown. Due to the non-interval nature of the CMS-RS (OLS 
regression would be used if CMS-RS were interval data) and the desire to retain 
the information contained in the order of the CMS-RS, ordinal logistic regression 
was chosen for this analysis.  
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To produce the ordinal CMS-RS, each of the components of the CMS 
definition (abnormal blood glucose levels, visceral obesity, dyslipidemia, low HDL-
cholesterol, hypertension, and the presence of microalbuminuria) were 
dichotomized as present or absent. Individuals received a score reflective of the 
number of components of CMS they had at the time of data collection (Table 2.3). 
These scores were assessed in an ordinal manner for associations with UM-VOCs. 
Table 2.3. Cardiometabolic Syndrome Risk Score. 
CMS-RS Number of Risk Factors CMS 
0 0 No 
1 1 No 
2 2 No 
3 3 No 
4 4 No 
5 CMS Yes 
6 CMS + 1 Yes 
7 CMS + 2 Yes 
Note: CMS-RS= cardiometabolic syndrome risk 
score; CMS= cardiometabolic syndrome 
 In contrast to binary logistic regression, which models the response itself, 
ordinal logistic regression uses logistic regression to model the probability of 
events. In ordinal logistic regression a cumulative logit model assumes that the 
effect of an explanatory variable is identical for all modeled logits. This assumption 
is known as the assumption of proportional odds (243). Survey-weighted 
proportional-odds cumulative logit models were used to investigate the response, 
CMS-RS with respect to each individual UM-VOC. The Chi-Square Score test was 
used to test the proportional odds assumption. For simplicity a model with one 
predictor would take the form: 𝑙𝑜𝑔𝑖𝑡 𝑃(𝑌 ≤ 𝑗) = 𝛼𝑗 𝛽𝑥  and the cumulative 
probabilities would be 𝑃(𝑌 ≤ 𝑗) = exp(𝛼𝑗 + 𝛽𝑥) /(1 + exp(𝛼𝑗 + 𝛽𝑥)) . Beta is
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constant; therefore, the curves of the cumulative probabilities plotted against x are 
parallel. The odds ratios for these models are proportional to the differences 
between x1 and x2 where beta is the constant of proportionality: exp[𝛽(𝑥1 − 𝑥2)]
(233). 
Backwards Selection 
Potential two-way interactions between UM-VOCs were identified using a 
binary logistic regression backward selection method. The backwards elimination 
technique begins with a full model, including all effects. The effects with the 
smallest contribution were removed one by one until a specified threshold was 
met; for this analysis effects were removed from the model until all effects were 
significant at the 0.05 level. This analysis was conducted using CMS 
(dichotomous), rather than the ordinal CMS-RS because as the number of 
predictors increases in an ordinal logistic regression model the less likely that the 
proportional odds assumption will be met. Initially, an unadjusted logistic 
regression model was used to identify the interactions of interest. Subsequently, 
the identified important interactions were placed in an adjusted survey weighted 
logistic regression model. 
Log-transformed metabolites with greater that 40% of the samples above 
the LOD were used to assess two-way interactions. To minimize any potential 
multicollinearity, 2-way interactions were assessed in non-tobacco smoke exposed 
individuals, and only 1 metabolite per parent VOC was selected for inclusion in the 
logistic regression backwards selection analysis. A representative metabolite for 
each parent VOC was selected. If a parent VOC had multiple metabolites, the 
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metabolite with the greatest significance was selected; if none of the metabolites 
were significant, the most abundant metabolite was selected to represent the 
parent VOC. 
To assess if the response of CMS depends on the interaction identified from 
the backward selection model, significant interaction terms were then placed 
(CMS= 0 + 1UM-VOC1 + 2UM-VOC2 + 3 (UM-VOC1 * UM-VOC2) + adjustments) 
into survey weighted ordinal logistic regression models adjusted for age, sex, race, 
the interaction between sex and race, and NHANES cohort year. If the interaction 
term was not significant (p-value <0.05) in the adjusted survey weighted logistic 
regression model, then a model removing the interaction term while maintaining 
the individual UM-VOCs that made up the interaction term was built and assessed, 
if the UM-VOCs were significant (p-value <0.05) (CMS= 0 + 1UM-VOC1 + 2UM-
VOC2 + adjustments). 
Factor Analysis 
Another method that was used to examine the effects of multiple UM-VOCs 
was factor analysis. Factor analysis is a statistical method that describes the 
variability among variables and is often used as a dimension reduction technique. 
Factor analysis groups correlated data into unobserved terms known as factors. 
The purpose of the factor analysis in this investigation was to group the UM-VOCs 
into a reduced number of unobserved latent variables or factors. 
After the initial extraction of the 3 latent factors, preformed in aim 2, a rotated 
factor pattern analysis in the non-tobacco smoke exposed cohort was conducted 
using UM-VOCs with greater the 40% above LOD (16 metabolites). The maximum 
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likelihood estimation factor extraction method with squared multiple correlations 
prior communality estimates were used in the SAS Proc FACTOR procedure. An 
oblique rotation, which allows the factors to be correlated with one another, was 
implemented via the quartimin rotation.  A path diagram showing directed links 
from the 3 factors identified in aim 2 to variables that are associated with a 0.3 or 
greater magnitude in loading estimates was created in this aim. Once the factors 
were identified, an adjusted ordinal logistic regression analysis was conducted with 
the 3 identified latent variables and the CMS-RS. 
Least Absolute Shrinkage and Selection Operator (LASSO) Method 
Traditional stepwise selection methods, like the backward selection 
previously used, can experience high variability and low prediction accuracy, 
especially when there are many predictor variables or correlated predictor 
variables (or both). Therefore, the least absolute shrinkage and selection operator 
or LASSO penalized regression method was additionally used to explore the 
prediction accuracy of UM-VOC concentrations and prevalent CMS. The LASSO 
method shrinks the maximum likelihood estimates of model parameters toward 
zero by imposing an L1 norm penalty (the sum of the absolute values of the 
estimates) to the log likelihood function used in parameter estimations (244). A 
regression model of all 21 UM-VOCs was conducted using SAS Proc 
GLMSELECT on the full cohort. The LASSO method was used to identify the most 
parsimonious model for all UM-VOCs individually in a model as well as for all 2-
way interactions in a model, for the best predictive model of UM-VOCs and CMS 
(dichotomous). The SAS Selection statement requesting a LASSO fit procedure 
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was used for this analysis. The LASSO analysis method can be used as a variable 
selection method as the penalizations often shrink coefficients of less explanatory 
variables to zero within the regression model. The penalization process and 
subsequent coefficient shrinkage leading to fewer variables in the LASSO method 
also decrease overfitting.   
The large sample size of the cohort allowed for the optimum model to be 
selected via calculating the prediction error of the models directly; using training 
observations (n= 2886) to produce the solution path and a validation set (n= 1186) 
as the tuning method by estimating the prediction error of each model on the 
solution path. The model with the smallest average square error (ASE) produced 
by the validation data was selected as the optimum model. A coefficients plot was 
generated, which shows how the standardized coefficients change during the 
selection process. The coefficients plot shows on the x-axis what can be 
interpreted as the shrinkage parameter “t” and the y-axis shows the standardized 
coefficients for the variables.  
Cumulative VOC Exposure Score (UM-VOC) 
A cumulative VOC exposure score (UM-VOC) was generated as a 
mixtures or multiple exposures-approach of assessing the association of 
multipollutant VOC exposures with CMS. To minimize any potential 
multicollinearity, the cumulative VOC exposure score was generated in the non-
tobacco smoke exposed participants of the cohort, and only with metabolites with 
greater than 40% of samples measured above the LOD. For each parent VOC, a 
representative metabolite was selected. If a parent VOC had multiple eligible 
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metabolites, the more significant metabolite from the ordinal logistic regression 
models was selected as the representative. If none were significant, the metabolite 
with the highest abundance was selected as the representative metabolite for that 
VOC. The representative UM-VOCs were categorized into quintiles using cutoff 
points of 20th, 40th, 60th, and 80th percentile values, and assigned rank values of 1 
through 5, respectively. UM-VOCs at or below the LOD were forced into the lowest 
exposure group, the 20th percentile group. 
To generate a cumulative measure for UM-VOCs, the ranks were summed 
for each of the representative UM-VOCs. The summary values were subsequently 
treated as a new continuous exposure measure with a maximum value of 65 (5 
rank values x 13 metabolites). The cumulative VOC exposure score was then used 
in survey-weighted regression models as the independent variable to assess the 





Characteristics of the Study Cohort 
Demographic data from 4654 participants who were at least 20 years of 
age, not pregnant or breastfeeding, have UM-VOC and all CMS criteria data, and 
had no prevalent CVD at the time of data collection are presented in Table 3.1.1 
by NHANES cycle (2005-2006, 2011-2012, and 2013-2014). The means, 
percents, and standard errors presented in this table have all been appropriately 
weighted for the complex survey design of NHANES. Throughout the years of the 
cross-sectional NHANES cohorts used in this study, the basic sociodemographic 
and behavioral characteristics of the 3 cohorts had no significant change among 
age (mean 45.68 year), sex (female: 51.31%, male: 48.69%), race (non-Hispanic 
white: 68.51%, non-Hispanic black: 10.88%, Mexican American: 8.53%, other 
Hispanic: 5.25%, and other/multi-racial: 6.83%), education (15.04% obtain less 
than a high school education), household income (13.58% below $20,000 
annually), alcohol consumption (78.34%), or physical inactivity (27.83%). 
There was a significant difference among the percent of participants
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exposed to tobacco smoke, with trends towards less exposure in recent years. A 
number of medical history outcomes and covariates assessed varied significantly 
by year. The percent of participants having type 2 diabetes mellitus, dysglycemia, 
and CMS as well as the mean HbA1c and urinary creatinine (mg/dL) were all 
significantly different across NHANES waves with highest percent/means being 
observed in the 2011-2012 NHANES wave with the exception of urinary creatinine 
whose highest mean was observed in the 2005-2006 NHANES wave. 
Table 3.1.1. Study Population Characteristics Stratified by NHANES Survey 
Cycle 
n n miss mean/% SE n mean/% SE n mean/% SE n mean/% SE p-value 
Age 0 45.68 0.39 45.23 0.67 45.86 0.87 46.11 0.40 0.272
Sex (%) 0 0.753
Female 2351 51.31 0.69 890 50.73 0.80 682 52.03 1.32 779 51.38 1.56
Male 2303 48.69 0.69 894 49.27 0.80 698 47.97 1.32 711 48.62 1.56
Race or ethnic origin (%) 0 0.282
Mexican American 734 8.53 0.95 378 8.12 1.08 128 7.38 1.83 228 10.20 2.16
Other Hispanic 338 5.25 0.67 54 3.43 0.87 145 7.39 1.60 139 5.64 1.19
Non-Hispanic White 2006 68.51 1.84 870 72.06 2.48 505 67.19 3.86 631 65.02 3.47
Non-Hispanic Black 1042 10.88 1.15 405 10.83 1.98 352 10.94 2.17 285 10.88 1.70
Other/Multi-Racial 534 6.83 0.49 77 5.57 0.73 250 7.10 1.00 207 8.25 0.87
Medical History 
BMI (kg/m2) 0 28.58 0.14 28.41 0.23 28.56 0.30 28.85 0.21 0.372
Overwieght (%) 2563 0 54.46 1.13 957 52.79 1.93 752 54.71 2.58 854 56.47 1.26 0.408
Type 2 diabetes (%) 460 0 7.70 0.47 164 6.48 0.78 154 9.36 0.66 142 7.72 0.87 0.030
Glycohemoglobin(%)-HbA1c 0 5.51 0.02 5.42 0.03 5.61 0.02 5.53 0.02 <.0001
Dysglycemia (%) 1595 0 26.79 0.80 504 21.68 1.25 560 31.68 1.31 531 28.91 1.61 <.0001
HDL-cholesterol 0
Men 48.32 0.38 48.20 0.46 47.90 0.72 48.87 0.84 0.676
Women 58.65 0.41 58.88 0.69 58.28 0.80 58.70 0.65 0.846
Low HDL-cholesterol (%) 495 0 10.39 0.68 175 9.86 0.88 144 10.66 1.55 176 10.84 1.20 0.818
Systolic Blood Pressure 0 121.26 0.37 122.01 0.52 120.44 0.86 121.03 0.55 0.227
Diastolic Blood Pressure 0 70.98 0.34 71.34 0.52 71.37 0.73 70.13 0.52 0.204
Hypertension (%) 1412 0 26.87 0.79 544 26.64 1.29 410 26.01 1.74 458 28.02 1.02 0.603
Albumin:Creatinine Ratio (mg/g) 0 23.93 2.02 25.69 3.39 21.20 2.65 24.22 4.14 0.562
Microalbuminuria (%) 460 0 7.80 0.46 184 7.81 0.49 144 8.07 0.89 132 7.52 1.09 0.908
Urinary creatinine (mg/dL) 0 116.99 1.45 122.56 2.06 114.06 3.15 112.33 2.39 0.005
Cardiometacolic Syndrome (%) 811 0 13.80 0.55 264 11.21 0.69 268 16.08 1.24 279 15.07 1.03 0.001
Blood pressure treatment (%) 987 264 19.84 0.76 354 18.65 1.03 302 20.41 1.64 331 20.89 1.40 0.437
Cancer (%) 350 232 8.58 0.58 135 8.12 0.93 94 8.27 0.99 121 9.49 1.14 0.585
Lifestyle 
<High school Education (%) 1064 15.04 0.97 470 15.88 1.48 288 14.80 2.07 306 14.14 1.52 0.751
Below $20,000 HH income (%) 867 294 13.58 0.77 321 12.58 0.83 284 15.89 1.88 262 12.76 1.52 0.195
Smoking exposure (%) 368 <.0001
Current smoker 1234 29.04 1.05 513 31.01 1.98 331 26.56 1.56 390 28.70 1.60
Secondhand Smoke exp 942 19.83 0.79 447 24.69 1.13 235 15.17 1.26 260 17.52 1.80
Non-exposed  2110 51.13 1.35 725 44.31 2.18 693 58.27 1.90 692 53.78 2.90
Serum cotinine (ng/mL) 4652 2 60.19 3.11 1784 62.91 5.02 1380 51.41 4.29 1488 65.08 6.52 0.118
Consume alcohol (%) 3128 353 78.34 1.14 1183 75.76 1.92 932 81.54 1.77 1013 78.82 2.24 0.114
Physically inactive (%) 1521 11 27.83 1.08 658 31.62 2.30 425 25.08 1.24 438 25.39 1.27 0.435
N=4654 n=1784 n=1380 n=1490
Data are mean (SE), % (SE). All percentages are weighted to account for NHANES complex sampling design and survey weights. 
Full Cohort 2005-06  2011-12 2013-14
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Demographic characteristics stratified by cardiometabolic syndrome status 
for the 4,654 participants from the three NHANES cycles are presented in Table 
3.1.2, with appropriate survey weighting variables applied. Sex and tobacco smoke 
exposure did not vary significantly by CMS status. However, individuals with CMS 
were significantly older (56.8 years) than individuals without CMS (43.9 years). A 
significant difference in race/ethnic origin was observed among individuals with 
CMS when compared to individuals without CMS (p <0.0001); Non-Hispanic 
blacks had a disproportionate number of individuals with CMS. In fact, non-
Hispanic blacks accounted for 17.5% of individuals with CMS as compared to only 
9.8% of individuals without CMS. Over a quarter of non-Hispanic blacks had CMS 
as compared to an average of 15.6% among all other races. Additionally, women 
had a slightly higher prevalence of CMS as compared to men (56.0% vs. 44.0%) 
(p=0.0718) and non-Hispanic black women had the highest prevalence of CMS 
(29.1%) as compared to all other race/ethnic origin or sex groups (appendix Table 
A.1.) 
Individuals with CMS had significantly unhealthier medical history outcomes 
and covariates as compared to individuals without CMS including all components 
of the CMS definition. More specifically, individuals with CMS compared to 
individuals without CMS had significantly higher BMI (kg/m2) (34.1 vs. 27.7), 
HbA1c (glycohemoglobin percent) (6.5 vs. 5.4), systolic blood pressure (mmHg) 
(132.9 vs. 119.4), diastolic blood pressure (mmHg) (73.2 vs. 70.6), 
albumin:creatinine ratio (mg/g) (84.5 vs. 14.2), and lower HDL-cholesterol levels 
(men: 42.4 vs. 49.2, women: 51.2 vs. 60.0). Individuals with CMS were more likely 
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to be over weight (94.1% vs. 48.1%), have type 2 diabetes mellitus (39.8% vs. 
2.9%), dysglycemia (100% vs. 15.1%), low HDL-cholesterol (24.5% vs. 8.1%), 
hypertension (80.9% vs.18.2%), microalbuminuria (25.9% vs. 4.9%) and high 
blood pressure (65.3% vs. 12.5%) and nearly twice as likely to have had cancer 
(14.6% vs. 7.6%). Individuals without CMS did not have significantly higher 
(p=0.465) urinary creatinine (mg/dL) as compared to individuals with CMS (117.4 
vs. 114.7, p=0.465). Additionally, individuals with CMS were significantly more 
likely to have less than a high school education (p<0.0001), have a household 
income less than $20,000 annually (p=0.0017), and be less physically active 
(p=0.0048). 
 109 
Table 3.1.2. Study Population Characteristics Stratified by Cardiometabolic 
Syndrome Status  
 
Urinary Metabolites of Volatile Organic Compounds Characteristics   
Data from 27 urinary metabolites of volatile organic compounds (UM-VOCs) 
n mean/% SE n mean/% SE n mean/% SE p-value 
Age (years) 4654 45.68 0.39 811 56.81 0.56 3843 43.90 0.40 <.0001
Sex (%) 0.0718
Female 2351 51.31 0.69 460 56.04 2.62 1891 50.55 0.85
Male 2303 48.69 0.69 351 43.96 2.62 1952 49.45 0.85
Race or ethnic origin (%) <.0001
Mexican American 734 8.53 0.95 136 8.91 1.59 598 8.47 0.92
Other Hispanic 338 5.25 0.67 52 4.34 0.85 286 5.40 0.69
Non-Hispanic White 2006 68.51 1.84 286 62.69 2.77 1720 69.45 1.79
Non-Hispanic Black 1042 10.88 1.15 261 17.54 2.14 781 9.81 1.03
Other/Multi-Racial 534 6.83 0.49 76 6.53 1.00 458 6.87 0.50
Medical History 
BMI (kg/m2) 28.58 0.14 808 34.07 0.38 3837 27.71 0.14 <.0001
Overweight (%) 2563 54.46 1.13 745 94.13 1.14 1818 48.11 1.20 <.0001
Type 2 diabetes (%) 460 7.70 0.47 308 39.77 2.06 152 2.86 0.31 <.0001
HbA1c 5.51 0.02 810 6.53 0.05 3843 5.35 0.01 <.0001
Dysglycemia (%) 1595 26.79 0.80 811 100.00 0.00 784 15.07 0.65
HDL-cholesterol 
Men 48.32 0.38 351 42.40 0.96 1952 49.16 0.42 <.0001
Women 58.65 0.41 460 51.16 0.80 1891 59.98 0.46 <.0001
Low HDL-cholesterol (%) 495 10.39 0.68 187 24.48 2.23 308 8.13 0.70 <.0001
Systolic Blood Pressure 121.26 0.37 780 132.85 1.23 3728 119.42 0.34 <.0001
Diastolic Blood Pressure 70.98 0.34 775 73.24 0.74 3718 70.63 0.33 0.0003
Hypertension (%) 1412 26.87 0.79 663 80.93 2.13 749 18.21 0.68 <.0001
Albumin:Creatinine Ratio 23.93 2.02 811 84.47 13.69 3843 14.23 0.99 <.0001
Microalbuminuria (%) 460 7.80 0.46 241 25.92 2.40 219 4.90 0.40 <.0001
Urinary creatinine 116.99 1.45 811 114.70 3.30 3843 117.35 1.58 0.465
Blood pressure treatment (%) 987 19.84 0.76 512 65.33 2.56 475 12.48 0.68 <.0001
Ever had Cancer (%) 350 8.58 0.58 100 14.59 1.18 250 7.61 0.62 <.0001
Lifestyle 
< High school Education (%) 1064 15.04 0.97 252 20.76 1.86 812 14.13 0.96 <.0001
Below $20,000 HH income (%) 867 13.58 0.77 194 18.47 1.71 673 12.80 0.86 0.0017
Smoking exposure (%) 0.0634
Current smoker 1234 29.04 1.05 183 24.70 2.10 1051 29.75 1.17
Secondhand Smoke exp 942 19.83 0.79 173 19.32 2.15 769 19.91 0.77
Non-exposed  2110 51.13 1.35 397 55.98 2.21 1713 50.34 1.45
Serum cotinine 4652 60.19 3.11 811 54.90 6.12 3841 61.03 3.41
Consume alcohol (%) 3128 78.34 1.14 479 69.10 2.43 2649 79.83 1.14 <.0001
Physically inactive (%) 1521 27.83 1.08 355 39.17 2.11 1166 26.01 1.21 0.0048
Data are mean (SE), % (SE). All percentages are weighted to account for NHANES complex sampling design and 
survey weights. 
Full Cohort CMS No CMS
N=4654 n=811 (17.43%) n=3843 (82.57%)
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metabolized from 19 parent VOCs are presented in Table 3.1.3. Table 3.1.3 
includes the International Union of Pure and Applied Chemistry (IUPAC) name, the 
abbreviation of each UM-VOC as well as the lower level of detection (LLOD) and 
the percent of participants with values for each UM-VOC at or above the level of 
detection (LOD) for the full-appended cohort as well as for each wave of NHANES 
assessed. Percent values for UM-VOCs at or above the LOD varied from less than 
1% for N-Acetyl-S-(1,2-dichlorovinyl)-L-cysteine (1,2DCVMA) to over 99% for N-
Acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine (ATCA). There were six UM-
VOCs that had less than 15% of participants with values at or above the LOD. 
These metabolites were two 1,3-Butadiene metabolites N-Acetyl-S-(1-
hydroxymethyl-2-propenyl)-L-cysteine (MHBMA1), N-Acetyl-S-(2-hydroxy-3-
butenyl)-L-cysteine (MHBMA2), the tetrachloroehtylene metabolite N-Acetyl-S-
(trichlorovinyl)-L-cysteine (TCVMA), two trichloroethylene metabolites N-Acetyl-S-
(1,2-dichlorovinyl)-L-cysteine (1,2DCVMA), N-Acetyl-S-(2,2-dichlorovinyl)-L-
cysteine (2,2DCVMA), and one xylene metabolite N-Acetyl-S-(dimethylphenyl)-L-
cysteine (DPMA). These six UM-VOCs were removed from any further analyses 
due to unreliability of statistical tests with very limited sample sizes. Therefore, 
further analyses were limited to the remaining 21 UM-VOCs from 17 parent VOCs, 
namely, N-Acetyl-S- (2-carboxyethyl)-L-cysteine (CEMA), N-Acetyl-S- (3-
Hydroxypropyl)-L-cysteine (3HPMA), N-Acetyl-S-(2-carbamoylethyl)-L-cysteine 
(AAMA), N-Acetyl-S-(2-carbamoyl-2-hydroxyethyl)-L-cysteine (GAMA), N-Acetyl-
S-(2-cyanoethyl)-L-cysteine (CYMA), N-Acetyl-S- (2-hydroxyethyl)-L-cysteine 
(HEMA), N-Acetyl-S-(phenyl)-L-cysteine (PMA), N-Acetyl-S-(n-propyl)-L-cysteine 
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(BPMA), N-Acetyl-S- (3,4-dihydroxybutyl)-L-cysteine (DHBMA), N-Acetyl-S-(4-
hydroxy-2-buten-1-yl)-L-cysteine (MHBMA3), 2-Thioxothiazolidine-4-carboxylic 
acid (TTCA), N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine (HPMMA), 2-
Aminothiazoline-4-carboxylic acid (ATCA), N-Acetyl-S-(N-methylcarbamoyl)-L-
cysteine (AMCC), Phenylglyoxylic acid (PGA), N-Acetyl-S-(2-hydroxypropyl)-L-
cysteine (2HPMA), N-Acetyl-S-(1-phenyl-2-hydroxyethyl-L-cysteine + N-Acetyl-S-
(2-phenyl-2-hydroxyethyl)-L-cysteine (PHEMA), Mandelic acid (MA), N-Acetyl-S-
(benzyl)-L-cysteine (BMA), 2-Methylhippuric acid (2MHA), and 3-Methylhippuric 
acid + 4-Methylhippuric acid (3&4MHA). 
Table 3.1.3. Volatile Organic Compound Metabolite Level of Detection 













N-Acetyl-S- (2-carboxyethyl)-L-cysteine CEMA 6.96 98.62 97.94 99.26 98.83
N-Acetyl-S- (3-Hydroxypropyl)-L-cysteine 3HPMA 13.0 99.41 98.63 99.93 99.86
N-Acetyl-S-(2-carbamoylethyl)-L-cysteine AAMA 2.20 99.49 98.86 99.93 99.86
N-Acetyl-S-(2-carbamoyl-2-hydroxyethyl)-L-
cysteine 
GAMA 9.40 47.93 58.60 43.26 39.54




N-Acetyl-S- (2-hydroxyethyl)-L-cysteine HEMA 0.791 40.63 27.16 54.97 43.47
Benzene N-Acetyl-S-(phenyl)-L-cysteine PMA 0.600 32.42 20.64 44.58 35.30
1-Bromopropane N-Acetyl-S-(n -propyl)-L-cysteine BPMA 1.20 73.02 70.50 79.33 70.33
N-Acetyl-S- (3,4-dihydroxybutyl)-L-cysteine DHBMA 5.25 99.76 99.43 99.93 100.00
N-Acetyl-S-(1-hydroxymethyl-2-propenyl)-L-
cysteine 
MHBMA1 0.700 0.88* 0.69 1.25 0.76
N-Acetyl-S-(2-hydroxy-3-butenyl)-L-cysteine MHBMA2 0.700 14.08* 15.61 12.82 13.42
N-Acetyl-S-(4-hydroxy-2-buten-1-yl)-L-
cysteine 
MHBMA3 0.600 97.51 96.91 97.27 98.49
Carbon-disulfide 2-Thioxothiazolidine-4-carboxylic acid TTCA 11.2 38.38 39.62 38.61 36.69
Crotonaldehyde N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-
cysteine 
HPMMA 2.00 99.93 99.83 100.00 100.00
Cyanide 2-Aminothiazoline-4-carboxylic acid ATCA 15.0 85.45 69.58 96.32 94.72
N, N - 
Dimethylformamide 
N-Acetyl-S-(N-methylcarbamoyl)-L-cysteine AMCC 6.26 99.28 98.34 99.85 99.86
Ethylbenzene, 
styrene 
Phenylglyoxylic acid PGA 12.0 92.99 83.70 98.97 98.67
Propylene oxide N-Acetyl-S-(2-hydroxypropyl)-L-cysteine 2HPMA 5.30 93.89 93.08 95.06 93.77
N-Acetyl-S-(1-phenyl-2-hydroxyethyl-L-
cysteine + N -Acetyl-S-(2-phenyl-2-
hydroxyethyl)-L-cysteine 
PHEMA 0.700 24.97 8.46 34.41 36.17
Mandelic acid MA 12.0 98.52 98.63 98.82 98.09
Tetrachloroethylene N-Acetyl-S-(trichlorovinyl)-L-cysteine TCVMA 3.00 0.07* 0.11 0.07 0.00
Toluene N-Acetyl-S-(benzyl)-L-cysteine BMA 0.500 99.12 99.09 99.26 99.04
N-Acetyl-S-(1,2-dichlorovinyl)-L-cysteine 1,2DCVMA 12.6 0.04* 0.06 0.00 0.07
N-Acetyl-S-(2,2-dichlorovinyl)-L-cysteine 2,2DCVMA 4.70 0.35* 0.69 0.29 0.00
N-Acetyl-S-(dimethylphenyl)-L-cysteine DPMA 0.500 0.31* 0.29 0.29 0.36
2-Methylhippuric acid 2MHA 5.00 93.82 94.28 95.43 91.56
3-Methylhippuric acid + 4-Methylhippuric acid 3&4MHA 8.00 99.54 99.31 99.93 99.45
†App- Appended Full Cohort, LLOD- lower level of detection, *UM-VOC with less than 15% above LOD 
Xylene 







To ensure that the cut-point (15% at or above the LOD) wasn’t driven by the 
nearly 50% of participants who were exposed to tobacco smoke, Table 3.1.3 was 
stratified by tobacco smoke exposure status (Appendix Table A.2). Upon 
stratification there were no additional UM-VOCs that had significantly lower values 
for the percent of measurements at or above the LOD and therefore the previously 
identified 21 UM-VOCs from 17 parent VOCs were maintained for further analysis. 
The descriptive statistics for the 21-creatinine normalized UM-VOCs from 
17 parent VOCs including geometric mean, standard error, minimum, quartile one, 
median, quartile three, and maximum values from the full-appended cohort are 
presented in Table 3.1.4. Table A.3 further stratifies Table 3.1.4 by NHANES wave. 
There were 12 UM-VOCs with significant differences between the NHANES cycles 
(2005-06, 2011-12, 2013-14). All significant differences observed in UM-VOCs 
between the NHANES waves were significant increases in UM-VOCs throughout 
the years, except a metabolite of propylene oxide, 2HPMA (p-value=0.0287), 
which decreased from a geometric mean of 38.3ng/mg creatinine in the 2005-06 
NHANES cycle to a geometric mean of 31.5ng/mg creatinine in the 2013-14 
NHANES cycle. 
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Table 3.1.4. Description of Volatile Organic Compound Metabolites for Appended 
NHANES Study Population 
UM-VOCs stratified by CMS status are presented in Table 3.1.5. Eight of 
the 21 UM-VOCs were significantly different between individuals with CMS and 
individuals without CMS. Four UM-VOCs were significantly higher in individuals 
with CMS: one acrolein metabolite CEMA, a metabolite of 1,3-butadiene DHBMA, 
one cyanide metabolite ATCA, and a metabolite of ethylbenzene/styrene PGA. 
Four UM-VOCs were significantly lower in individuals with CMS: a metabolite of 
acrylamide AAMA, two metabolites of acrylonitrile CYMA and HEMA, and a 
metabolite of xylene 2MHA. 
Parent Compound Metabolite GM SE Min Q1 Median Q3 Max
CEMA 93.97 2.20 1.02 54.41 90.00 157.02 4352.63
3HPMA 259.47 7.13 1.90 130.31 214.95 450.64 8782.05
Acrylamide AAMA 55.49 1.29 0.32 32.47 51.48 90.91 1518.75
GAMA 12.83 0.23 1.37 7.92 12.55 20.38 168.57
Acrylonitrile CYMA 4.39 0.21 0.07 1.04 1.78 12.22 1623.08
Acrylonitrile, vinyl chloride, 
ethylene oxide 
HEMA 1.05 0.03 0.10 0.51 0.96 1.93 44.63
Benzene PMA 0.66 0.02 0.08 0.37 0.64 1.10 21.43
1-Bromopropane BPMA 4.34 0.12 0.18 1.62 4.01 10.34 2288.89
DHBMA 275.63 6.39 0.77 210.55 279.20 371.51 3800.00
MHBMA3 6.61 0.21 0.09 3.10 5.32 10.99 328.42
Carbon-disulfide TTCA 15.36 0.32 1.43 7.26 13.38 27.14 2140.74
Crotonaldehyde HPMMA 478.45 13.50 0.29 248.10 366.35 741.47 19421.00
Cyanide ATCA 90.29 3.62 1.92 46.87 111.12 216.57 2179.41
N, N - Dimethylformamide AMCC 164.95 4.54 0.92 88.16 161.33 301.14 3578.95
Ethylbenzene, styrene PGA 149.80 4.30 1.76 110.01 177.67 259.90 55667.00
Propylene oxide 2HPMA 36.03 1.05 0.77 19.06 31.61 60.66 28130.00
PHEMA 0.73 0.01 0.09 0.39 0.67 1.24 665.56
MA 141.71 2.95 1.76 95.00 135.17 204.80 31000.00
Toluene BMA 7.08 0.14 0.07 3.99 6.46 11.45 7144.14
2MHA 37.16 1.14 0.73 16.66 35.59 80.63 18384.00
3&4MHA 258.20 6.82 1.17 113.21 225.55 583.49 102459.00





Appended Full Cohort (N=4654)
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Table 3.1.5. Description of Volatile Organic Compound Metabolites Stratified by 
Cardiometabolic Syndrome Status 
Among the tobacco smoke exposed study population, CEMA (p=0.0208) 
and PGA (p=0.0203), metabolites of acrolein and ethlybenzene/styrene, 
respectively, were significantly higher in individuals exposed to tobacco smoke 
with CMS as compared to individuals exposed to tobacco smoke without CMS 
(Tablem3.1.6). AAMA (p=0.0403) a metabolite of acrylamide was significantly 
lower in individuals exposed to tobacco smoke with CMS as compared to 
individuals exposed to tobacco smoke without CMS. Amongst the non-tobacco 
smoke exposed inindividuals the study population all six UM-VOCs that were 
significantly different were higher in individuals exposed to tobacco smoke with 
CMS (CEMA: p<0.0001, DHBMA: p=0.0010, MHBMA3: p=0.0424, HPMMA: 
p=0.0034, ATCA: p=0.0075, PGA: p=0.0003) (Table 3.1.6). 
Parent Compound Metabolite
GM SE Min Q1 Median Q3 Max GM SE Min Q1 Median Q3 Max p-value
CEMA 112.85 5.13 2.54 68.22 103.48 181.70 1538.46 91.29 2.17 1.02 52.99 86.32 153.75 4352.63 <.0001
3HPMA 260.15 12.51 6.81 142.27 217.31 406.96 7205.13 259.36 7.58 1.90 128.45 214.42 458.26 8782.05 0.9519
AAMA 51.43 2.21 1.16 31.15 48.88 81.65 616.67 56.16 1.31 0.32 32.80 51.95 91.53 1518.75 0.0308
GAMA 12.52 0.37 2.00 8.15 12.07 18.47 162.05 12.88 0.25 1.37 7.91 12.69 20.78 168.57 0.3827




HEMA 0.97 0.05 0.10 0.50 0.90 1.63 38.43 1.07 0.03 0.12 0.51 0.97 1.99 44.63 0.0336
Benzene PMA 0.66 0.03 0.08 0.37 0.61 0.99 14.44 0.66 0.02 0.09 0.37 0.65 1.11 21.43 0.8877
1-Bromopropane BPMA 4.45 0.27 0.25 1.60 4.22 9.60 369.85 4.32 0.13 0.18 1.63 3.95 10.45 2288.89 0.6542
DHBMA 299.47 9.61 2.75 233.98 304.29 402.59 2294.87 272.02 6.45 0.77 206.96 276.35 366.56 3800.00 0.0011
MHBMA3 6.75 0.34 0.31 3.43 5.49 10.30 255.81 6.59 0.22 0.09 3.03 5.29 11.25 328.42 0.6286
Carbon-disulfide TTCA 16.55 0.87 1.43 7.11 14.22 26.72 1169.01 15.18 0.35 1.64 7.28 13.23 27.17 2140.74 0.1360
Crotonaldehyde HPMMA 514.44 23.92 2.11 285.93 397.75 765.52 16462.00 472.95 13.77 0.29 243.97 360.71 730.45 19421.00 0.0644
Cyanide ATCA 105.12 5.48 1.92 57.56 125.47 226.45 1121.43 88.15 4.00 2.19 44.55 109.04 211.73 2179.41 0.0130
N, N - 
Dimethylformamide 
AMCC 171.63 7.36 3.28 92.15 162.58 296.04 2507.14 163.91 4.67 0.92 87.42 160.99 301.16 3578.95 0.2629
Ethylbenzene, styrene PGA 175.84 6.82 4.59 126.84 185.68 272.58 32525.00 146.01 4.68 1.76 106.32 176.05 256.50 55667.00 0.0003
Propylene oxide 2HPMA 35.32 2.04 1.94 19.38 31.18 56.08 5421.05 36.15 1.10 0.77 19.03 31.71 60.88 28130.00 0.6921
PHEMA 0.72 0.03 0.09 0.39 0.66 1.17 555.56 0.73 0.01 0.10 0.39 0.68 1.24 665.56 0.7112
MA 142.69 5.19 4.67 94.43 133.59 207.03 27778.00 141.56 3.15 1.76 95.11 135.59 204.58 31000.00 0.8367
Toluene BMA 7.19 0.25 0.26 4.17 6.75 12.15 216.67 7.06 0.14 0.07 3.96 6.44 11.33 7144.14 0.6203
2MHA 33.06 2.53 1.32 14.89 30.20 68.04 18384.00 37.86 1.04 0.73 16.77 36.42 81.82 1537.31 0.0469
3&4MHA 239.87 12.96 11.55 109.32 193.06 520.73 102459.00 261.24 6.70 1.17 114.09 233.17 593.97 12456.00 0.0835





CMS (n=811) NonCMS (n=3843)
Acrolein 
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Table 3.1.6 Description of Volatile Organic Compound Metabolites with 
Significant Differences Based on CMS Status Stratified by Tobacco Smoke 
Exposure 
Note: GM- geometric mean. Values are ng/mg creatinine. Tobacco smoke 
exposed defined using serum cotinine values (n= 4652) and questionnaire 
responses (n= 4286).     
Correlation matrices revealed an abundance of moderate correlations; 
correlation coefficient r= 0.3-0.7, for creatinine normalized log transformed UM-
VOCs. A few highly correlated UM-VOCs were observed; correlation coefficient 
r>0.7. The highly correlated creatinine normalized log transformed UM-VOCs for 
the full study group were the two metabolites of xylene MHA2 and 3&4MHA 
(r=0.841), followed by MHBMA3 a metabolite of 1,3-butadiene and HPMMA and 
metabolite of crotonaldehyde (r=0.840), MHBMA3 and CYMA a metabolite of 
acrylonitrile (r=0.800), and MHBMA3 and HPMA3 a metabolite of acrolein 
(r=0.798). The least correlated UM-VOCs were in the full study group were 
3&4MHA and BPMA a metabolite of 1-bromopropane (r=0.003), AMCC a 
metabolite of N,N-dimethylformamide and BPMA (r=0.015), and 3&4MHA and 
TTCA a metabolite of carbon-disulfide (r=0.032). Additionally, a very weak inverse 
correlation was observed between BPMA a metabolite of 1-bromopropane and 
CYMA a metabolite of acrylonitrile (r=-0.008) (Figure 3.1.1). Tobacco smoke 
Parent Compound 
Metabolite GM SE Min Q1 Median Q3 Max GM SE Min Q1 Median Q3 Max p-value
Acrolein CEMA 143.041 10.143 15.375 76.662 144.535 258.620 1538.462 119.942 3.327 1.017 64.457 117.964 215.989 2026.087 0.0208
Acrylamide AAMA 68.237 3.830 3.900 40.593 60.468 115.345 502.347 76.878 2.588 0.322 42.479 76.008 143.161 1408.163 0.0403
Ethylbenzene, 
styrene PGA 199.981 13.200 9.043 144.530 214.848 313.434 32525.000 165.028 6.062 1.756 116.218 192.295 310.570 2708.571 0.0203
Parent Compound 
Metabolite GM SE Min Q1 Median Q3 Max GM SE Min Q1 Median Q3 Max p-value
Acrolein CEMA 93.91 5.81 2.54 63.28 96.47 137.24 1120.00 72.10 1.98 1.77 47.63 72.16 110.06 4352.63 <.0001
DHBMA 288.11 11.35 2.75 228.18 285.68 377.95 2294.87 253.72 5.89 4.03 199.34 260.24 339.42 3800.00 0.0010
MHBMA3 4.76 0.23 0.31 3.12 4.49 7.07 126.90 4.32 0.15 0.24 2.67 4.24 6.78 328.42 0.0424
Crotonaldehyde HPMMA 397.16 19.86 2.11 265.72 362.05 519.53 16462.00 337.90 10.05 1.52 228.07 305.69 464.09 19421.00 0.0034
Cyanide ATCA 112.49 8.47 1.92 58.64 140.18 239.92 969.05 88.66 4.33 2.43 46.42 112.03 203.76 2179.41 0.0075
Ethylbenzene, 
styrene PGA 162.01 8.70 5.09 120.60 180.31 246.18 3461.54 128.86 5.54 2.59 100.45 164.03 230.89 55667.00 0.0003
GM- geometric mean. Values are ng/mg creatinine
1,3-Butadiene 
Smoke Exposed 
Non Smoke Exposed 
CMS (n=356) NonCMS (n=1820)
CMS (n=397) NonCMS (n=1713)
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exposed individuals had many more correlated UM-VOCs than non-tobacco 
tobacco smoke exposed individuals (Figure A1 and Figure A2). 
Theoretically, metabolites from different parent VOCs may be correlated 
without the parent VOCs themselves being correlated. These correlations may 
reflect common sources and/or metabolic pathways. Disentangling the effects of 
highly correlated UM-VOCs on outcomes may be challenging and therefore 
important to identify (Table A.4 Figure 3.1.1, Figure A.1., and Figure A.2.). 




UM-VOCs Associated with CMS 
UM-VOCs were individually assessed to identify if particular metabolites 
were associated with CMS status using survey-weighted logistic regression 
models. Figure 3.2.1 shows the forest plot of the unadjusted odds ratios and 95% 
confidence intervals for each metabolite for the full study cohort. Overall, eight 
metabolites were significantly associated with CMS prevalence. Four UM-VOCs 
(CEMA- acrolein, DHBMA-1,3-butadiene, ATCA- cyanide, and PGA- 
ethylbenzene/styrene) were associated with significant increases in the odds of 
CMS, while 4 UM-VOCs (AAMA-acrylamide, CYMA-acrylonitrile, PMA- benzene, 
2MHA- xylene) were associated with a significant decrease in the odds of CMS 
(Table A.5).  
To reduce the likelihood of a type I error, a multiple comparisons adjustment 
was calculated and a new significance threshold was identified. The multiple 
comparisons adjusted p-value was calculated by dividing alpha, 0.05, by the 
number of factors that were identified in the factor analysis. Based on the factor 
analysis, three latent variables were identified from the VOC metabolites. The 
multiple comparisons adjusted p-value threshold is <0.0167. 
After adjustment for multiple comparisons, the full cohort unadjusted 
models showed 4 odds ratios of UM-VOCs associated with CMS (dichotomous) 
remained significant (CEMA OR: 1.35, 95%CI, 1.19-1.54; DHBMA OR: 1.44, 
95%CI, 1.15-1.81; ATCA OR: 1.13, 95%CI, 1.03-1.24; PGA OR: 1.24 95%CI, 1.11-
1.37) (Figure 3.2.1 and Table A.5). 
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When stratified by smoking status, the non-tobacco smoke exposed cohort 
had 6 metabolites significantly positively associated with CMS (CEMA, DHBMA, 
MHBMA3, HPMMA, ATCA and PGA) (Figure 3.2.2 and Table A.6), while tobacco 
smoke exposed participants showed 3 metabolites significantly associations with 
CMS; two were positively associated with CMS (CEMA and PGA) and 1 negatively 
associated with CMS (AAMA) (Figure 3.2.3 and Table A.6) 
To further investigate the UM-VOC and CMS relationship, logistic 
regression models adjusted for age, NHANES cohort year, and a race and sex 
interaction term were used. 5 UM-VOCs were associated with CMS in the full 
cohort fully adjusted models (Figure 3.2.4 and Table A5). Two UM-VOCs (CEMA-
acrolein and PGA-ethylbenzene/styrene) were significantly associated with 
increased odds of CMS (Figure 3.2.4). Three UM-VOCs (HEMA-acrylonitrile/vinyl 
chloride/ethylene oxide, PHEMA- styrene, and 3MHA/4MHA-xylene) were 
significantly associated with decreased odds of CMS. After adjustment for multiple 
comparisons, the cull cohort fully adjusted models showed 2 adjusted odds ratios 
of UM-VOCs associated with the prevalence of CMS remained significant (CEMA 
OR: 1.24, 95%CI: 1.08-1.43; PGA OR: 1.20, 95%CI: 1.06-1.37) (Table A.5). The 
odds ratios associated with a decreased risk did not maintain statistical 
significance at the multiple comparisons p-value threshold. 
Figures 3.2.5 and Figure 3.2.6 display fully adjusted logistic regression 
models stratified by tobacco smoke exposure status. Among the non-tobacco 
smoke exposure fully adjusted models, 7 metabolites were significantly associated 
with CMS. Again, CEMA-acrolein and PGA-ethylbenzene/styrene were 
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significantly associated with increased odds of CMS. Decreased odds of CMS 
were associated with HEMA-acrylonitrile/vinyl chloride/ethylene oxide, PMA- 
benzene, PHEMA- styrene, 2MHA-xylene, and 3MHA/4MHA-xylene (Figure 3.2.5 
and Table A.7).  After adjustment for multiple comparisons, none of the adjusted 
odds ratios of UM-VOCs associated with the prevalence of CMS remained 
significant among non-tobacco smoke expose participants. Among the smoke 
exposed individuals, zero UM-VOC were significantly associated with CMS (Figure 
3.2.6). 
Figure 3.2.1. Forest Plot- Full Study Cohort Unadjusted Odds And 95% CI For 21 UM-VOCs and CMS (Dichotomous) 








Figure 3.2.2. Forest Plot- Non-Tobacco Smoke Exposed Sub-Population, Unadjusted Odds And 95% CI For 21 UM-VOCs 
and CMS (Dichotomous)   





Figure 3.2.3. Forest Plot-Tobacco Smoke Exposed Sub-Population, Unadjusted Odds And 95% CI For 21 UM-VOCs and 
CMS (Dichotomous)  








Figure 3.2.4. Forest Plot- Full Cohort, Adjusted Odds and 95% CI for 21 UM-VOCs and CMS (Dichotomous) 





Figure 3.2.5. Forest Plot- Non-Tobacco Smoke Exposed Sub-Population, Adjusted Odds And 95% CI For 21 UM-VOCs 
and CMS (Dichotomous)   








Figure 3.2.6. Forest Plot- Tobacco Smoke Exposed Sub-Population, Adjusted Odds And 95% CI For 21 UM-VOCs and 
CMS (Dichotomous)   







Dose-response Relationships of UM-VOCs and CMS 
Dose-response relationships were assessed by plotting CMS prevalence 
on the y-axis against UM-VOC quantile concentration cut-points on the x-axis. 
VOC dose was defined using measures urinary metabolites of VOC as a proxy for 
exposure. UM-VOC quintiles were treated ordinally to assess linear trends, as well 
as categorically, to examine whether any of the quintiles had significantly higher 
odds of CMS versus the referent category (lowest exposure quintile). 
Unadjusted Trends 
Metabolites of seven VOCs had significant linear trends for the prevalence 
of CMS at p-value <0.05; five UM-VOC (quintiles) were associated with increased 
odds of CMS (CEMA, DHBMA, HPMMA, ATCA and PGA) (Figure 3.3.1). When 
the multiple comparisons adjusted significance threshold was applied (p-value 
<0.0167), three metabolites had significant linear trends with the prevalence of 
CMS (CEMA OR: 1.20, 95%CI, 1.12-1.29; DHBMA OR, 1.18, 95%CI: 1.09-1.28; 
HPMMA OR, 1.11, 95%CI: 1.03-1.19) (Table A8). All three metabolites had an 
increased odds CMS (Figure 3.3.1). Neither of metabolites inversely associated 





Figure 3.3.1. Forest Plot- Full Cohort, Unadjusted Odds and 95% CI for 21 UM-VOCs (quantiles) and CMS (Dichotomous) 






CEMA (acrolein) and DHBMA (1,3-butadiene) had significant dose-
response type relationships– with both significant linear and step-wise categorical 
relationships with CMS prevalence (Figure 3.3.2). CEMA and DHBMA have 
significant increases in the prevalence of CMS with each quintile increase in 
metabolite concentration. HPMMA, a crotonaldehyde metabolite, exhibits a similar 
pattern with an overall significant linear trend; however, the last quintile of HPMMA 
concentration falls off with a decrease in prevalence of CMS. ATCA (cyanide) and 
PGA (ethylbenzene) did not have significant step-wise dose-response 
relationships but did show a significant (p-value <0.05) linear trend of increasing 
CMS prevalence with increasing metabolite concentration. The trends observed 
with ATCA and PGA did not hold their significance at the p-value < 0.0167 







Figure 3.3.2. Full-Cohort, CMS Prevalence by UM-VOC Quintile concentration. 
Note: p-values are the Wald chi-square statistic for linear logistic regression 
trends; * = p-value for significant (<0.05) categorical Wald chi-square 
comparisons statistic with the referent group being the first quintile of exposure. 
Adjusted Trends 
The multivariable logistic regression models adjusted for race, sex, cohort 
year, and the race and sex interaction showed an increasing trend in the odds of 
CMS (dichotomous) as CEMA (acrolein) quintiles increased (Figure 3.3.3). 
Participants had approximately 15% (CEMA OR: 1.15, 95%CI: 1.07-1.24) greater 
odds of CMS with each ng of CEMA per mg creatinine increase (p-value: 0.0004) 
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(Table A.9). This relationship was persevered even after the multiple comparisons 
p-value threshold adjustment. CEMA also displayed significant step-wise 
increases in CMS with each quintile increase in metabolite concentration. A 
styrene metabolite, PHEMA, displayed significant decreases in the odds of CMS 
with increasing metabolite concentrations (PHEMA OR: 0.89, 95%CI: 0.81-0.98) 
(p-value= 0.0146) (Table A.9). HEMA, PMA, and both xylene metabolites showed 
significant decreasing trends in the odds of CMS with each quintile increase in 
metabolite concentration at the p-value<0.05 threshold but these relationships did 





Figure 3.3.3. Forest Plot- Full Cohort, Adjusted Odds and 95% CI for 21 UM-VOCs (quantiles) and CMS (Dichotomous) 
Note: Adjusted for age, sex, race and the interaction between sex and race, and NHANES cohort year; odds ratio 
estimates and the corresponding 95% Wald confidence intervals (CI); p-value of the Wald chi-square statistic * = 






Smoking and Non-Smoking Results 
Among the participants in the full appended NHANES cohort who were not 
exposed to tobacco smoke, two metabolites were significantly associated with 
CMS at the multiple comparisons adjusted p-value threshold. One UM-VOC was 
significantly positively associated with CMS at the p-value threshold of 0.0167; 
CMEA, a metabolite of acrolein, was associated with increased odds of CMS 
(CEMA OR: 1.226, 95% CI: 0.078-0.391) (Figure 3.3.4). Quintiles of CEMA also 
maintained a significant step-wise/dose-response type relationship with CMS, as 
was observed in the unadjusted analysis. 3 and 4 MHA a metabolite of xylene was 
significantly inversely associated with CMS (3&4MHA OR: 0.88, 95% CI: 0.79-
0.97) (Table A.10). 
Among the participants in the cohort who were exposed to tobacco smoke, 
a styrene and a toluene metabolite were inversely associated with CMS at the 
significance threshold of p-value <0.05; however, CMS was not significantly 
associated with any metabolites at the multiple comparisons adjusted significance 
threshold (p-value 0.0167) (Figure 3.3.5 and Table A.11).
Figure 3.3.4. Forest Plot- Non-Smoke Exposed: Adjusted Odds and 95% CI for 21 UM-VOCs (quantiles) and CMS 
(Dichotomous) 
Note: Adjusted for age, sex, race and the interaction between sex and race, and NHANES cohort year; odds ratio 
estimates and the corresponding 95% Wald confidence intervals (CI); p-value of the Wald chi-square statistic * = 








Figure 3.3.5. Forest Plot- Smoke Exposed, Adjusted Odds and 95% CI for 21 UM-VOCs (quantiles) and CMS 
(Dichotomous) 
 Note: Adjusted for age, sex, race and the interaction between sex and race, and NHANES cohort year; odds ratio 
estimates and the corresponding 95% Wald confidence intervals (CI); p-value of the Wald chi-square statistic * = 







The combinatory effects of VOCs associated with CMS. 
 Ordinal Logistic Regression 
UM-VOCs were first individually assessed for associations with the ordinal 
CMS-risk score (CMS-RS). The CMS-RS is an ordinal variable designed to 
organize individuals into ordinal categories based on the number of CMS risk 
factors an individual has (0-7) (Table 2.3). Due to low numbers in categories 4 and 
7 of the proposed ordinal categories for the CMS-RS, categories 3 and 4 and 
categories 6 and 7 were condensed into 1 category each; making 6 categories 
(CMS-RS 0-5) instead of 8. The Score Chi-Square test for proportional odds 
assumption was not significant with respect to the chi-square distribution, which 
indicates that the proportional odds model adequately fit the data for all VOC’s. 
The unadjusted ordinal survey-weighted logistic regression models 
identified 8 UM-VOCs significant at the p-value <0.05 threshold, with six 
metabolites positively associated with the ordinal CMS risk score (Figure 3.4.1) 
After applying the multiple comparisons adjusted p-value threshold, (p-value 
<0.0167) four UM-VOCs remained significantly positively associated with the 
ordinal CMS-RS (CEMA OR: 1.38, 95%CI: 1.27-1.51; DHBMA OR: 1.34, 95%CI: 
1.14-1.58; AMCC OR: 1.12, 95%CI: 1.03-1.21; PGA OR: 1.18, 95%CI: 1.11-1.25;) 
(Table A.12). CYMA (OR: 1.20, 95%CI: 1.12-1.29) was significantly negatively 
associated with CMS-RS (Table A.12). 
Ordinal logistic regression models adjusted for age, sex, race, the 
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interaction between sex and race, and NHANES cohort year were significant for 
six metabolites (Figure 3.4.2); two of these metabolites were positively associated 
with the CMS-RS (CEMA OR: 1.27, 95%CI: 1.16-1.39; PGA OR: 1.17, 95%CI: 
1.09-1.25), and four were negatively associated (HEMA OR: 0.89, 95%CI: 0.82-
0.98; PMA OR: 0.80, 95%CI: 0.71-0.89; TTCA OR: 0.90, 95%CI: 0.84-0.96; 
PHEMA OR: 0.84, 95%CI: 0.76-0.93) (Table A.13). 
Figure 3.4.1. Forest Plot- Full cohort, Unadjusted ordinal odds and 95% CI for 21 UM-VOCs and cardiometabolic 
syndrome risk score (CMS-RS). 





Figure 3.4.2. Forest Plot- Full cohort, Adjusted ordinal odds and 95% CI for 21 UM-VOCs and cardiometabolic syndrome 
risk score (CMS-RS). 
Note: Adjusted for age, sex, race and the interaction between sex and race, and NHANES cohort year; odds ratio 
estimates and the corresponding 95% Wald confidence intervals (CI); p-value of the Wald chi-square statistic * = 







The models were then stratified by tobacco smoke exposure. Among the 
tobacco smoke exposed subpopulation, only one metabolite, PGA (a metabolite of 
ethylbenzene/styrene) was significantly positively associated (p-value threshold 
<0.0167) with the CMS-RS (PGA OR: 1.17, 95%CI: 1.05-1.31) (Figure 3.4.3, Table 
A.14). Among the non-tobacco smoke exposed cohort, one metabolite, CEMA (a 
metabolite of acrolein) was significantly positively associated (p <0.0167) with the 
CMS-RS (CEMA OR: 1.39, 95%CI: 1.19-1.62) (Figure 3.4.4, Table A.15). Several 
of the VOC’s were significantly inversely associated with the CMS-RS in both the 
smoke and non-smoke exposed subpopulations. 
Figure 3.4.3. Forest Plot- Tobacco Smoke Exposed, Adjusted ordinal odds and 95% CI for 21 UM-VOCs and 
cardiometabolic syndrome risk score (CMS-RS). 
Note: Adjusted for age, sex, race and the interaction between sex and race, and NHANES cohort year; odds ratio 
estimates and the corresponding 95% Wald confidence intervals (CI); p-value of the Wald chi-square statistic * = 








Figure 3.4.4. Forest Plot- Non-tobacco Smoke Exposed, Adjusted ordinal odds and 95% CI for 21 UM-VOCs and 
cardiometabolic syndrome risk score (CMS-RS). 
Note: Adjusted for age, sex, race and the interaction between sex and race, and NHANES cohort year; odds ratio 
estimates and the corresponding 95% Wald confidence intervals (CI); p-value of the Wald chi-square statistic * = 







Two-way interactions were assessed to address if the effect of a given 
metabolite is dependent on the concentrations of another metabolite, ultimately 
affecting the response of CMS. UM-VOCs selected for inclusion in the backward 
elimination analysis to identify potentially significant 2-way interactions are 
identified in Table 3.4.1. Thirteen representative UM-VOCs were included in the 
logistic regression backward elimination analysis, including one representative 
metabolite for each parent VOC. Representative metabolites were selected only 
from metabolites with greater than 40% of samples measured above LOD. If a 
parent VOC had multiple metabolites, the metabolite with the greatest significance 
in the fully adjusted ordinal logistic regression models was selected. If a VOC had 
multiple metabolites but none with significant associations with CMS in the fully 
adjusted ordinal logistic regression models, the metabolite with the greatest 
abundance was selected as the representative metabolite for that VOC. 
The backward elimination analysis utilized PROC LOGISTIC. Ninety-two 
effects were entered into the model; 10 individual UM-VOCs and 6 two-way 
interactions between UM-VOCs were retained in the model using a significance 
level of 0.05. The 10 individual UM-VOCs retained in the model were; CEMA, 
AAMA, CYMA, BPMA, DHBMA, HPMMA, ATCA, PGA, MA, and 2MHA. The six 
two-way interactions that were retained in the model were: AAMA and BPMA, 
CYMA and BPMA, AAMA and HPMMA, ATCA and MA, CEMA and 2MHA, and 
DHBMA and 2MHA. 
To assess how the response to CMS depends on the interactions identified 
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from the backward selection analysis, each of the six identified interaction terms 
and each of the 10 individual UM-VOCs, were then individually placed into its own 
survey weighted logistic regression model adjusted for age, sex, race, the 
interaction between sex and race, and NHANES cohort year. 
After assessing the significance (p-value <0.05) of the interaction terms and 
the individual UM-VOCs in their own models, the final model identified from the 
backwards selection logistic regression technique with CMS (yes/no) as the 
outcome variable included the individual UM-VOCs CEMA, PGA, and 2MHA as 
well as an interaction term and lower order components for CYMA and BPMA; 
adjustments for age, sex, race, the interaction between sex and race, and 
NHANES cohort year were also included in the model. 
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Table 3.4.1. Identification of UM-VOCs included in backward selection analysis. 
 
Note: UM-VOC significance in ordinal logistic regression models and percent 
above LOD for each metabolite for the full cohort, tobacco smoke exposed 
individuals, and non-tobacco smoke exposed individuals. ^ = < 40% of samples 
above LOD. * = Wald chi-square statistic, significance at a p-value threshold of 
<0.05; † = significant at a p-value threshold of <0.0167. # = metabolite selected 
for each parent VOC to be tested for 2-way interactions.  
 
In the final full model built using the backward selection technique, the betas 
for CYMA and BPMA were not significant. However, the betas for CEMA, PGA, 
2MHA, and the interaction term CYMA*BPMA were significant. The beta for the 
interaction of CYMA and BPMA was negative, indicating that the combined effect 
of both VOC’s is slightly less than would be expected if they were behaving 












Appended     
n=4654
Smoke 




Exposed       
n=2110
CEMA # †* †* 98.62 99.27 97.49
3HPMA 99.41 99.56 99.06
AAMA # †* 99.49 99.68 99.38
GAMA 47.93 60.66 37.73^
Acrylonitrile CYMA # †* 90.09 95.29 82.32
Acrylonitrile, vinyl 
chloride, ethylene oxide 
HEMA †* * †* 40.63 50.59 26.87^
Benzene PMA †* †* †* 32.42^ 35.99^ 29.45^
1-Bromopropane BPMA # 73.02 72.03 71.50
DHBMA # 99.76 99.64 99.79
MHBMA3 97.51 97.87 96.37
Carbon-disulfide TTCA †* †* 38.38^ 39.99^ 33.82^
Crotonaldehyde HPMMA # 99.93 99.94 99.99
Cyanide ATCA # 85.45 82.58 84.85
N, N - 
Dimethylformamide 
AMCC # 99.28 99.51 99.24
Ethylbenzene, styrene PGA # †* †* * 92.99 92.48 91.11
Propylene oxide 2HPMA # * * * 93.89 96.52 91.04
PHEMA †* †* * 24.97^ 27.94^ 16.87^
MA # 98.52 98.97 98.29
Toluene BMA # 99.12 98.61 99.09
2MHA # †* †* †* 93.82 96.84 91.47






Significance in Ordinal 
Logistic Regrassion 
Models Percent Above LOD
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Table 3.4.2. Analysis of maximum likelihood estimates 
for the final logistic regression model produced by the 
backwards selection method 
Factor Analysis 
Three latent variables were identified from the factor analysis conducted in 
Aim 2. To help reduce collinearity, the factor analysis was conducted using only 
the non-tobacco smoke exposed population of the cohort and only with UM-VOCs 
with greater than 40% of samples measured above LOD. The rotated factor pattern 
analysis and accompanying path diagram (Figure 3.4.5) show directed links from 
factors to variables that are associated with a 0.3 or greater magnitude in loading 
estimates. The key metabolites found in factor 1 were toluene, N,N-
dimethylformamide, 1,3-butadiene, acrylamide, ethylbenzene/styrene, and 
styrene, which explained 56% of the variance in the data. Factor 2, which 
explained 36% of the variance in the data, was distinguished by propylene oxide, 
1-brompropane, and acrolein. Factors 1 and 2 share crotonaldehyde, 1,3-
butadiene, and acrolein. Factor 3 explained 8% of the variance in the data. The 
metabolites extracted by factor 3 were both of the xylene metabolites. 
In an ordinal logistic regression analysis of the identified 3 latent factors and 
the CMS-RS, factors 1 and 2 were not significant in the model after adjusting for 
CYMA 0.171 0.197 0.3904
BPMA 0.055 0.0654 0.4089
CYMA*BPMA -0.198 0.0776 0.0143
CEMA 0.326 0.1604 0.0476
PGA 0.253 0.0962 0.0114
MHA2 -0.195 0.0693 0.0072




age, sex, race, the interaction between sex and race, and NHANES cohort year 
(factor 1 OR: 1.11, 95%CI: 0.97-1.26; factor 2 OR: 0.96, 95%CI: 0.85-1.08). Factor 
3 was significantly associated with a decreased odds of ordinal CMS risk. For 
every unit increase in of factor 3 there was a significant 0.79 (95%CI: 0.72-0.87) 
times lower odds in ordinal CMS risk. The proportional odds assumption was met 




Figure 3.4.5. Factor analysis path diagram of NHANES urinary metabolites of volatile organic compounds.   
Note: Creatinine-normalized log-transformed UM-VOCs were used in the factor analysis. Loading estimates >0.3 are 
indicated by the directed links from factors to variables. The double-headed links show correlations between factors. 






Least Absolute Shrinkage and Selection Operator (LASSO) Method 
A generalized linear model employing the LASSO fit procedure was used 
to identify which of the 21 UM-VOCs best predicts prevalent CMS. The large 
sample size of the cohort allowed for the optimum model to be selected by 
estimating the prediction error of the models directly via the use of a validation data 
set to tune the penalized regression. The training observations set (n= 2886) was 
used to produce the solution path while the validation set (n= 1186) was used to 
estimate the prediction error of each of the models on the solution path. 
Figure 3.4.6 shows the ASE of the models on the LASSO solution path 
separately for the training and validation sets. The LASSO solution path is created 
on a grid of the tuning parameter value (t). Along the X axis is the normalized tuning 
values (the L1 norm of the regression coefficients divided by the L1 norm of the 
ordinary least squares solution). Model 18 is the model with the smallest ASE 
produced by the validation data and is therefore the best fit model. Moving from 
left to right across the X axis, the model complexity increases; i.e., the amount of 
shrinkage that is imposed on the regression coefficients deceases. For the training 
data, the model complexity increases and the ASE decreases; but for the validation 
data, the prediction error decreases and then increases as the model gets more 
complex. The vertical line in the errors plots indicate the point of minimum ASE. 
This point indicates that the variables before this line of distinction have important 
effects in explaining the variation in CMS. The variables after this line describe 
random noise in the training data that is not reproducibly observed in the validation 
data. 
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The variables with explanatory value chosen by the validation criteria in a 
generalized linear model employing the LASSO fit procedure for all 21 UM-VOCs 
in the full study cohort can be observed in the coefficient progression plot (Figure 
3.4.7). The UM-VOCs with explanatory power in a linear model predicting 
prevalent CMS are: CEMA, 3HPMA, AAMA, GAMA, CYMA, HEMA, PMA, BPMA, 
DHBMA, TTCA, HPMMA, ATCA, AMCC, PGA, 2HPMA, PHEMA, MA, and 2MHA. 
Figure 3.4.6. Training set and validation set errors plots for the generalized linear 
model employing the LASSO fit for 21 UM-VOCs in the full cohort. 
Note: The vertical line labeled “selected step” is the model with the smallest 
ASE= best fit model.  
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Figure 3.4.7 Coefficient Progression Plot- Standardized coefficients estimates as 
a function of the validations tuning parameter values for the generalized linear 
model employing the LASSO fit for 21 UM-VOCs in the full cohort.   
 
Additionally, a linear model requesting the LASSO fit method for the full 
cohort was built using all 21 UM-VOCs and their two-way interactions. Again 30% 
of the data was reserved as validation data for tuning the model, which was used 
to estimate the prediction error for model selection; the remaining 70% of the data 
was used as the training data to fit the models. 232 variables were considered for 
selection which includes all two-way interactions.  
Figure 3.4.8 shows the optimum model for predicting prevalent CMS using 
all 21 UM-VOCs and their two-way interactions (Model 30). The variables with 
explanatory value were chosen by the validation criteria in a generalized linear 
model employing the LASSO fit procedure for all 21 UM-VOCs and all two-way 
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interactions in the full study cohort can be observed in the coefficient progression 
plot (Figure 3.4.9). The UM-VOCs with most explanatory power in a linear model 
including all two-way interactions predicting prevalent CMS were 3HPMA and 
2HPMA, and the two-way interactions retained in the model were: 3HPMA*AAMA, 
AAMA*CYMA, CEMA*DHBMA, AAMA*MHBMA3, BPMA*TTCA, CEMA*HPMMA, 
DHBMA*HPMMA, CEMA*ATCA, HEMA*ATCA, CEMA*AMCC, TTCA*AMCC, 
CEMA*PGA, HPMMA*PGA, PMA*PHEMA, CEMA*BMA, HEMA*BMA, 
AAMA*MHA2, PMA*2MHA. 
Figure 3.4.8. Training set and validation set errors for the generalized linear 
model employing the LASSO fit for 21 UM-VOCs and all two-way interactions in 
the full cohort.  
Note: The vertical line labeled “selected step” is the model with the smallest 
ASE= best fit model.  
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Figure 3.4.9 Coefficient Progression Plot- Standardized coefficients estimates as 
a function of the validations tuning parameter values for the generalized linear 
model employing the LASSO fit for 21 UM-VOCs and all two-way interactions in 
the full cohort.   
Cumulative VOC Exposure Score (UM-VOC) 
A cumulative VOC exposure score was computed by adding quintile scores 
for thirteen representative UM-VOCs for each NHANES participant. The UM-
VOC exposure score was then used to identify if cumulative VOC exposures were 
associated with prevalent CMS and ordinal disease progression in non-tobacco 
smoke exposed participants. There were significant mean differences in the UM-
VOC exposure score for all model adjustment variables (age, sex, race, and 
NHANES cohort year) (Table 3.4.3). 
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Table 3.4.3 Mean UM-VOC exposure score for all adjustment variables in the 
UM-VOC exposure score logistic regression models for non-tobacco smoke 
exposed participants.  
 
 
The mean UM-VOC exposure score for participants without CMS was 
(37.79 ± 0.48), while the mean UM-VOC exposure score for participants with 
CMS was (39.93 ± 0.99); representing a significant mean difference in cumulative 
VOC concentrations between individuals with and without CMS (p-value= 0.0170). 
For every one unit increase in the UM-VOC exposure score, the odds of having 
CMS increased by a factor of 1.020 (95% CI: 1.003, 1.037); however, after 
adjusting for age, sex, race, the interaction between sex and race, and NHANES 





Non-Smoke Exposed 38.12 (0.50) 0.017
CMS 388 39.93 (0.99)
No CMS 1691 37.79 (0.48)
Age 2079 38.12 (0.59) <.0001
≤51.0 1076 36.10 (0.57) 
>51.0 1103 40.63 (0.63)
Sex 2079 38.12 (0.50) <.0001
Male 896 35.59 (0.56)
Female 1183 40.04 (0.59)
Race or Ethnic Origin 2079 38.12 (0.50) <.0001
Mexican American 364 38.62 (0.74)
Other Hispanic 197 37.74 (0.79)
Non-Hispanic White 921 38.52 (0.62)
Non-Hispanic Black 333 34.31 (0.65)
Other/Multi Racial 264 37.55 (1.24)
NHANES Cohort Year 2079 38.12 (0.50) <.0001
2005-2006 713 36.02 (5.8)
2011-2012 680 40.82 (0.56)
2013-2014 686 37.69 (1.26)
Note: 51.0 was the mean age of non-smokers 
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1.021). Additionally, the UM-VOC exposure score was significantly associated 
with the progression of disease towards clinically diagnosable CMS. There was a 
significant linear trend in the mean UM-VOC exposure score as the number of 
components of CMS increased (p-value= 0.0018) (Figure 3.4.10). An unadjusted 
ordinal logistic regression model also demonstrated a significant association 
between UM-VOC and CMS components treated ordinally (OR= 1.015; 95% CI: 
1.007, 1.024). However, after adjusting for covariates, the association became 
attenuated (OR=0.996; 95% CI: 0.988, 1.004). 
Figure 3.4.10. Box plot of UM-VOC exposure scores for the non-tobacco smoke 
exposed study cohort stratified by increasing number of components of CMS.  
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CHAPTER FOUR 
SUMMARY AND DISCUSSION 
In this study nationally-representative associations of CMS and individual-
level concentrations of VOCs were examined, from both an individual VOC 
exposure perspective as well as a multipollutant exposure perspective. UM-VOC 
concentrations were significantly different between individuals with CMS 
compared with individuals without CMS and both prevalence and disease 
progression towards clinically diagnosable CMS was associated with UM-VOC 
concentrations. Furthermore, dose-response type relationships were observed 
with metabolites, supporting the hypothesis that CMS is positively associated with 
increasing UM-VOC concentrations. Taken together, these findings suggest that 
current general-population VOC exposures are of public health significance and 
may be playing a meaningful role in the increasing global CMS rates. 
VOCs have been most widely studied with respect to their acute health 
effects or with respect to their carcinogenicity; however, exposure to VOCs is 
ubiquitous and the VOCs of interest in this study have previously been associated 
with numerous other adverse health effects. Additionally, in vivo investigations 
have established probable mechanistic links (136, 157, 159, 160); occupational
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 studies have established significant associations with acute and chronic relatively-
high-dose VOC exposures (141-143, 157, 158); and environmental and 
epidemiologic studies have provided significant evidence of associations between 
lower-dose chronic, and air pollution-related VOC exposures and CMS or 
components of CMS (126, 133). However, few studies have produced national 
estimates of personal-level VOC exposures. This research expands considerably 
on previous epidemiologic findings and provides support that relatively-low 
concentration, general-population VOC exposure levels are associated with CMS.  
National-level distributions of personal-level measures of exposure to VOCs 
are lacking. This analysis is the first quantitative and representative investigation 
to use urinary metabolites of VOCs to assess associations with CMS. The majority 
of previous environmental and epidemiologic research demonstrating adverse 
health effects with VOCs have been conducted using exposure estimates 
generated with modeling techniques. The two most widely used modeling 
approaches are the bottom-up approach using emissions inventories and the top-
down approach using ambient measures modeling (22, 245, 246). A limited 
number of studies have used other more individual-level exposure estimates such 
as personal air monitors and blood VOC measures (225, 230, 247). Still fewer have 
used urinary metabolites as the measure of exposure(248-253). 
Urinary metabolites of VOCs were used to estimate total VOC exposure in 
this analysis. These urinary metabolites of VOCs are measures of urinary 
mercapturic acids (MAs) and can be used as biomarkers of an individuals’ internal 
toxicant dose (254). Excretion of MAs denotes electrophilic compound absorption 
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or formation in the body from glutathione S-conjugates via the glutathione-pathway 
(235). Because glutathione is an essential endogenous compound used to protect 
against electrophiles and radicals, MAs reflect a toxicologically relevant absorbed 
dose (255). In comparison with blood VOC measures, the urinary metabolites of 
VOCs have fewer kinetic influences and have a relatively delayed clearance, 
resulting in measurements representative of a broader exposure window: minutes 
to hours for blood, versus hours to days for urine (256). Consequently, UM-VOCs 
better reflect an individual’s day-to-day VOC exposure spectrum, and therefore 
UM-VOCs are able to capture indoor, personal-care, and volatile chemical 
products exposures, whose concentrations would quickly diminish in blood 
biomonitoring measurements. 
Additionally, MAs have been used in environmental, biological, biological 
effects, and health surveillance monitoring for decades, and federal agencies have 
widely used MAs such as UM-VOCs as accurate, sensitive, and precise 
biomarkers of occupational and environmental exposures (254, 255, 257, 258). 
UM-VOCs have been used as biomarkers for tobacco-smoke exposure, and the 
detection and quantitation of numerous MAs has become an important tool for 
characterizing chemical exposures (25, 254, 255). External measures of exposure 
to VOCs can present significant challenges. It has been shown that personal 
exposures are often greater than the sum of indoor and outdoor pollution levels, 
perhaps because fully accounting for the numerous routes and sources of 
exposure is extremely challenging (259). However, biomarker estimates better 
account for variations in toxicant absorption and metabolism which provide an 
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individuals’ internal toxicant dose (255). 
Among the non-tobacco smoke exposed individuals investigated in this 
study, increased odds of CMS were found with metabolites of acrolein, 1,3-
butadiene, crotonaldehyde, cyanide, and ethylbenzene/styrene. Dose-response 
type relationships with metabolites of acrolein, 1,3-butadiene, and crotonaldehyde 
were observed. Acrolein and ethylbenzene/styrene metabolites were associated 
with disease progression towards clinically diagnosable CMS. 
One of the major VOCs that was associated with CMS in this study was 
acrolein. Not only was acrolein associated with CMS dichotomously and ordinally 
in all sub-population analyses, but acrolein showed strong evidence of a dose-
response relationship with CMS. These patterns reflect the importance of acrolein 
exposures. The unwavering association between CEMA and CMS indicates the 
public health importance of even very low-dose exposures to acrolein. The 
relationship between CMS and acrolein at the population level suggest acrolein 
may be playing a role in the development or progression of CMS. Due to 
inadequate evidence, acrolein has not been classified as a carcinogen (41). 
However, acrolein is a known respiratory toxicant and has been liked to numerous 
adverse health effects including pulmonary edema, chronic obstructive pulmonary 
disease, and Alzheimer’s (41, 260, 261). More importantly for the support of this 
research, a limited number of studies have found acrolein is associated with 
increased risk of cardiovascular disease, atherosclerosis, diabetes, diabetic 
complications, and insulin resistance (249, 250, 262-264). Furthermore, recent in 
vitro human endothelial cell work has shown acrolein exposure is associated with 
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dysregulation of glucose transport and in vivo mice studies have begun to elucidate 
a potential mechanism (265, 266).  
The mechanistic hypothesis for health effects associated with acrolein 
exposure involves the transient receptor potential ankyrin 1 (TRPA1) channel. 
TRPA1 is a non-selective cation (calcium) channel that is an uninhibited sensory 
receptor which mediates pain reception/transmission and irritant-related reflexes 
and is known to play a primary role in the inflammatory pain response (267).  
TRPA1 receptors are concentrated in sensory fibers but have also been identified 
in non-neuronal location, including the endothelium, urothelium, vasculature, and 
heart (268-277). The health effects hypothesis for acrolein exposure begins with 
acrolein activating the TRPA1 channel through aldehyde conjugation with free 
cysteines in the TRPA1 channel. The activation of the TRPA1 receptor incites an 
inflammatory/pain response known as ‘neurogenic inflammation’. The neurogenic 
inflammation response induces the release of vasoactive peptides, substance P (a 
neuropeptide which acts as a neurotransmitter and as a neuromodulator), and 
calcitonin gene-related peptide, which increase blood flow, vascular permeability, 
and leukocyte binding (269, 278-285). Chronic systemic activation of the 
neurogenic inflammatory response would lead to endothelial dysfunction, pro-
atherosclerotic changes, hypertension, and cardiometabolic dysfunction.   
Crotonaldehyde and 1,3-butadiene were significantly associated with CMS 
in this study. Because crotonaldehyde is a major metabolite of 1,3-butadiene, it 
can be assumed that crotonaldehyde and 1,3-butadiene associations would likely 
be parallel and/or correlated. Like acrolein, crotonaldehyde is also an unsaturated 
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aldehyde and preliminary unpublished work has shown crotonaldehyde produces 
similar TRPA1 neurogenic inflammatory effects as acrolein exposures (286). 
Furthermore, this study identified that acrolein had significant interactions with both 
1,3-butadiene and crotonaldehyde in multipollutant model building analyses and 
all 3 VOCs were shared between factor 1 and 2 in the factor analysis, suggesting 
they explain a sizable amount of variance in both factors. Despite data showing 
the negative cardiovascular effects of unsaturated aldehydes are TRPA1-
dependent, the role of TRPA1 in the potential cardiometabolic toxicity of other 
aldehydes and mixtures is not well known (267, 287-289). The findings from this 
research support the hypothesis that the activation of the TRPA1 channel by 
unsaturated aldehydes, which is proposed to occur through aldehyde conjugation 
with the TRPA1 N-terminal free cysteines, may induce cardiometabolic toxicity 
(290).  
The ethylbenzene/styrene metabolite PGA was significantly associated with 
CMS in fully adjusted models as well as in tobacco smoke and non-tobacco smoke 
exposed subpopulation analyses. PGA was the only metabolite that was 
consistently associated with CMS in the tobacco smoke exposed subpopulation 
analyses. Ethylbenzene and styrene generate reactive oxygen species in the body. 
Styrene exposure has even been shown to increase lipid peroxidation and reactive 
oxygen species (ROS) formation in a dose-dependent manner (291, 292). ROS 
formation has also been shown to activate the TRPA1 channel (271, 293-295). 
While, the effect of styrene exposure on the general population at current levels of 
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exposure is not known, findings in this study indicate an important link between 
ethylbenzene/styrene metabolites and CMS. 
Acrolein, crotonaldehyde, and 1,3-butadiene were the three most 
associated VOCs with CMS. Evidence that all three activate neurogenic 
inflammation via the TRPA1 receptor has been reported. While, 
ethylbenzene/styrene metabolite activation of the TRPA1 receptor via ROS 
formation has not been explicitly studied ethylbenzene and styrene are known to 
generate high levels of oxidative stress and ROS has additionally been identified 
as an activator of the neurogenic inflammatory response via the TRPA1 receptor. 
Due to the cross-sectional nature of this study, evidence for causative links cannot 
be provided; however, the findings support speculation that chronic unsaturated 
aldehyde activation of the TRPA1 receptor is likely to be an important major 
contributor of the observed associations between VOCs and CMS. 
In this study, differences between individuals exposed to tobacco smoke 
and those not exposed to tobacco smoke were explored. It has been well 
established that smokers and tobacco-smoke exposed individuals have 
significantly elevated levels of a number of the VOCs investigated in this study (25, 
32, 33, 224, 296). Therefore, it was hypothesized that including individuals 
exposed to tobacco smoke would represent the high end of VOC exposure and 
that associations with VOCs and CMS would not only be maintained in the 
tobacco-smoke exposed individuals but would show greater associations. 
However, it was unexpected that individuals exposed to tobacco-smoke had few 
significant UM-VOCs associated with CMS. This lack of a relationship between 
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VOC concentrations and CMS in tobacco smoke-exposed individuals has not been 
previously shown. While it was found that significant differences in the 
concentrations of VOCs existed between tobacco-smoke exposed and non-
tobacco smoke exposed individuals, there was not consistent evidence of a 
compelling relationship between VOC exposure and CMS in tobacco smoke 
exposed individuals. The inability to establish a relationship between VOCs and 
CMS in the tobacco smoke exposed subpopulation may be partially explained by 
the significantly higher VOC concentrations in the tobacco smoke-exposed 
individuals. The very high levels of VOCs in all individuals in this subpopulation 
make uncovering any association between UM-VOCs and CMS difficult. Factors, 
other than VOC exposure, are likely playing a larger role in determining the 
development of CMS among those exposed to tobacco smoke.   
There are many strengths of this study. The study includes participants from 
three different NHANES cohorts and covers a relatively large span of time. The 
inclusion of multiple cohort years is noteworthy as it ensures that associations are 
steadfast and not identified by chance or mistake in one study population. The data 
analyzed come from a well-powered cohort representative of the entire United 
States. Few studies have assessed health effects of VOCs in a nationally 
representative manner. Still fewer have assessed these health effects from a 
multipollutant perspective. Several meaningful multipollutant groupings and 
interactions were found among UM-VOCs, and their associations with CMS. The 
logistic regression backward-selection method identified six significant two-way 
interactions between UM-VOC and CMS; whereas the LASSO penalized 
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regression method, which is more equipped to handle the correlated exposures, 
identified eighteen significant two-way interactions. These two model-building 
techniques identifying such large numbers of two-way interactions emphasizes the 
importance of multipollutant approaches that consider the joint effects of multiple 
constituents. Furthermore, the cumulative VOC exposure score provided 
significant linear and unadjusted ordinal trends towards clinically diagnosable 
CMS, further illustrating the importance of the multipollutant mixtures perspective. 
Hence, the present study is the first to assess multipollutant health effects of VOCs 
using urinary metabolites as biomarkers of individual-level exposure to VOCs. The 
NHANES data are unique and valuable in providing a quantitative multi-year 
history of population exposures to VOCs in the U.S. Finally, the novel generation 
of a cumulative VOC exposure score provides unique insight into the nature and 
the associations of CMS and VOC exposures on a national level. 
Nonetheless, the study has some limitations. First, all analytical methods of 
UM-VOC analysis in each NHANES waves were unchanged. However, upon close 
review of NHANES documentation, it was noted the 2005-2006 UM-VOC analysis 
was conducted on residual urine samples (NCHS, 2018). The 2005-2006 surplus 
urine samples were processed and then stored at less than -20ºC until samples 
were pulled for VOC analysis. Urinary metabolites are generally stable, and 
internal stability studies conducted by NHANES showed no evidence for 
metabolite degradation. The proper handling of samples, stability of the urinary 
VOC metabolites, consistency of analytical protocol, and internal validation studies 
provide a sufficient indication of the validity of the observed concentrations. 
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A second limitation is the fact that inverse associations suggesting that 
increases in some UM-VOC concentrations are protective of CMS were observed 
in all subgroup analyses, in both adjusted and unadjusted models. Inverse 
associations between VOC exposures and health effects are not particularly 
plausible. VOCs are not likely to be protective of CMS status. It is possible that the 
metabolites associated with decreased odds of CMS are indicative of demographic 
subgroups with less CMS prevalence. For example, walking/cycling and home 
renovations have been identified as determinates of toluene exposure in a number 
of previous studies (247). Lifestyle factors such as physical activity and home 
renovations or new construction could be indicative of specific subpopulations with 
generally healthier lifestyles or overall better health for any number of reasons.  
It has been well established that benzene is highly correlated with exposure 
to tobacco smoke and is a known carcinogen, endocrine disruptor and has been 
previously linked to cardiometabolic disease (50, 63, 247, 297). Findings that 
benzene is inversely associated with CMS in the tobacco smoke exposed 
subpopulation is suspect. It is possible that confounding may have played a role in 
the inverse associations identified with VOCs and CMS. Some evidence of 
confounding by age was present in this analysis. The inverse associations 
between UM-VOCs and CMS identified among the tobacco smoke exposed 
populations of this study warrant further investigation.  
Finally, uncertainties arise from the lack of information on actual exposures 
and individual variation including genetic and physiological differences that likely 
lead to variation in rates of VOC metabolism. The analysis showed age, sex, and 
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race were important variables to adjust for in models. Age, sex, and race each 
influence metabolism but individual variation or subgroup variation 
characterizations have not been well studied or defined. As the field of 
metabolomics continues to evolve, attention to the subgroup variations and the 
ability to handle these discrepancies will undoubtedly need special consideration. 
There is sufficient warrant to conduct more detailed exposure assessments and 
metabolomic analyses to identify new potential factors responsible for variations 
within and across populations. Once identified, these data could be added to future 
studies to aid in the identification of the major contributors of subpopulation 
differences in VOCs to help improve future analyses.   
Additional work is also needed to assess VOC exposures geographically 
and by urban/rural subgroups. It is currently unknown if or to what extent spatial 
variability exists in personal exposure to VOCs; however, the observed 
associations between VOCs and CMS in the United States, identified in this 
investigation, are not likely to be solely attributed to this variation. Nevertheless, 
the increasing proportion of people living in urban environments may be an 
important contributing factor. Additional analyses of other cardiometabolic health 
related effects and updated economic implications of national level health effects 
associated with VOC exposures is needed. It is probable that the direct and indirect 
economic losses accrued over several generations could outweigh the capital 
investments needed for the implementation of volatile organic compound-
reduction initiatives. These analyses would strengthen the rationale for the 
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Recent work suggests that exposure to environmental air pollution is an 
important contributor to cardiovascular and metabolic dysfunction. Exceedingly 
little is known about the extent to which environmental air pollution exposures 
contribute to cardiometabolic syndrome or if VOCs are an important contributor to 
insulin resistance and cardiometabolic syndrome. Exposure and disease rate 
associations are important to study as their implications are significant for public 
health, clinical and mechanistic advances. 
 The importance of mixtures investigations in exposure science has recently 
been underscored by academic researchers and policy makers. Numerous single-
exposure-type investigations of the health effects of VOCs have been conducted 
but to date only a handful of investigations have assessed multipollutant VOC 
exposures and their associations with health effects; this is the first investigation 
to study the combinatory effects of these specific VOCs using urinary metabolites, 
or to investigate mixtures of these UM-VOCs and their associations with CMS. 
The findings from this research are an important step in elucidating the 
importance of VOCs’ contributions to chronic disease processes, specifically CMS. 
Information regarding the links between VOC and CMS would strongly reinforce 
priorities in public health policy and planning and incentives for pursuing specific 
strategies to change unhealthy environmental contributions and ultimately reduce 
cardiometabolic health–related burdens. This investigation of the associations
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between VOCs with CMS have provided fundamental insight into the contribution 
of a major modifiable environmental pollutant and its role in CMS.  
These novel nationally-representative estimates of personal-level exposure 
to VOCs derived from individual participants’ urinary metabolites provide unique 
insight into associations and patterns of personal exposure to VOCs and their 
associations with CMS in the United States. To date, quantitative and nationally 
representative associations of individual-level exposure to VOCs using urinary 
biomarkers of exposure and their associations with CMS prevalence have not been 
reported. 
In conclusion, it was hypothesized that increasing levels of UM-VOCs would 
be positively associated with an increase in the prevalence of CMS. Significant 
associations were found with a number of VOCs, namely acrolein, 1,3-butadiene, 
crotanaldehyde, ethylbenzene and styrene, and CMS. The heart and vascular 
system are highly vulnerable structures. There are a multitude of vehicles for injury 
to these systems as well as a multitude of outcomes associated with these injuries. 
The specific processes of these injuries are important to define. Cardiometabolic 
syndrome is an amalgamation of these processes of injuries and the resulting 
conditions. These findings significantly contribute to the growing body of evidence 
demonstrating the importance of chronic neurogenic inflammation via the 
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Table A.1. Study Population with Cardiometabolic Syndrome Characteristics 




n mean/% SE n mean/% SE n mean/% SE p-value	
Age	(years) 811 56.81 0.56 460 57.72 0.82 351 55.65 1.03 0.158
Race	or	ethnic	origin	(%) 0.0497
Mexican	American	 136 8.91 1.59 72 7.40 1.68 64 10.83 1.82
Other	Hispanic	 52 4.34 0.85 32 4.37 1.11 20 4.30 1.11
Non-Hispanic	White	 286 62.69 2.77 159 60.62 3.89 127 65.34 2.52
Non-Hispanic	Black	 261 17.54 2.14 150 19.74 2.88 111 14.72 1.98
Other/Multi-Racial 76 6.53 1.00 47 7.88 1.18 29 4.80 1.44
Medical	History	
BMI	(kg/m2) 808 34.07 0.38 458 34.73 0.61 350 33.23 0.42 0.0597
Overweight	(%) 745 94.13 1.14 442 96.72 0.81 303 90.83 2.11 0.0003
Type	2	diabetes	(%) 308 39.77 2.06 174 38.37 3.07 134 41.60 2.87 0.4629
HbA1c 810 6.53 0.05 459 6.53 0.07 351 6.52 0.07 0.8682
Dysglycemia	(%) 811 100.00 0.00 460 100.00 0.00 351 100.00 0.00
HDL-cholesterol	 <.0001
men 351 42.40 0.96 	--- 	---	 	--- 351 42.40 0.96
Women	 460 51.16 0.80 460 51.16 0.80 	--- 	--- 	---
Low	HDL-cholesterol	(%) 187 24.48 2.23 90 21.89 2.56 97 27.79 3.68 0.1679
Systolic	Blood	Pressure	 780 132.85 1.23 437 132.79 1.33 343 132.94 1.74 0.9364
Diastolic	Blood	Pressure	 775 73.24 0.74 433 71.20 0.87 342 75.78 1.31 0.0073
Hypertension	(%) 663 80.93 2.13 384 82.13 2.38 279 79.42 3.36 0.4719
Albumin:Creatinine	Ratio	 811 84.47 13.69 460 79.61 18.94 351 90.66 18.57 0.6721
Microalbuminuria	(%) 241 25.92 2.40 123 26.70 3.20 118 24.93 3.14 0.6724
Urinary	creatinine	 811 114.70 3.30 460 102.39 4.17 351 130.40 4.98 <.0001
Cardiometacolic	Syndrome	(%) 811 13.80 0.55 460 7.74 0.45 351 6.07 0.45 0.0718
Blood	pressure	treatment	 512 65.33 2.56 315 69.32 2.74 197 60.04 4.05 0.0348
Lifestyle	
<	High	school	Education	(%) 252 20.76 1.86 142 19.49 2.30 110 22.40 2.46 0.3309
Below	$20,000	HH	income	(%) 194 18.47 1.71 120 22.73 2.32 74 13.03 1.74 <.0001
Smoking	exposure	(%) 0.0002
Current	smoker	 183 24.70 2.10 79 18.30 2.27 104 32.57 3.27
Secondhand	Smoke	exp 173 19.32 2.15 98 19.99 2.86 75 18.49 2.09
Non-exposed		 397 55.98 2.21 245 61.70 2.74 152 48.94 3.61
Serum	cotinine	 811 54.90 6.12 460 43.27 6.13 351 69.73 9.40 0.0063
Consume	alcohol	(%) 479 69.10 2.43 211 56.93 3.53 268 84.60 2.72 <.0001







Table A.2. Volatile Organic Compound Metabolite Level of Detection Stratified by 







N-Acetyl-S-	(2-carboxyethyl)-L-cysteine CEMA 6.96 97.49 99.27
N-Acetyl-S-	(3-Hydroxypropyl)-L-cysteine 3HPMA 13.0 99.06 99.56
N-Acetyl-S-(2-carbamoylethyl)-L-cysteine	 AAMA 2.20 99.38 99.68
N-Acetyl-S-(2-carbamoyl-2-hydroxyethyl)-L-
cysteine	
GAMA 9.40 37.73 60.66
Acrylonitrile	 N-Acetyl-S-(2-cyanoethyl)-L-cysteine	 CYMA 0.500 82.32 95.29
Acrylonitrile,	vinyl	
chloride,	ethylene	oxide	
N-Acetyl-S-	(2-hydroxyethyl)-L-cysteine	 HEMA 0.791 26.87 50.59
Benzene N-Acetyl-S-(phenyl)-L-cysteine PMA 0.600 29.45 35.99
1-Bromopropane	 N-Acetyl-S-(n-propyl)-L-cysteine	 BPMA 1.20 71.50 72.03
N-Acetyl-S-	(3,4-dihydroxybutyl)-L-cysteine	 DHBMA 5.25 99.79 99.64
N-Acetyl-S-(4-hydroxy-2-buten-1-yl)-L-cysteine	 MHBMA3 0.600 96.37 97.87
Carbon-disulfide	 2-Thioxothiazolidine-4-carboxylic	acid	 TTCA	 11.2 33.82 39.99
Crotonaldehyde N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine	HPMMA 2.00 99.99 99.94
Cyanide 2-Aminothiazoline-4-carboxylic	acid	 ATCA 15.0 84.85 82.58
N,	N -	Dimethylformamide	 N-Acetyl-S-(N-methylcarbamoyl)-L-cysteine	 AMCC 6.26 99.24 99.51
Ethylbenzene,	styrene	 Phenylglyoxylic	acid	 PGA 12.0 91.11 92.48
Propylene	oxide	 N-Acetyl-S-(2-hydroxypropyl)-L-cysteine	 2HPMA 5.30 91.04 96.52
N-Acetyl-S-(1-phenyl-2-hydroxyethyl-L-cysteine	+	
N -Acetyl-S-(2-phenyl-2-hydroxyethyl)-L-cysteine	
PHEMA 0.700 16.87 27.94
Mandelic	acid	 MA 12.0 98.29 98.97
Toluene	 N-Acetyl-S-(benzyl)-L-cysteine	 BMA 0.500 99.09 98.61
2-Methylhippuric	acid	 2MHA 5.00 91.47 96.84
3-Methylhippuric	acid	+	4-Methylhippuric	acid	 3&4MHA 8.00 99.39 99.84
1,3-Butadiene	
Xylene	





Table A.3. Description of Volatile Organic Compound Metabolites by NHANES Cycle. 
Parent Compound Metabolite GM SE Min Q1 Median Q3 Max GM SE Min Q1 Median Q3 Max GM SE Min Q1 Median Q3 Max p-Value
CEMA 88.60 3.26 1.02 51.66 85.03 151.42 2026.09 101.73 3.31 3.64 58.35 95.60 164.40 1538.46 94.16 4.67 6.00 55.32 90.15 155.07 4352.63 0.0250
3HPMA 257.11 12.78 1.90 124.07 215.52 445.87 8076.92 265.33 8.57 6.81 134.60 211.68 452.11 6480.00 256.98 13.84 13.28 133.03 216.21 459.64 8782.05 0.8102
Acrylamide AAMA 57.91 1.83 0.32 34.66 53.56 96.31 1518.75 53.02 1.79 1.16 31.59 48.84 81.99 1408.16 54.72 3.13 3.99 31.28 51.13 90.90 922.22 0.1681
GAMA 14.51 0.39 1.37 9.20 14.27 23.71 118.49 11.75 0.32 1.53 7.32 11.46 17.93 168.57 11.84 0.43 1.83 7.34 11.31 18.78 165.79 <.0001
Acrylonitrile CYMA 4.57 0.43 0.07 1.02 1.68 26.71 981.32 4.32 0.29 0.26 1.07 1.83 8.47 907.14 4.20 0.31 0.19 1.05 1.89 8.90 1623.08 0.7809
Acrylonitrile, vinyl chloride, 
ethylene oxide 
HEMA 0.89 0.06 0.10 0.41 0.75 1.65 31.50 1.25 0.05 0.13 0.62 1.16 2.23 42.65 1.11 0.04 0.12 0.58 1.03 1.86 44.63 0.0002
Benzene PMA 0.55 0.02 0.08 0.30 0.49 0.94 21.43 0.79 0.03 0.11 0.48 0.79 1.24 13.00 0.72 0.04 0.09 0.42 0.71 1.17 14.44 <.0001
1-Bromopropane BPMA 3.95 0.16 0.18 1.52 3.51 9.54 436.00 5.22 0.26 0.20 1.93 4.89 12.68 853.66 4.12 0.24 0.18 1.54 3.86 9.55 2288.89 0.0003
DHBMA 260.90 12.47 0.77 198.83 272.20 358.88 1908.33 291.92 6.87 2.75 225.03 286.81 379.19 3160.00 280.65 10.67 19.23 211.20 281.44 376.81 3800.00 0.1112
MHBMA3 6.52 0.37 0.09 2.91 5.16 11.42 263.64 6.65 0.27 0.31 3.15 5.32 10.23 270.00 6.70 0.40 0.24 3.40 5.45 11.00 328.42 0.9411
Carbon-disulfide TTCA 14.33 0.43 1.43 6.87 12.77 24.03 1460.00 15.77 0.75 1.82 7.46 13.39 27.68 1169.01 16.44 0.51 1.71 7.45 14.60 29.12 2140.74 0.0092
Crotonaldehyde HPMMA 448.42 25.59 0.29 229.64 339.17 719.50 12188.00 529.32 17.21 2.11 275.65 405.51 729.70 15500.00 473.03 19.67 32.24 254.14 375.82 788.50 19421.00 0.0209
Cyanide ATCA 66.64 6.18 1.92 20.73 93.97 210.19 1828.21 114.96 4.77 2.44 59.65 120.90 220.20 1453.78 108.16 5.00 3.09 59.07 122.40 213.87 2179.41 <.0001
N, N - Dimethylformamide AMCC 152.80 7.36 0.92 79.55 153.31 280.14 2023.08 182.83 6.63 3.28 99.79 174.47 330.52 2507.14 165.41 8.89 6.78 87.56 162.83 299.69 3578.95 0.0150
Ethylbenzene, styrene PGA 100.46 4.69 1.76 51.11 135.79 223.50 55667.00 201.25 7.11 9.66 145.89 204.65 284.42 32525.00 194.24 8.88 6.44 134.91 191.83 281.52 3461.54 <.0001
Propylene oxide 2HPMA 38.30 1.60 0.77 20.84 34.03 67.49 28130.00 37.94 1.93 2.74 19.65 31.84 60.64 5421.05 31.49 1.93 2.11 16.72 27.40 52.69 5000.00 0.0287
PHEMA 0.59 0.01 0.09 0.31 0.51 0.98 665.56 0.83 0.02 0.11 0.46 0.75 1.31 555.56 0.86 0.03 0.11 0.49 0.81 1.41 144.04 <.0001
MA 144.56 3.29 1.76 99.07 138.20 207.93 31000.00 146.45 5.96 6.20 97.41 133.88 205.62 27778.00 133.30 6.68 4.17 85.73 129.08 199.87 3115.79 0.2935
Toluene BMA 6.91 0.15 0.07 3.96 6.29 10.58 7144.14 7.29 0.24 0.26 4.14 6.71 12.05 347.22 7.11 0.34 0.22 3.93 6.51 12.04 258.00 0.3853
2MHA 36.16 1.65 0.73 16.43 33.40 78.06 1950.82 39.94 2.01 2.41 17.88 37.60 88.01 18384.00 35.81 2.38 1.33 15.98 36.39 78.57 1458.97 0.2723
3&4MHA 266.40 10.84 1.17 123.39 227.48 551.60 102459.00 259.29 10.98 9.12 109.29 217.98 613.56 55556.00 246.49 13.64 5.33 106.25 227.51 591.84 12456.00 0.5323










   
 
Table A.4.  Full Appended Study Group UM-VOC Correlation Matrix. 
 
 
CEMA HPMA3 AAMA GAMA CYMA HEMA PMA BPMA DHBMA MHBMA3 TTCA HPMMA ATCA AMCC PGA HPMA2 PHEMA MA BMA MHA2 MHA34
CEMA 1.000 0.703 0.464 0.354 0.538 0.414 0.187 0.219 0.523 0.655 0.210 0.624 0.193 0.473 0.303 0.425 0.233 0.426 0.213 0.319 0.332
HPMA3 0.703 1.000 0.548 0.410 0.682 0.485 0.279 0.314 0.516 0.798 0.247 0.798 0.220 0.549 0.347 0.501 0.307 0.521 0.186 0.436 0.423
AAMA 0.464 0.548 1.000 0.551 0.621 0.359 0.163 0.098 0.466 0.593 0.097 0.538 0.131 0.488 0.253 0.354 0.211 0.406 0.139 0.376 0.380
GAMA 0.354 0.410 0.551 1.000 0.451 0.504 0.392 0.144 0.319 0.434 0.247 0.429 0.179 0.410 0.182 0.331 0.403 0.350 0.100 0.329 0.290





0.414 0.485 0.359 0.504 0.469 1.000 0.504 0.260 0.285 0.481 0.295 0.496 0.339 0.403 0.237 0.365 0.520 0.389 0.116 0.349 0.283
Benzene PMA 0.187 0.279 0.163 0.392 0.148 0.504 1.000 0.225 0.226 0.268 0.365 0.283 0.294 0.213 0.170 0.216 0.583 0.270 0.117 0.237 0.107
1-Bromopropane BPMA 0.219 0.314 0.098 0.144 -0.008 0.260 0.225 1.000 0.169 0.120 0.229 0.100 0.211 0.015 0.103 0.304 0.173 0.098 0.124 0.081 0.003
DHBMA 0.523 0.516 0.466 0.319 0.338 0.285 0.226 0.169 1.000 0.540 0.166 0.579 0.220 0.482 0.470 0.340 0.237 0.443 0.305 0.280 0.315
MHBMA3 0.655 0.798 0.593 0.434 0.800 0.481 0.268 0.120 0.540 1.000 0.162 0.840 0.220 0.614 0.337 0.449 0.298 0.549 0.142 0.456 0.459
Carbon-disulfide TTCA 0.210 0.247 0.097 0.247 0.071 0.295 0.365 0.229 0.166 0.162 1.000 0.171 0.228 0.104 0.118 0.158 0.311 0.161 0.109 0.110 0.032
Crotonaldehyde HPMMA 0.624 0.798 0.538 0.429 0.716 0.496 0.283 0.100 0.579 0.840 0.171 1.000 0.244 0.629 0.385 0.449 0.342 0.561 0.189 0.446 0.469
Cyanide ATCA 0.193 0.220 0.131 0.179 0.115 0.339 0.294 0.211 0.220 0.220 0.228 0.244 1.000 0.188 0.175 0.171 0.308 0.231 0.152 0.133 0.104








0.303 0.347 0.253 0.182 0.300 0.237 0.170 0.103 0.470 0.337 0.118 0.385 0.175 0.437 1.000 0.215 0.230 0.407 0.174 0.281 0.314
Propylene oxide HPMA2 0.425 0.501 0.354 0.331 0.393 0.365 0.216 0.304 0.340 0.449 0.158 0.449 0.171 0.371 0.215 1.000 0.203 0.329 0.144 0.275 0.286
PHEMA 0.233 0.307 0.211 0.403 0.253 0.520 0.583 0.173 0.237 0.298 0.311 0.342 0.308 0.250 0.230 0.203 1.000 0.367 0.160 0.277 0.174
MA 0.426 0.521 0.406 0.350 0.512 0.389 0.270 0.098 0.443 0.549 0.161 0.561 0.231 0.481 0.407 0.329 0.367 1.000 0.208 0.444 0.456
Toluene BMA 0.213 0.186 0.139 0.100 0.069 0.116 0.117 0.124 0.305 0.142 0.109 0.189 0.152 0.132 0.174 0.144 0.160 0.208 1.000 0.104 0.129
MHA2 0.319 0.436 0.376 0.329 0.479 0.349 0.237 0.081 0.280 0.456 0.110 0.446 0.133 0.455 0.281 0.275 0.277 0.444 0.104 1.000 0.841
3&4MHA 0.332 0.423 0.380 0.290 0.510 0.283 0.107 0.003 0.315 0.459 0.032 0.469 0.104 0.484 0.314 0.286 0.174 0.456 0.129 0.841 1.000











Figure A.1. Correlations of each UM-VOC with each UM-VOC- non-tobacco 
smoke exposed cohort.  
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Figure A.2. Correlations of each UM-VOC with each UM-VOC- tobacco smoke 










































































































































Table A.5. Unadjusted and adjusted odds of prevalent cardiometabolic disease 
associated with 21 urinary metabolites of volatile organic compound 
concentrations in NHANES participants 2005–06, 2011–12, and 2013–14. 
Note: Adjusted for age, sex, race, the interaction between sex and race, and 
NHANES cohort year; odds ratio estimates and the corresponding 95% Wald 

















CEMA 1.35 1.19 1.54 <.0001 1.24 1.08 1.43 0.0032
3HPMA 1.00 0.91 1.11 0.9516 1.06 0.96 1.18 0.2561
AAMA 0.87 0.78 0.98 0.0254 0.94 0.83 1.07 0.3442
GAMA 0.94 0.83 1.08 0.3824 0.94 0.80 1.09 0.3951
Acrylonitrile 
CYMA 0.94 0.90 0.99 0.0186 1.00 0.95 1.06 0.8718
Acrylonitrile, vinyl 
chloride, ethylene oxide 
HEMA 0.90 0.81 0.99 0.0364 0.87 0.77 0.98 0.0275
Benzene PMA 0.99 0.87 1.13 0.8873 0.87 0.74 1.02 0.0788
1-Bromopropane BPMA 1.02 0.95 1.09 0.6489 1.02 0.95 1.10 0.5377
DHBMA 1.44 1.15 1.81 0.0017 1.13 0.89 1.42 0.3093
MHBMA3 1.02 0.94 1.11 0.6248 1.04 0.94 1.15 0.4439
Carbon-disulfide TTCA 1.08 0.98 1.19 0.1218 1.01 0.90 1.12 0.9229
Crotonaldehyde HPMMA 1.09 1.00 1.19 0.0533 1.06 0.96 1.17 0.2753
Cyanide ATCA 1.13 1.03 1.24 0.0084 1.03 0.93 1.15 0.5599
N, N - 
Dimethylformamide 
AMCC 1.05 0.96 1.15 0.2551 0.96 0.86 1.06 0.3856
Ethylbenzene, styrene PGA 1.24 1.11 1.37 <.0001 1.20 1.06 1.36 0.0048
Propylene oxide 2HPMA 0.98 0.87 1.10 0.6935 0.99 0.89 1.11 0.8590
PHEMA 0.98 0.87 1.10 0.7130 0.83 0.71 0.97 0.0222
MA 1.02 0.87 1.18 0.8357 1.03 0.88 1.21 0.6962
Toluene BMA 1.02 0.94 1.12 0.6148 0.93 0.83 1.03 0.1576
2MHA 0.90 0.81 1.00 0.0411 0.90 0.81 1.01 0.0602









Table A.6. Unadjusted tobacco smoke exposed and non-tobacco smoke exposed 
odds of prevalent cardiometabolic disease associated with 21 urinary metabolites 
of volatile organic compound concentrations in NHANES participants 2005–06, 
















CEMA 1.26 1.03 1.53 0.0226 1.65 1.26 2.16 0.0005
3HPMA 1.00 0.87 1.15 1.0000 1.12 0.94 1.34 0.1969
AAMA 0.85 0.73 0.99 0.0404 0.94 0.75 1.19 0.6074
GAMA 0.95 0.80 1.13 0.5573 0.95 0.78 1.15 0.5652
Acrylonitrile 
CYMA 0.95 0.88 1.02 0.1424 1.02 0.85 1.22 0.8667
Acrylonitrile, vinyl 
chloride, ethylene oxide 
HEMA 0.90 0.78 1.04 0.1656 0.91 0.79 1.04 0.1756
Benzene PMA 1.02 0.84 1.24 0.8338 0.94 0.79 1.11 0.4213
1-Bromopropane BPMA 1.03 0.93 1.14 0.5508 0.99 0.88 1.12 0.8926
DHBMA 1.30 0.93 1.81 0.1165 1.71 1.17 2.48 0.0060
MHBMA3 1.01 0.89 1.14 0.9424 1.22 1.01 1.47 0.0359
Carbon-disulfide TTCA 1.19 0.99 1.43 0.0597 1.00 0.84 1.18 0.9562
Crotonaldehyde HPMMA 1.05 0.92 1.19 0.4678 1.38 1.11 1.70 0.0045
Cyanide ATCA 1.06 0.94 1.19 0.3343 1.19 1.04 1.36 0.0105
N, N - 
Dimethylformamide 
AMCC 1.06 0.93 1.21 0.4027 1.15 0.98 1.34 0.0825
Ethylbenzene, styrene PGA 1.21 1.03 1.42 0.0207 1.36 1.15 1.60 0.0005
Propylene oxide 2HPMA 0.97 0.80 1.18 0.7374 1.00 0.87 1.14 0.9522
PHEMA 1.00 0.85 1.17 0.9592 0.94 0.82 1.08 0.3866
MA 1.07 0.87 1.33 0.5161 1.04 0.79 1.35 0.7869
Toluene BMA 0.95 0.82 1.09 0.4428 1.07 0.94 1.21 0.3249
2MHA 0.96 0.83 1.10 0.5124 0.87 0.75 1.01 0.0657
3&4MHA 0.97 0.85 1.12 0.6927 0.92 0.82 1.04 0.1717
Styrene 
Xylene 








Table A.7. Adjusted tobacco smoke exposed and non-tobacco smoke exposed 
odds of prevalent cardiometabolic disease associated with 21 urinary metabolites 
of volatile organic compound concentrations in NHANES participants 2005–06, 
2011–12, and 2013–14. 
Note: Adjusted for age, sex, race, the interaction between sex and race, and 
NHANES cohort year; odds ratio estimates and the corresponding 95% Wald 
















CEMA 1.07 0.87 1.33 0.5184 1.38 1.05 1.80 0.0207
3HPMA 1.00 0.85 1.17 0.9664 1.10 0.92 1.31 0.2916
AAMA 0.90 0.76 1.08 0.2556 0.89 0.70 1.14 0.3394
GAMA 0.93 0.75 1.15 0.5002 0.86 0.70 1.06 0.1490
Acrylonitrile 
CYMA 0.97 0.90 1.05 0.4760 0.94 0.75 1.18 0.5993
Acrylonitrile, vinyl 
chloride, ethylene oxide 
HEMA 0.86 0.72 1.02 0.0742 0.81 0.69 0.96 0.0171
Benzene PMA 0.89 0.70 1.13 0.3304 0.82 0.68 0.99 0.0403
1-Bromopropane BPMA 1.01 0.89 1.14 0.8771 1.02 0.90 1.15 0.7734
DHBMA 1.01 0.76 1.35 0.9486 1.20 0.86 1.69 0.2816
MHBMA3 0.99 0.85 1.14 0.8312 1.04 0.83 1.29 0.7312
Carbon-disulfide TTCA 1.12 0.92 1.37 0.2398 0.93 0.77 1.13 0.4763
Crotonaldehyde HPMMA 0.99 0.86 1.15 0.9023 1.11 0.90 1.38 0.3214
Cyanide ATCA 0.99 0.86 1.14 0.8779 1.07 0.91 1.25 0.4113
N, N - 
Dimethylformamide 
AMCC 0.94 0.80 1.11 0.4806 0.92 0.76 1.10 0.3313
Ethylbenzene, styrene PGA 1.16 0.98 1.38 0.0922 1.25 1.03 1.52 0.0272
Propylene oxide 2HPMA 0.95 0.77 1.18 0.6533 0.97 0.86 1.10 0.6269
PHEMA 0.83 0.67 1.03 0.0911 0.78 0.64 0.96 0.0178
MA 1.03 0.82 1.30 0.8032 0.97 0.75 1.27 0.8448
Toluene BMA 0.87 0.75 1.02 0.0931 0.95 0.83 1.09 0.4730
2MHA 0.92 0.80 1.07 0.2705 0.84 0.72 0.98 0.0239
3&4MHA 0.94 0.80 1.09 0.3946 0.84 0.73 0.97 0.0182
Styrene 
Xylene 








Table A.8. Full Cohort, Unadjusted odds of prevalent cardiometabolic syndrome 
(dichotomous) associated with 21 urinary metabolites of volatile organic 
compound concentrations (quintiles) in NHANES participants 2005–06, 2011–12, 
and 2013–14.  
Note: Unadjusted odds ratio estimates and the corresponding 95% Wald 








Trend   
p-value
1 vs 0 
p-value
2 vs 0 
p-value
3 vs 0 
p-value 
4 vs 0 
p-value
CEMA 1.20 1.12 1.29 <.0001 0.2426 0.0034 0.0004 0.0004
3HPMA 1.02 0.95 1.09 0.5832 0.3533 0.0004 0.0736 0.7737
AAMA 0.93 0.86 1.00 0.0436 0.0546 0.6732 0.0244 0.0383
GAMA 0.96 0.89 1.03 0.2646 0.0609 0.9660 0.1835 0.4046
Acrylonitrile CYMA 0.94 0.87 1.01 0.0744 0.1896 0.1920 0.3229 0.3294
Acrylonitrile, vinyl 
chloride, ethylene oxide 
HEMA 0.94 0.87 1.01 0.0832 0.7512 0.4261 0.2764 0.1555
Benzene PMA 0.99 0.92 1.06 0.6645 0.7845 0.0568 0.6521 0.6557
1-Bromopropane BPMA 1.01 0.94 1.08 0.8625 0.2111 0.7857 0.6536 0.7816
DHBMA 1.18 1.09 1.28 <.0001 0.0455 0.0174 0.0042 0.0001
MHBMA3 1.03 0.96 1.10 0.3891 0.0008 0.0235 0.0022 0.1941
Carbon-disulfide TTCA 1.03 0.95 1.12 0.4335 0.1591 0.7441 0.6264 0.7448
Crotonaldehyde HPMMA 1.11 1.03 1.19 0.0061 0.0194 <.0001 0.0004 0.0282
Cyanide ATCA 1.08 1.00 1.17 0.0486 0.2600 0.0461 0.0845 0.0586
N, N - 
Dimethylformamide 
AMCC 1.01 0.94 1.08 0.7884 0.0688 0.1004 0.1601 0.3879
Ethylbenzene, styrene PGA 1.10 1.01 1.19 0.0265 0.2087 0.0325 0.0202 0.0583
Propylene oxide 2HPMA 0.99 0.90 1.08 0.7256 0.2126 0.4517 0.7477 0.8143
PHEMA 0.99 0.92 1.06 0.7246 0.3211 0.2821 0.2418 0.5746
MA 1.00 0.93 1.07 0.9868 0.5986 0.8959 0.6912 0.8777
Toluene BMA 1.01 0.95 1.08 0.6866 0.4883 0.8151 0.7410 0.3088
2MHA 0.92 0.85 0.99 0.0277 0.6118 0.9915 0.1050 0.0635
3&4MHA 0.94 0.88 1.00 0.0557 0.7350 0.5142 0.2210 0.2299
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Table A.9. Full Cohort, Adjusted odds of cardiometabolic syndrome 
(dichotomous) associated with 21 urinary metabolites of volatile organic 
compound concentrations (quintiles) in NHANES participants 2005–06, 2011–12, 
and 2013–14. 
 
Note: Adjusted for age, sex, race, the interaction between sex and race, and 
NHANES cohort year; odds ratio estimates and the corresponding 95% Wald 









Trend    
p-value
1 vs 0 
p-value
2 vs 0  
p-value
3 vs 0    
p-value 
4 vs 0    
p-value
CEMA 1.15 1.07 1.24 0.0004 0.3714 0.0158 0.0036 0.0054
3HPMA 1.07 0.99 1.15 0.0793 0.1232 <.0001 0.0027 0.1834
AAMA 0.97 0.90 1.05 0.4636 0.0464 0.9084 0.0595 0.4153
GAMA 0.96 0.89 1.04 0.3082 0.3430 0.4262 0.5170 0.3068
Acrylonitrile CYMA 1.00 0.93 1.09 0.9122 0.3091 0.3591 0.6702 0.4882
Acrylonitrile, vinyl 
chloride, ethylene oxide 
HEMA 0.92 0.85 0.99 0.0366 0.1122 0.2095 0.0436 0.0419
Benzene PMA 0.91 0.84 0.99 0.0343 0.2093 0.9645 0.2464 0.0250
1-Bromopropane BPMA 1.01 0.94 1.09 0.7577 0.0961 0.8884 0.2910 0.9265
DHBMA 1.07 0.98 1.17 0.1483 0.0821 0.1402 0.1568 0.0444
MHBMA3 1.04 0.96 1.12 0.3711 0.0202 0.3155 0.0841 0.1520
Carbon-disulfide TTCA 0.97 0.89 1.06 0.4879 0.0171 0.0954 0.0292 0.2797
Crotonaldehyde HPMMA 1.06 0.98 1.15 0.1413 0.1151 0.0068 0.0531 0.1203
Cyanide ATCA 1.00 0.92 1.10 0.9315 0.3268 0.2872 0.3770 0.8534
N, N - 
Dimethylformamide 
AMCC 0.94 0.87 1.02 0.1301 0.1842 0.6730 0.8971 0.6436
Ethylbenzene, styrene PGA 1.06 0.97 1.15 0.2212 0.0422 0.0088 0.0645 0.1310
Propylene oxide 2HPMA 1.01 0.93 1.10 0.8619 0.2300 0.4362 0.6456 0.6142
PHEMA 0.89 0.81 0.98 0.0146 0.6824 0.2702 0.2993 0.0151
MA 1.01 0.94 1.09 0.7226 0.7601 0.8491 0.9981 0.8519
Toluene BMA 0.95 0.88 1.02 0.1637 0.6318 0.5142 0.2043 0.4320
2MHA 0.92 0.85 0.99 0.0301 0.8788 0.8719 0.2374 0.0612
3&4MHA 0.92 0.86 0.99 0.0252 0.7750 0.7293 0.2695 0.0526
Xylene 
Acrylamide 





Table A.10. Non-tobacco smoke exposed, Adjusted odds of prevalent 
cardiometabolic syndrome associated with 21 urinary metabolites of volatile 
organic compound concentrations in NHANES participants 2005–06, 2011–12, 
and 2013–14. 
Note: Adjusted for age, sex, race, the interaction between sex and race, and 
NHANES cohort year; odds ratio estimates and the corresponding 95% Wald 










1 vs 0 
p-value
2 vs 0 
p-value
3 vs 0 
p-value 
4 vs 0 
p-value
CEMA 1.23 1.08 1.39 0.0025 0.4078 0.0220 0.0186 0.0084
3HPMA 1.08 0.98 1.19 0.1177 0.1713 0.0004 0.2815 0.5801
AAMA 0.94 0.82 1.08 0.3645 0.0053 0.2376 0.0599 0.5225
GAMA 0.92 0.82 1.04 0.1670 0.4715 0.1395 0.6096 0.1354
Acrylonitrile CYMA 0.93 0.79 1.09 0.3382 0.4047 0.6143 0.1886 0.8769
Acrylonitrile, vinyl 
chloride, ethylene oxide 
HEMA 0.89 0.80 0.99 0.0377 0.3153 0.4474 0.1291 0.0457
Benzene PMA 0.91 0.82 1.01 0.0638 0.9807 0.9010 0.7167 0.0989
1-Bromopropane BPMA 1.01 0.89 1.15 0.8642 0.2629 0.9021 0.2166 0.8308
DHBMA 1.09 0.95 1.25 0.2291 0.8703 0.3063 0.7593 0.1663
MHBMA3 1.00 0.88 1.13 0.9467 0.3562 0.6709 0.8260 0.9577
Carbon-disulfide TTCA 0.93 0.80 1.07 0.2971 0.0517 0.0083 0.0605 0.1702
Crotonaldehyde HPMMA 1.09 0.96 1.24 0.1777 0.3779 0.0184 0.2172 0.3234
Cyanide ATCA 1.06 0.93 1.20 0.3779 0.4095 0.7193 0.5495 0.7332
N, N - 
Dimethylformamide 
AMCC 0.89 0.80 0.99 0.0344 0.7000 0.5679 0.4762 0.0775
Ethylbenzene, styrene PGA 1.03 0.90 1.18 0.6474 0.0317 0.0519 0.2643 0.3652
Propylene oxide 2HPMA 1.00 0.91 1.09 0.9128 0.0506 0.2560 0.2991 0.9477
PHEMA 0.88 0.78 0.99 0.0303 0.5646 0.7826 0.5683 0.1004
MA 1.00 0.90 1.10 0.9186 0.3728 0.5557 0.5080 0.9609
Toluene BMA 0.98 0.88 1.09 0.6758 0.7842 0.7350 0.4570 0.9949
2MHA 0.87 0.77 0.98 0.0218 0.7629 0.2757 0.1112 0.0513








Table A.11.Tobacco smoke exposed, Adjusted odds of prevalent cardiometabolic 
disease associated with 21 urinary metabolites of volatile organic compound 
concentrations in NHANES participants 2005–06, 2011–12, and 2013–14. 
Note: Adjusted for age, sex, race, the interaction between sex and race, and 
NHANES cohort year; odds ratio estimates and the corresponding 95% Wald 










1 vs 0 
p-value
2 vs 0 
p-value
3 vs 0 
p-value 
4 vs 0 
p-value
CEMA 1.05 0.90 1.22 0.5292 0.4904 0.4236 0.6374 0.4351
3HPMA 1.02 0.90 1.17 0.7308 0.7854 0.4504 0.0943 0.8245
Acrylamide AAMA 0.96 0.85 1.08 0.4466 0.3107 0.0356 0.6316 0.8240
GAMA 0.95 0.85 1.07 0.3996 0.7019 0.8976 0.8309 0.5205
Acrylonitrile CYMA 0.98 0.86 1.13 0.8177 0.4179 0.5750 0.7857 0.8660
Acrylonitrile, vinyl 
chloride, ethylene oxide 
HEMA 0.91 0.80 1.03 0.1382 0.2127 0.4353 0.1143 0.1101
Benzene PMA 0.92 0.81 1.05 0.2061 0.0756 0.8438 0.4036 0.0911
1-Bromopropane BPMA 0.98 0.88 1.11 0.7814 0.0645 0.2657 0.4860 0.3854
DHBMA 1.06 0.93 1.19 0.3805 0.0047 0.1447 0.0110 0.0436
MHBMA3 1.02 0.89 1.18 0.7540 0.0195 0.1911 0.0580 0.2534
Carbon-disulfide TTCA 1.01 0.87 1.18 0.8602 0.1567 0.8439 0.0722 0.8849
Crotonaldehyde HPMMA 1.03 0.90 1.17 0.7094 0.1709 0.3356 0.0620 0.5342
Cyanide ATCA 0.95 0.84 1.08 0.4079 0.0658 0.2579 0.7546 0.8219
N, N - 
Dimethylformamide 
AMCC 0.97 0.85 1.10 0.5868 0.0560 0.2333 0.2589 0.4770
Ethylbenzene, styrene PGA 1.08 0.94 1.24 0.2610 0.3660 0.0497 0.1585 0.2331
Propylene oxide 2HPMA 1.00 0.85 1.17 0.9768 0.0806 0.2939 0.2859 0.5651
PHEMA 0.88 0.78 0.99 0.0388 0.1949 0.2462 0.3165 0.0093
MA 1.01 0.89 1.14 0.9003 0.6781 0.4226 0.4400 0.7588
Toluene BMA 0.90 0.81 1.00 0.0464 0.9237 0.5197 0.1440 0.2024
2MHA 0.94 0.85 1.04 0.2367 0.7566 0.1011 0.9655 0.5588
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Table A.12. Full cohort, Unadjusted odds of ordinal cardiometabolic syndrome 
risk score associated with 21 urinary metabolites of volatile organic compound 
concentrations in NHANES participants 2005–06, 2011–12, and 2013–14.  
 










CEMA 1.38 1.27 1.51 <.0001
3HPMA 1.01 0.94 1.08 0.7715
AAMA 0.92 0.85 0.99 0.0368
GAMA 0.98 0.88 1.09 0.6993
Acrylonitrile CYMA 0.96 0.93 0.99 0.0149
Acrylonitrile, vinyl 
chloride, ethylene oxide HEMA 0.94 0.86 1.03 0.1832
Benzene PMA 0.95 0.86 1.05 0.2972
1-Bromopropane BPMA 0.97 0.92 1.02 0.1923
DHBMA 1.34 1.14 1.58 0.0007
MHBMA3 1.03 0.97 1.10 0.3304
Carbon-disulfide TTCA 1.00 0.93 1.07 0.9265
Crotonaldehyde HPMMA 1.08 1.01 1.16 0.0366
Cyanide ATCA 1.08 1.02 1.16 0.0179
N, N - 
Dimethylformamide 
AMCC 1.12 1.03 1.21 0.0059
Ethylbenzene, styrene PGA 1.18 1.11 1.25 <.0001
Propylene oxide 2HPMA 0.94 0.88 1.01 0.1142
PHEMA 1.00 0.91 1.09 0.9320
MA 1.03 0.94 1.13 0.5379
Toluene BMA 1.04 0.96 1.12 0.3712
2MHA 0.93 0.87 1.00 0.0649
3&4MHA 0.99 0.93 1.06 0.7798
Xylene 
Styrene 





Table A.13. Adjusted odds of ordinal cardiometabolic syndrome risk score 
associated with 21 urinary metabolites of volatile organic compound 
concentrations in NHANES participants 2005–06, 2011–12, and 2013–14. 
Note: Adjusted for age, sex, race, the interaction between sex and race, and 










CEMA 1.27 1.16 1.39 <.0001
3HPMA 1.04 0.97 1.13 0.2560
AAMA 0.97 0.90 1.04 0.3726
GAMA 0.93 0.83 1.04 0.2130
Acrylonitrile CYMA 1.01 0.98 1.04 0.5123
Acrylonitrile, vinyl 
chloride, ethylene oxide HEMA 0.89 0.82 0.98 0.0136
Benzene PMA 0.80 0.71 0.89 0.0002
1-Bromopropane BPMA 0.96 0.91 1.00 0.0607
DHBMA 1.07 0.91 1.26 0.4205
MHBMA3 1.03 0.96 1.10 0.3750
Carbon-disulfide TTCA 0.90 0.84 0.96 0.0012
Crotonaldehyde HPMMA 1.03 0.96 1.11 0.3908
Cyanide ATCA 0.96 0.89 1.04 0.3482
N, N - 
Dimethylformamide 
AMCC 0.99 0.93 1.07 0.8646
Ethylbenzene, styrene PGA 1.17 1.09 1.25 <.0001
Propylene oxide 2HPMA 0.93 0.87 1.00 0.0420
PHEMA 0.84 0.76 0.93 0.0009
MA 1.00 0.91 1.10 0.9549
Toluene BMA 0.94 0.87 1.01 0.0939
2MHA 0.92 0.85 0.99 0.0248
3&4MHA 0.96 0.89 1.03 0.2111
Xylene 






Table A.14. Tobacco Smoke Exposed- Adjusted odds of ordinal cardiometabolic 
syndrome risk score associated with 21 urinary metabolites of volatile organic 
compound concentrations in NHANES participants 2005–06, 2011–12, and 
2013–14.  
Note: Adjusted for age, sex, race, the interaction between sex and race, and 










CEMA 1.07 0.93 1.24 0.3283
3HPMA 0.94 0.85 1.05 0.2857
AAMA 0.86 0.77 0.97 0.0144
GAMA 0.89 0.77 1.03 0.1139
Acrylonitrile CYMA 0.96 0.91 1.01 0.1094
Acrylonitrile, vinyl 
chloride, ethylene oxide HEMA 0.88 0.79 0.98 0.0244
Benzene PMA 0.78 0.68 0.91 0.0014
1-Bromopropane BPMA 0.96 0.88 1.05 0.3567
DHBMA 1.01 0.81 1.26 0.9075
MHBMA3 0.96 0.87 1.05 0.3040
Carbon-disulfide TTCA 0.94 0.83 1.06 0.2949
Crotonaldehyde HPMMA 0.96 0.87 1.06 0.3963
Cyanide ATCA 0.90 0.81 1.00 0.0516
N, N - 
Dimethylformamide 
AMCC 0.94 0.84 1.04 0.2265
Ethylbenzene, styrene PGA 1.17 1.05 1.31 0.0047
Propylene oxide 2HPMA 0.88 0.78 0.99 0.0291
PHEMA 0.80 0.70 0.92 0.0020
MA 0.94 0.81 1.09 0.3748
Toluene BMA 0.91 0.81 1.03 0.1276
2MHA 0.88 0.79 0.97 0.0093
3&4MHA 0.92 0.83 1.01 0.0838
Styrene 
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Table A.15. Non-Tobacco Smoke Exposed- Adjusted odds of ordinal 
cardiometabolic syndrome risk score associated with 21 urinary metabolites of 
volatile organic compound concentrations in NHANES participants 2005–06, 
2011–12, and 2013–14.  
 
Note: Adjusted for age, sex, race, the interaction between sex and race, and 










CEMA 1.39 1.19 1.62 <.0001
3HPMA 1.05 0.92 1.20 0.4776
AAMA 0.89 0.76 1.05 0.1747
GAMA 0.85 0.71 1.01 0.0615
Acrylonitrile CYMA 0.83 0.72 0.95 0.0078
Acrylonitrile, vinyl 
chloride, ethylene oxide HEMA 0.79 0.68 0.93 0.0046
Benzene PMA 0.81 0.70 0.95 0.0103
1-Bromopropane BPMA 0.96 0.89 1.04 0.2992
DHBMA 1.00 0.82 1.23 0.9904
MHBMA3 0.96 0.82 1.11 0.5684
Carbon-disulfide TTCA 0.88 0.81 0.97 0.0077
Crotonaldehyde HPMMA 0.94 0.82 1.08 0.3649
Cyanide ATCA 1.01 0.91 1.12 0.8693
N, N - 
Dimethylformamide 
AMCC 0.91 0.79 1.05 0.1837
Ethylbenzene, styrene PGA 1.12 1.02 1.23 0.0175
Propylene oxide 2HPMA 0.90 0.83 0.98 0.0177
PHEMA 0.85 0.73 0.98 0.0252
MA 0.95 0.81 1.11 0.4863
Toluene BMA 0.93 0.84 1.03 0.1572
2MHA 0.87 0.77 0.97 0.0115
3&4MHA 0.90 0.81 1.00 0.0421
Styrene 







Stacey L. Konkle 
CONTACT INFORMATION 
Email: Stacey.Konkle@Louisville.edu
Personal Email: S_Konkle@aol.com    
Linkedin.com/in/Stacey-Konkle 
EDUCATION 
University of Louisville May 2020 
Louisville, Kentucky  
Ph.D. Epidemiology
Dissertation: “Volatile Organic Compound Exposure and Cardiometabolic Syndrome Risk in a 
Nationally Representative Cohort”  
Dissertation Committee Co-Chairs: Kristina M. Zierold, Ph.D., and Kira C. Taylor, Ph.D.  
Cumulative GPA: 3.89 
University of Louisville           May 2014 
Louisville, Kentucky  
Masters of Public Health 
Cumulative GPA: 3.94 
Purdue University           May 2011 
West Lafayette, Indiana 
B.S. Food Science 
Cumulative GPA: 3.41 
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FELLOWSHIPS 
University of Louisville, School of Medicine, Institute of Molecular Cardiology/Envirome 
Institute   
Graduate Research Assistant         2015 – Present 
Mentor: Aruni Bhatnagar, Ph.D. 
• Conduct research focused on urinary volatile organic compound (VOC)
metabolite concentrations as biomarkers of exposure and associations with
cardiovascular and metabolic injury. My present work utilizes the National Health
and Nutrition Examination Survey (NHANES), which is a complex multistage
probability sampled survey designed to provide a nationally representative sample
cohort and the National Monitoring Program (NMP) for air toxics data to establish
temporal trends in associations with ambient air VOCs and actual personal
biomarkers of exposure and associations with cardiometabolic health endpoints at
the national level.
• Assist in the study design and implementation of an innovative and complex
community-based intervention trial. This real-world public health study focuses
on mitigating the effects air pollution via increasing aerial greenness.
National Institute of Environmental Health Sciences (NIEHS)- University of Louisville 
Superfund Research Center 
Superfund Research Program Fellow  2018 – Present     
Mentor: Aruni Bhatnagar, Ph.D., and Sanjay Srivastava, Ph.D. 
• Conduct analysis of environmental biomarkers of exposure and cardiometabolic
outcomes to establish national representative benchmarks to inform and
complement the development of the University of Louisville Superfund Center
projects.
• Present research findings at regional, national, and international scientific
meetings.
• Work in a multidisciplinary research teams addressing the central hypothesis that
exposure to environmental volatile organic compounds cause/exacerbate insulin
resistance, leading to cardiometabolic disease.
• Participate in training on grant writing, presentation skills, professional
development, problem solving, regulatory science, community engagement, and
research translation.
National Institutes of Health- Tobacco Centers of Regulatory Science (NIH-TCORS)- American 
Heart Association Tobacco Regulation and Addiction Center  
Early Career Investigator Fellow  2015 – 2017    
Mentor: Aruni Bhatnagar, Ph.D., Glenn Hirsch, M.D., Emelia Benjamin, M.D.        
• Conducted research focused on FDA tobacco-related interests of reducing
toxicity, carcinogenicity, and adverse health consequences. This research focused
on smoking associated urinary volatile organic compound metabolite
concentrations and cardiovascular injury biomarkers.
• Presented research findings at regional and national scientific meetings.
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• Training included presentations during weekly trainee meetings, progress reports, 
and peer mentoring activists.   
• Weekly training sessions covering various aspects of tobacco regulatory science 
including career development, addiction training, translating scientific research 
into policy, research and writing skills, responsiveness to FDA research 




Louisville Metro Department of Public Health and Wellness  
Medical Reserve Corp- Member                                                                 2017 – Present                                                                          
• Actively participate in monthly meetings and trainings; Stop the Bleed certified, 
HIPPA certified, Incident Command Structure (ICS) 100-800 training, survey 
design and interviewing skills training, data collection tools–Epi Info software, 
terrorism awareness and first responders, highly Communicable Diseases: 
Isolation/Quarantine trainings. FEMA student ID #0004175749 
• Assisted county wide mass vaccination efforts during a 2017-18 Hepatitis A 
outbreak. Duties included confirming patient vaccination histories using the 
Kentucky Immunization Registry; administering consent forms; and providing 
basic information about Hepatitis A, the ongoing outbreak, and information about 
the vaccination options. 
 
Kentucky Hospital Association 
Data Improvement Analyst                                                                                      2014 – 2015 
• Assisted in the development and management of federal, state and private grant 
funded hospital improvement databases for Kentucky hospitals to aid in reaching 
and maintaining state benchmarks in health care associated infections, 
readmissions, obstetrics harm and patient safety. Maintain daily and monthly 
uploads and data updates of all Kentucky Hospital Engagement Network 
databases. Communicate with hospital infection preventionist and support data 
collection protocol and question inquires. Generated statistical reports and 
summary analysis for maintained databases.  
• Developed automated reporting system for Kentucky Hospital Engagement 
Network databases. 
• Support the Kentucky Hospital Association in communications functions 
including member contact information database, weekly newsletters, webinars, 
hospital staff coaching, conference calls, meeting scheduling, maintaining the 
Kentucky Hospital Engagement Network website and resources and in-house 
calendar and communications.   
 
Kentucky Cabinet for Health and Family Services- Kentucky Department for Public Health 
Division of Healthcare-Associated Infections- Intern   2013 – 2014
  
• Supported the Kentucky Department for Public Health’s division of Healthcare-
associated infections in both epidemiological and biostatistical roles.  
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• Worked on the development of a statewide Multidrug-resistant Organism
surveillance system.
• Assisted in healthcare-associated infection outbreak investigations throughout the
state of Kentucky and generated epidemiologic reports, which resulted in two
Council of State and Territorial Epidemiology (CSTE) presentations.
• Contributed to the amendment process for the state disease surveillance regulation
requiring mandatory reporting of multidrug-resistant organisms.
Brown Forman Corporation 
Quality Control (QC) Analyst, Research and Development (R&D)            2011
• Obtained and maintained product compliant management records of all quality
assurance actions. Quality assurance sample were tests collected and tested
throughout processing from ingredient receiving to finished product
specifications to variance testing of customer complaint specimens.
• Performed statistical process control surveillance analysis. Executed regular
production line quality control checks as well as maintained federal regulatory
affairs records of processing and analytical test data, details, inconsistencies and
complications.
• Assisted Corporate R&D Food Scientists with market driven product
development for new alcohol-based beverage and beverage systems.  Product
development processes included analytical, sensory, financial and production
consideration. Responsible for maintaining detailed dilution and scale-up
processes, procedures, and records. Maintained a comprehensive flavors and
analytical lab including equipment standardization and materials inventory.
Yum! Brands Inc. 
Corporate Kentucky Fried Chicken Research and Development (R&D)- Intern  2010
• Supported Yum! Brands Corporate research and development (R&D) and quality
assurance (QA) food scientists with new product development for the Kentucky
Fried Chicken (KFC) system.  Testing included analytical, sensory, nutrition, and
operational process methodologies on all projects.
• Organized and executed product shows and brainstorming sessions for new
product development.  Maintained electronic records of testing and effectively
communicated results to other corporate scientists and business professionals.
• Conducted competitive research on other quick service restaurants (QSR) to assist
in corporate strategy. 
Purdue University, Department of Food Science- Food Technology Development Laboratory 
Laboratory Technician 2007 – 2011    
• Conducted research on quality measurements of lipid coated shell eggs. Involved
grading egg quality, pH analysis, shell strength, quantitative chemical analysis
titrations, and microbiological assessment.
• Supported the development and implementation of proof of concept for an
innovative in package sterilization plasma food treatment process. Performed
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ozone analysis and full microbial work-ups including agar and plate preparation, 
pour plates, dilutions, incubation, colony identification and plate counts. 
MANUSCRIPTS  
Stacey Konkle, Kristina Zierold, Kira Taylor, Daniel Riggs, Aruni Bhatnagar. 
National Secular Trends in Ambient Air Volatile Organic Compound Levels and Biomarkers of 
Exposure in the United States. -Environmental Research March 2020 
Stacey Konkle, Jordan Finch, Sanjay Srivastava, Russel Barnett, Aruni Bhatnagar. 
Superfund Site Human Health Risk Assessment for Evaluating Sustainable Reuse Options. -In 
Preparation  
PEER-REVIEWED POSTER PRESENTATIONS 
Stacey Konkle, Jordan Finch, Aruni Bhatnagar, Katlyn McGraw, Haley Metcalf, Jamar Wheeler, 
Lauren Heberle.  What Do We Know?  A Critical Review of Site Condition and Public Health Risk 
Assessments in EPA Five-Year Reviews of the Lee’s Lane Superfund Site in Louisville, KY. 
November 2019; Seattle, WA 
Stacey Konkle, Kristina Zierold, Kira Taylor, Daniel Riggs, Aruni Bhatnagar. National Secular 
Trends in Ambient Air Volatile Organic Compound Levels and Biomarkers of Exposure in the 
United States. Presented at: The International Society for Environmental Epidemiology annual 
meeting. August, 2019- Utrecht, Netherlands; University of Louisville Research Symposium. 
September, 2019- Louisville Kentucky; Regional Society of Toxicology Annual Meeting. October 
2019; Cincinnati, Ohio 
Stacey Konkle, Kristina Zierold, Kira Taylor, Matthew Groenewold, Aruni Bhatnagar. Secular 
Trends in Ambient Volatile Organic Compound Levels, Biomarkers of Exposure and Associations 
with Cardiometabolic Syndrome: An Analysis of Data from the National Health and Nutrition 
Examination Survey (NHANES) and the National Monitoring Program. Presented at Kentucky 
Public Health Association annual meeting. April, 2019; Cincinnati, Ohio 
Stacey Konkle, Kristina Zierold, Kira Taylor, Daniel Riggs, Aruni Bhatnagar. National Secular 
Trends in Ambient Air Volatile Organic Compound Levels and Biomarkers of Exposure in the 
United States. Presented at Cardiovascular Research Symposium. April, 2019; Louisville, 
Kentucky 
Stacey Konkle, Kristina Zierold, Kira Taylor, Matthew Groenewold, Aruni Bhatnagar. Secular 
Trends in Ambient Volatile Organic Compound Levels, Biomarkers of Exposure and Associations 
with Cardiometabolic Syndrome: An Analysis of Data from the National Health and Nutrition 
Examination Survey (NHANES) and the National Monitoring Program (NMP). Presented at 
NIEHS Superfund Research Program (SRP) annual meeting. December, 2018; Sacramento, 
California 
Stacey Konkle, Kristina Zierold, Kira Taylor, Matthew Groenewold, Aruni Bhatnagar. Secular 
Trends in Ambient Volatile Organic Compound Levels, Biomarkers of Exposure and Associations 
with Cardiometabolic Syndrome: An Analysis of Data from the National Health and Nutrition 
Examination Survey (NHANES) and the National Monitoring Program (NMP). Presented at 
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Research Louisville Poster Symposium. September, 2018; Louisville, Kentucky – Doctoral Student 
Award Winner 
 
Stacey Konkle, Kristina Zierold, Kira Taylor, Matthew Groenewold, Aruni Bhatnagar. Secular 
Trends in Ambient Volatile Organic Compound Levels, Biomarkers of Exposure and Associations 
with Cardiometabolic Syndrome: An Analysis of Data from the National Health and Nutrition 
Examination Survey (NHANES) and the National Monitoring Program (NMP). Presented at 
American College of Epidemiology Conference and published in Annals of Epidemiology. 
September, 2018; Cincinnati, Ohio 
 
Stacey Konkle, Daniel Riggs, Aruni Bhatnagar. Associations Between Volatile Organic 
Compounds and Serum Lipids in the National Health and Nutrition Examination Survey 
(NHANES). Presented at Annual Kentucky Public Health Association Conference. April, 2018; 
Covington, Kentucky  – Outstanding Student Epidemiology Poster Award Winner 
 
Stacey Konkle, Daniel Riggs, Aruni Bhatnagar. Associations Between Volatile Organic 
Compounds and Serum Lipids in the National Health and Nutrition Examination Survey 
(NHANES). Presented at Society of Toxicology Annual Conference and Published in The 
Toxicologist. March, 2018; San Antonio, Texas 
 
Stacey Konkle, Daniel Riggs, Aruni Bhatnagar. Associations Between Volatile Organic 
Compounds and Serum Lipids in the National Health and Nutrition Examination Survey 
(NHANES). Presented at Regional Society of Toxicology Annual Meeting. September, 2017; West 
Lafayette, Indiana 
 
Stacey Konkle, Daniel Riggs, Aruni Bhatnagar. Associations Between Volatile Organic 
Compounds and Serum Lipids in the National Health and Nutrition Examination Survey 
(NHANES). Presented at Research Louisville Poster Symposium. September, 2017; Louisville, 
Kentucky – Doctoral Student Award Winner 
 
Stacey Konkle, Daniel Riggs, Tim O'Toole, Wesley Abplanalp, Aruni Bhatnagar, Natasha 
DeJarnett, Shesh Rai. The Association of Benzene Exposure with Cardiovascular Disease Risk. 
Presented at Research Louisville Poster Symposium. October, 2016; Louisville, Kentucky  
 
Wesley Abplanalp, Stacey Konkle, Daniel Riggs, Shesh Rai, Daniel Conklin, Sanjay Srivastava, 
Aruni Bhatnagar, Timothy O’Toole. Benzene Exposure is Associated with Insulin Resistance in 
Humans and Mice. Presented at Ohio Valley Society of Toxicology Annual Meeting Program. 
October, 2016; Indianapolis, Indiana 
 
Matthew Groenewold, Stacey Konkle, Colleen Roberts, Andrea Flinchum, Lynn Roser, Derek 
Foster, Kimberly Blanton, Cibina Harris, Robert Brawley. Investigation of an Outbreak of 
Burkholderia Cepacia Infections Among Non-Cystic Fibrosis ICU Patients in a Kentucky Hospital. 
Presented at the Council of State and Territorial Epidemiologists 2015 Annual Conference. June, 
2015; Boston, Massachusetts 
 
Matthew Groenewold, Elizabeth Russell, Stacey Konkle, Joyce Rice, Kelly Giesbrecht, Heather 
Moulton-Meissner, Andrea Flinchum, Lynn Roser, Robert Brawley. Investigation of a Cluster of 
Rapidly-Growing Mycobacteria Infections Associated with Joint Replacement Surgery in a 
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Kentucky Hospital. Presented at the Council of State and Territorial Epidemiologists 2014 Annual 
Conference. June, 2014; Nashville, Tennessee  
Stacey Konkle, Austin Donner, Jean Jensen, Kevin Keener. Eradication of Salmonella enteritidis 
on Raw, Shell Eggs Using an In-Package Ozonation Process. Presented at the Purdue 
Undergraduate Symposium. April, 2010; West Lafayette, Indiana 
FORMAL PRESENTATIONS 
Stacey Konkle. National Secular Trends in Ambient Air Volatile Organic Compound Levels and 
Biomarkers of Exposure in the United States. Presented at The Envirome Institute Seminar Series. 
February, 2019; Louisville Kentucky 
Stacey Konkle. Air Pollution: Global Burden, National Secular Trends, and Associations of 
Volatile Organic Compounds. Presented at post-doctoral seminar. November, 2018; Louisville 
Kentucky 
Stacey Konkle. Volatile Air Pollutants: Trends, Associations, and Mitigation Strategies. Invited 
talk: The Kentucky Department for Public Health Career Development Webinar. July, 2018; 
Louisville Kentucky 
Stacey Konkle. Trends in Ambient Volatile Organic Compound Levels, Biomarkers of Exposure 
and Associations with Cardiometabolic Syndrome. Presented at post-doctoral seminar. June, 2018; 
Louisville Kentucky 
Stacey Konkle. Associations of Volatile Organic Compounds in Two Human Cohorts. Presented 
at post-doctoral seminar. February, 2018; Louisville Kentucky  
Stacey Konkle. Associations of Volatile Organic Compounds and Cardiometabolic Syndrome Risk. 
Presented at post-doctoral seminar. July, 2017; Louisville Kentucky 
Stacey Konkle. Characterization of Select Urinary Volatile Organic Compounds (VOCs) by 
Smoking Status in the Jackson Heart Study Cohort. Presented at the American Heart Association, 
Tobacco Regulation and Addiction Center (A-TRAC) annual meeting. March, 2017; Louisville 
Kentucky  
Stacey Konkle. Volatile Organic Compound Exposure and Cardiometabolic Risk: An Analysis of 
Urinary Volatile Organic Compound Metabolite Exposures and Cardiometabolic Syndrome Risk. 
Presented at post-doctoral seminar. March, 2017; Louisville Kentucky  
Stacey Konkle. Benzene Exposure and Cardiometabolic Syndrome: An Analysis of Benzene 
Metabolite Exposures and Cardiometabolic Syndrome Risk In a Nationally Representative Cohort. 
Presented at post-doctoral seminar. November, 2016; Louisville Kentucky  
Stacey Konkle. The Association of Benzene Exposure with Cardiovascular Disease Risk. Presented 
at post-doctoral seminar. September, 2016; Louisville Kentucky  
Stacey Konkle. Benzene Exposure and Cardiometabolic Syndrome. Presented at post-doctoral 
seminar. August, 2016; Louisville Kentucky  
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Stacey Konkle. Analysis of VOC (Volatile Organic Compounds) Exposure and Cardiovascular 
Disease Risk Presented at post-doctoral seminar. February, 2016; Louisville Kentucky  
RECENT AWARDS AND HONORS 
Superfund Trainee selected to attend disaster research training. 2018 
University of Louisville Superfund Center Fellow. 2018 
Kentucky Public Health Association Outstanding Student Epidemiology Poster Award Winner. 
2018 
Research Louisville Poster Symposium Doctoral Student Award Winner. 2017, 2018 
American Heart Association Tobacco Regulation and Addiction Center Affiliated Fellow. 2017 
TRAINING 
Probability Surveys SAS Certified (2018), NIEHS Superfund Research Program- Disaster 
Research Training (2018), NIEHS Superfund Research Program- Washington D.C. Science in 
Policy Training (2018), Louisville Metro Medical Reserve Corp.*, Legal Epidemiology 
(2018), Community Assessment for Public Health Emergency Response (CASPER) (2017), 
EpiInfor7 certified (2015), Kentucky Public Health Assistance and Support Team (K-
PHAST)*, FEMA ICS100* ICS200* and IS800* certified, HACCP certified, basic biosafety*, 
NIH guidelines*, radiation safety*, shipping infectious and biological substances*, general 
laboratory safety and hazardous waste safety*, bloodborne pathogens safety*, human subjects 
and HIPAA research certified*, good clinical practice training*.  
*current
SERVICE TO THE COMMUNITY 
St. Vincent de Paul     2011 – Present 
• Dinner service at the soup kitchen, Christmas angel tree gift collection,
Thanksgiving dinner delivery to families that have utilized St. Vincent de Paul
services throughout the year, food and clothing drives, and additional assistance
as needed.
Southern Indiana Faith Community      2011 – Present 
• Set up and operate booths at several annual church picnics, organize fun-run
fundraiser, food pantry food drives, packed shelf stable meals for Texas, Haiti,
and Puerto Rico hurricane victims.
Kentucky Public Health Assistance and Support Team- Member  2013 – Present
• Trained with the Kentucky Department for Public Health to respond to public
health situations and provide assistance with Incident Command Structure (ICS),
survey design, Epi Info software, HIPPA, interviewing skills, and basic applied
epidemiology.
• Deployed in the field to conduct a community assessment for public health
emergency response (CASPER) in the Kentucky Green River Health District.
CASPER is an epidemiologic tool designed to complete rapid needs assessment
in communities. The CASPER system was used to systematically collect primary
data for the districts next Community Health Assessment.
Habitat for Humanity   2016 – Present 
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• Onsite build events – construction activities including painting, landscaping,
siding, mudding, cleaning and various installations.
PROFESSIONAL AFFILIATIONS 
International Society for Environmental Epidemiology (ISEE) 
Certified Public Health (CPH) 
Kentucky Public Health Association (KPHA) 
American Statistical Association (ASA) 
Society of Toxicology (SOT) 
Ohio Valley Society of Toxicology (OVSOT) 
Council of State and Territorial Epidemiologists (CSTE)   
Society of Epidemiologic Research (SER) 
American College of Epidemiology (ACE) 
SKILLS 
Proficient in SAS, SPSS, and EpiInfo7, competent in Esri ArcGIS, and R software, proficient 
in Microsoft Office including Excel, PowerPoint, Outlook and Word 
